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Abstract 
 
Human African trypanosomiasis (HAT) is a parasitic disease confined to the 
African continent and is caused by the protozoan Trypanosoma brucei (T. brucei). If left 
untreated is usually fatal. Disease control is dependent on drug therapy, since no human 
vaccine is available. However, the existing therapy is far from satisfactory owing to the 
emergence of resistances, toxicity and its limited efficacy. Thus, the necessity to discover 
and validate new drug targets with the ultimate goal of discovery new compounds is 
explicit. In the search for parasite specific enzymes and using an in silico comparative 
genomic approach we have selected, asparagine synthetase A (AS-A) and ribose 5-
phosphate isomerase B (RpiB) to undergo biochemical and genetic studies. This thesis 
presents the first functional characterization of these two potential therapeutic targets 
against T. brucei.  
Classically AS-A enzymes, using ammonia as nitrogen donor, convert aspartate 
into asparagine, which is important for nitrogen homeostasis and protein biosynthesis. T. 
brucei AS-A (TbAS-A) activity was proved through biochemical approaches, having the 
peculiarity of using both ammonia and glutamine as nitrogen donors. RNA interference 
(RNAi) against TbAS-A did not affect bloodstream parasites growth either in vitro or in 
vivo. However, growth was significantly impaired only when TbAS-A RNAi-induced 
parasites were grown in limiting asparagine environments suggesting that RNAi-mediated 
down-regulation of AS-A rendered T. brucei auxotrophic to asparagine. In conclusion, AS-
A is important for bloodstream parasites growth and infectivity only when asparagine is 
limiting and therefore is unlikely to be suitable as a drug target since under normal 
physiological conditions, asparagine is available in the blood. 
RpiB belongs to the non-oxidative branch of the pentose phosphate pathway, 
being involved in the interconversion of ribulose 5-phosphate (Ru5P) and ribose 5-
phosphate (R5P). The latter is a critical metabolite precursor for de novo synthesis of 
nucleotides and nucleic acids. In vitro biochemical studies confirmed T. brucei ribose 5-
phosphate isomerase (TbRpiB) activity. TbRpiB knockdown by RNAi affected in vitro 
growth of bloodstream forms, but more importantly parasites infectivity since mice infected 
with induced RNAi clones exhibited lower parasitaemia and a prolonged survival in 
comparison to mice infected with control parasites. Moreover, several attempts to 
generate double knockouts were unsuccessful. TbRpiB emerges as a new potential 
therapeutic target against HAT that deserves further studies. 
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Resumo 
 
A tripanossomíase Africana é uma doença parasitária confinada ao continente 
Africano sendo causada pelo protozoário Trypanosoma brucei (T. brucei). Se não for 
tratada é geralmente fatal. O controlo da doença está dependente de quimioterapia, uma 
vez que não existe nenhuma vacina. No entanto, a terapia existente está longe de ser 
satisfatória devido ao aparecimento de resistências, toxicidade e eficácia limitada. Assim, 
a necessidade de descobrir e validar novos alvos terapêuticos, com o objetivo de 
identificar novos compostos, é explícita. Na procura de enzimas específicas do parasita e 
utilizando uma abordagem comparativa do genoma foram escolhidas entre outras duas 
proteínas, nomeadamente asparagina sintetase A (AS-A) e ribose 5-fosfato isomerase B 
(RpiB) para estudos bioquímicos e genéticos. Esta tese apresenta a primeira 
caracterização funcional destes dois potenciais alvos terapêuticos contra o T. brucei. 
Classicamente as enzimas AS-A utilizam amônia como dador de azoto na 
conversão de aspartato em asparagina, sendo este aminoácido importante para a 
homeostasia do azoto e para a síntese proteica. A atividade da  AS-A de T. brucei (TbAS-
A) foi comprovada através de estudos bioquímicos e revelou a particularidade de usar 
tanto amônia como glutamina como dadores de azoto. RNA de interferência (RNAi) 
contra TbAS-A não afetou, nem in vitro nem in vivo, o crescimento das formas 
sanguíneas do parasita. No entanto, o crescimento foi significativamente comprometido 
quando os parasitas com RNAi induzido contra TbAS-A foram submetidos a condições 
limitantes em asparagina, sugerindo que a subexpressão da AS-A pelo RNAi torna o 
parasita auxotrófico para a asparagina. Em conclusão, a AS-A é importante para o 
crescimento e infetividade das formas sanguíneas do parasita apenas quando a 
quantidade de asparagina extracelular é limitada, e por isso é improvável que venha a 
constituir um alvo terapêutico uma vez que em condições fisiológicas a asparagina está 
disponível no sangue. 
 A RpiB pertence ao ramo não oxidativo da via das pentoses fosfato, estando 
envolvida na interconversão de ribulose 5-fosfato (Ru5P) e ribose 5-fosfato (R5P). Este 
último é um importante precursor metabólico para a síntese de novo de nucleótidos e 
ácidos nucleicos. Estudos bioquímicos in vitro confirmaram a atividade enzimática da 
ribose 5-fosfato isomerase de T. brucei (TbRpiB). A diminuição dos níveis de expressão 
desta enzima por RNAi afetou o crescimento das formas sanguíneas in vitro, mas mais 
importante afetou a infetividade dos parasitas, uma vez que ratinhos infetados com 
clones RNAi induzidos apresentaram parasitemias menores e sobrevivências 
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prolongadas quando comparados com ratinhos infetados com parasitas controlo. Além 
disso, diversas tentativas para obtenção de duplos knockout não foram bem sucedidas. 
TbRpiB surge como um novo potencial alvo terapêutico contra a trypanossomíase 
Africana, que merece ser alvo de mais estudos. 
 
Palavras-chave: Formas sanguíneas de T. brucei, asparagina sintetase A, ribose 5-
fosfato isomerase B, cinética enzimática e RNAi 
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strand separation, loading and modification to form the RISC, which then cleave and 
degrade the target mRNA. [Adapted from (Balana-Fouce & Reguera, 2007; Kolev et al, 
2011)]. ……………………………………….…...........................................................… 
 
Figure 12. Human host cell and T. brucei polyamine pathways. (A) Polyamine pathway in 
mammalian cells. (B) Polyamine and T(SH)2 biosynthetic pathway in T. brucei parasites. 
Abbreviations: ARG, arginase; AdoMet, S-adenosylmethionine; AdoMetDC, S-
adenosylmethionine decarboxylase; SAT, N1-acetyltransferase specific for spermidine and 
spermine; dcAdoMet, decarboxylated S-adenosylmethionine; MTA, methylthioadenosine; 
AcSpd, acetylated spermidine; AcSpm, acetylated spermine; ODC, ornithine 
decarboxylase; PAO, polyamine oxidase; Put, putrescine; Spd, spermidine; SpdSyn, 
spermidine synthase; Spm, spermine; SpmSyn, spermine synthase; GSH, glutathione; 
GSS, glutathionylspermidine synthase; ROS, reactive oxygen species; TryR, 
trypanothione reductase; TryS, trypanothione synthetase. [Adapted from (Heby et al, 
2007)]. ……………………………………………………………………………………...... 
 
Figure 13. Simplistic representation of GSH and T(SH)2 mediated redox homeostasis in 
mammalian host and T. brucei parasites. Detoxification of ROS is accomplished by a 
cascade derived from T(SH)2/TR and GSH/GR in parasites and mammalian host, 
respectively, with NADPH as the primary electron source. [Adapted from (Paul et al, 
2014)]. ......................................................................................................................... 
 
Figure 14. The energy metabolism of bloodstream (a) and procyclic (b) T. brucei foms. 
Enzymes: 1, hexokinase; 2, glucose-6-phosphate isomerase; 3, phosphofructokinase; 4, 
aldolase; 5, triosephosphate isomerase; 6, glyceraldehyde-3-phosphate dehydrogenase; 
7, phosphoglycerate kinase; 8, glycerol-3-phosphate dehydrogenase; 9, glycerol kinase; 
10, phosphoglycerate mutase; 11, enolase; 12, pyruvate kinase; 13, glycerol-3-phosphate 
oxidase; 14, phosphoenolpyruvate carboxykinase; 15, L-malate dehydrogenase; 16, 
fumarase; 17, fumarate reductase; 18, pyruvate phosphate dikinase; 19, pyruvate 
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dehydrogenase complex; 20, acetate:succinate CoA transferase; 21, proline oxidase; 22, 
Δ'-pyrroline-5-carboxylate reductase; 23, glutamate semialdehyde dehydrogenase; 24, 
glutamate dehydrogenase; 25, α-ketoglutarate dehydrogenase; 26, succinyl CoA 
synthetase; 27, FAD-dependent glycerol-3-phosphate dehydrogenase. Abbreviations: AA, 
amino acid; AcCoA, acetyl-CoA; 1,3-BPGA, 1,3- bisphosphoglycerate; c, cytochrome c; 
Citr, citrate; DHAP, dihydroxyacetone phosphate; Fum, fumarate; G-3-P, glyceraldehydes 
3-phosphate; Glu, glutamate; Gly-3-P, glycerol 3-phosphate; KG, α-ketoglutarate; Mal, 
malate; OA, 2-oxoacid; Oxac, oxaloacetate; PEP, phosphoenolpyruvate; 3-PGA, 3-
phosphoglycerate; Succ, succinate; Succ-CoA, succinyl CoA; UQ, ubiquinone. Substrates 
and secreted end-products are indicated in green and red boxes. Enzymes involved in 
reactions represented by dashed lines are present, but experiments indicated that no 
significant fluxes occurred through these steps. [Adapated from (Hannaert et al,2003a)].  
………………………………………………………………………………………………… 
 
Figure 15. Folate and biopterin reduction in T. brucei. (A) Folate reduction catalyzed by 
both DHFR and PTR1 enzymes. DHFR-TS [Protein Data Bank (PDB) code 2H2Q] is 
shown in the center of the cycle with DHFR and TS domains colored blue and red, 
respectively. (B) Two-stage reduction of biopterin catalyzed by PTR1. [Adapted from 
(Tulloch et al, 2010)]. .................................................................................................. 
 
Figure 16. Scheme of the PPP in T. brucei: components, biological relevance, and 
inhibitors. The substrates and products of the PPP that are shared with other metabolic 
pathways are labeled with a green dot. Characterized enzyme inhibitors are shown in red. 
The enzymes of the oxidative and non-oxidative phase of the PPP are in orange and blue, 
respectively. Salvage pathways for R5P are in lilac. Enzymes absent in infective T. brucei 
are marked with red dot. Enzymes of proved indispensability are indicated with yellow dot. 
[Adapted from (Comini et al, 2013)]. …………………………………………………....... 
 
Figure 17. Enzymes involved in asparagine metabolism. (A) Asparagine consumption, 
synthesis and uptake. Enzymes involved in tRNA-dependent and independent pathways 
within asparagine metabolism are depicted. (B) Hypothetical scenario for asparaginyl-
tRNA (AsnRS) and archeal AS (AS-AR) evolution. AsnRS and AS-AR derives from the 
same ancestor aspartyl-tRNA (AspRS). The gene of the AspRS ancestor duplicated, with 
one copy leading to archaeal/eukaryal AspRS and the other undergoing second gene 
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duplication. One gene of this second duplication gave rise to AsnRS, while the second 
copy evolved to AS-AR through loss of the anticodon binding domain and mutations in the  
catalytic site. Thereafter AsnRS and AS-AR were horizontally transferred from archaea to 
other phylae. [Adapted from (Blaise et al, 2011)]. ………………………...................... 
 
Figure 18. Phosphorylation of eIF2α is mediated by different kinases that respond to 
specific environmental stresses: 1) GCN2 which is activated during amino acid starvation; 
2) protein kinase R (PKR), which plays a key role in the cellular anti-viral response; 
3) protein kinase RNA-like endoplasmic reticulum kinase (PERK), which responds to 
protein misfolding in the endoplasmic reticulum; and 4) HRI that limits protein synthesis 
during heme-deficiency. Phosphorylated eIF2α suppresses global translation, but leads to 
a paradoxical increase in translation of specific mRNA species, such as that for ATF4, 
which consequently enhanced AS transcription, one of the hundreds of ATF4 target 
genes. [Adapted from (Balasubramanian et al, 2013; Kilberg et al, 2009)]. ............... 
 
Figure 19. Citrate synthase knockdown redirects oxaloacetate to aspartate and 
asparagine biosynthesis. Abbreviations are as follows: Glc, glucose; Pyr, pyruvate; Ac-
CoA, acetyl-CoA; CS, citrate synthase; Gln, glutamine; Glu, glutamate; Cit, citrate; a-KG, 
a-ketoglutarate; Suc, succinate; Fum, fumarate; Mal, malate; OAA, oxaloacetate; Asp, 
aspartate; Asn, asparagine. [Adaped from (Zhang et al, 2014)]. ............................... 
 
Figure 20. Induction of glycolysis/PPP transition during oxidative stress. In a stress 
situation, activity of the PPP is increased through orchestrated allosteric/post-translational 
and transcriptional regulation. The fastest response is made through oxidative inhibition of 
GAPDH and consequently forward glycolytic reactions, while PPP remains active. This 
process is also supported by post-translational modifications that increase G6PDH 
activity, a process comparatively slower but that allows cellular adaptation to stress in a 
long(er)-term response. [Adapted from (Stincone et al, 2014)]. ................................. 
 
Figure 21. Glucose labelled on the sixth, first and both first and second carbons can be 
used to determine relative flux through the oxidative and non-oxidative PPP by 
assessment of singly, doubly and non-labelled downstream intermediates. [Adapted from 
(Fan et al, 2014; Metallo & Vander Heiden, 2013)]. ................................................... 
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Figure 22. Alternative pathways to generate R5P bypassing the oxidative PPP. (A) The 
path from D-ribose to R5P in E. coli. RbsA a cytoplasmic ATPase, RbsC a membrane 
permease, RbsB the periplasmic ribose binding protein, RbsD is a mutarotase, that 
converts the pyranose form of ribose to the furanose form, and RbsK or ribokinase binds 
specifically the α-furanose form of ribose for its phosphorylation leading to R5P. (B) 
Ribose-1P synthesis within Plasmodium infected erythrocytes. (C) The light-independent 
reactions of carbon fixation in the Calvin cycle share enzymes and reactions with the PPP 
and glycolysis. (D) Yeast Shb17 feeds carbon into the non-oxidative PPP. The cells were 
fed with glucose labelled selectively at the 6-position with carbon 13 (6-13C-glucose). Flux 
through Shb17 into S7P can be measured using [6-13C1]-glucose. [6-
13C1]-glucose leads to 
[7-13C1]-S7P when S7P is made via the oxidative PPP or the non-oxidative PPP. However, 
when S7P is produced from SBP via Shb17, a fraction of the S7P pool is doubly labelled: 
[1,7-13C2]-S7P. This labelling pattern was observed preferentially when yeast cells were 
grown on media that decreased their need for NADPH (e.g. by providing them with lipids). 
Abbreviations: G6P, glucose-6-phosphate; F6P, frutose 6-phosphate; FBA or fba, fructose 
biphosphate aldolase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GAP, 
glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; TPI, triosephosphate 
isomerase; E4P, erythrose 4-phosphate; SBP, sedoheptulose-1,7-bisphosphate; S7P, 
sedoheptulose 7-phosphate; shb17 or SH17BPase, sedoheptulose-1,7-bisphosphatase; 
tal, transaldolase; TK or tkl, transketolase; RPI or rki1,  ribose phosphate isomerase; rpe1, 
ribose phosphate epimerase; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosphate; 
Xu5P, xylulose 5-phosphate; PGK, phosphoglycerate kinase; PRK, phosphoribulokinase; 
hPNP, human purine nucleoside phosphorylase; PfPNP, purine nucleoside 
phosphorylase; Ino, inosine; Hxt, hypoxanthine; RBC, red blood cell; PV, parasitophorous 
vacuole; MTI, methylthioinosine. [Adapted from (Clasquin et al, 2011; Downie et al, 2008; 
Roos, 2007; Stincone et al, 2014)]. ………………………………................................. 
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1 Historical perspective 
  
 Human African trypanosomiasis (HAT), also known as African sleeping sickness, 
is considered a third world country disease, circumscribed throughout time in the African 
continent. HAT was first described around the 14th century, but only in the beginning of the 
20th century, the population was decimated in Africa central areas (Louis & Simarro, 2005; 
Steverding, 2008). It was at that moment, when Sir David Bruce (Figure 1A) discovered 
Trypanosoma brucei (T. brucei) as the cause of Nagana disease (1895), and provided 
conclusive evidence that is transmitted by tsetse flies (1903) (Bruce, 1895; Cox, 2004; De 
Raadt, 1976). As a result local authorities set up control measures, which progressively 
controlled the disease, reaching a minimum of 4,435 cases declared in Africa, in 1964. 
Later on, the presence of social instability, conflicts and insecurity led the disease to 
resurge in the 1980s and 1990s, reaching an estimated 300,000 cases. Control programs 
were reinforced and, as a result, since 2000, the number of notified cases has been 
decreased, falling since 2009 to below 10,000 new reported cases (Figure 1B) (Franco et 
al, 2014).  Besides the fact that human cases have been declining in the past decade, the 
lack of full-scale screening programs associated with poor diagnostic tools (Wastling & 
Welburn, 2011), results in under-diagnosed and under-reported cases, which is likely to 
be at least threefold higher than the measured value (Phillips, 2012).  
 
 
Figure 1. HAT historical features. (A) Sir David Bruce. (B) Total number of new cases of 
HAT reported to the World Health Organization (WHO), 1940-2013. [Adapted from 
(Franco et al, 2014; Steverding, 2008)].   
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2 Causative agent  
 
 The causative agent of HAT, T. brucei, is an extracellular flagellated protozoan 
parasite, which belongs to the Family Trypanosomatidae within the Order Kinetoplastida 
(Figure 2A). There are three T. brucei subspecies, of which two are human infective, 
Trypanosoma brucei gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense 
(T. b. rhodesiense), and one non-infective for humans, Trypanosoma brucei brucei (T. b. 
brucei), therefore routinely used in laboratories (Barrett et al, 2003). Different to humans, 
Nagana disease in animals result from infections with T. congolense, T. vivax or T. b. 
brucei (Steverding, 2008). Gambiense HAT, caused by T. b. gambiense, is considered an 
anthroponotic disease with a minor role for animal reservoirs, while rhodesiense HAT, 
induced by T. b. rhodesiense, is regard as a zoonotic disease, affecting mainly animals; 
humans are only accidental hosts. Unlike T. b. rhodesiense infections, in which non-
human vertebrates are the primary reservoir and represent <5% of HAT cases, T. b. 
gambiense infections represent >95% of the cases (Solano et al, 2013). T. b. gambiense 
is classed in two different groups, that differ in genotype and phenotype (Balmer et al, 
2011; Gibson, 1986; Gibson et al, 1980; Hide et al, 1990; Jamonneau et al, 2004; Mehlitz 
et al, 1982; Paindavoine et al, 1986; Tait et al, 1984; Truc & Tibayrenc, 1993; Zillmann et 
al, 1984). Group one (“true-gambiense”) is less genetically diverse and displays low 
virulence in rodents, while group two (“non-gambiense”) is more genetically diverse, able 
to infect rodents and shows biological and genetic similarities to T. b. rhodesiense and T. 
b. brucei (Gibson, 1986).  
 
3 Geographical distribution 
 
 T. b. gambiense infections are found in West and Central sub-Saharan Africa, 
while T. b. rhodesiense causes infections in East sub-Saharan Africa (Figure 2B) (Barrett 
et al, 2003). The geographic barrier of the two forms of the disease coincides with the Rift 
Valley, with T. b. gambiense and T. b. rhodesiense present at the west and east side of 
the valley, respectively (Franco et al, 2014). Although some patients are occasionally 
reported outside Africa (Lejon et al, 2003a), 36 sub-Saharan African countries are still 
considered the endemic areas for HAT. Currently, there are approximately 300 gambiense 
HAT foci within 24 sub-Saharan Africa countries (Angola, Benin, Burkina Faso, 
Cameroon, Chad, Central African Republic, Congo, Côte d’Ivoire, Democratic Republic of 
the Congo, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea Bissau, Liberia, 
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Mali, Niger, Nigeria, Senegal, Sierra Leone, South Sudan, Togo, Uganda), and around 60 
foci of rhodesiense HAT in 13 African countries (Botswana, Burundi, Ethiopia, Kenya, 
Malawi, Mozambique, Namibia, Rwanda, Swaziland, Tanzania, Uganda, Zambia, and 
Zimbabwe) (Franco et al, 2014). Curiously, Uganda is the only country where the two 
subspecies co-exist, however there still remains a spatial separation between the 
subspecies, mainly due to the different climatic and vegetative conditions required by the 
two species (Berrang-Ford et al, 2010). 
 
4 Vector 
  
 HAT is transmitted through the bite of an infected tsetse fly (genus Glossina) 
(Figure 2C). Similarly to T. brucei subspecies, the different tsetse flies species are related 
to different habitats. Thirty-one species have been described, however in nature, 
infections are carried almost exclusively by Glossina palpalis (for T. b. gambiense; 
distributed in the Atlantic coast from Senegal to Angola), Glossina morsitans (for T. b. 
rhodesiense; located mainly in East Africa) and Glossina fuscipes (for both; present in 
central Africa from Cameroon and Congo to the Rift Valley) (Franco et al, 2014). Both 
female and male flies are able to transmit the parasite, however some tsetse flies species 
are refractory to infection by specific trypanosome species, and even when susceptible, 
the parasites population can suffer a pronounced reduction in the insect midgut. These 
facts point the tsetse fly as a low competent vector (Molyneux, 1980). In general tsetse 
flies are able to adapt to host availability, odor stimuli and visual factors are probably 
involved in the finding of a suitable host (Tirados et al, 2011). Sexual reproduction in 
insect salivary glands is not obligatory in trypanosomes but is an important event yielding 
the possibility of genetic exchange and rapid transmission of important characteristics, 
such as drug resistance and virulence (Peacock et al, 2014; Peacock et al, 2011). Genetic 
exchange is relatively frequent in T. b. rhodesiense, but it is more sporadic in T. b. 
gambiense (Koffi et al, 2007). 
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Figure 2. HAT causative agent, vector and geographical distribution. (A) T. brucei in thin 
blood smears stained with Giemsa. (B) Geographic distribution of HAT; cases reported 
from 2000–2009. (C) A close up of a tsetse fly. [Adapted from (CDC, 2012; Franco et al, 
2014)].  
 
5 Clinical features 
 
 Clinically HAT evolves in two stages. The first, known as early or haemato-
lymphatic stage, is defined by the presence of parasites in the lymph and blood systems, 
while the second, named as late or meningo-encephalitic stage, is characterized by the 
active invasion of trypanosomes in the central nervous system (CNS). The duration of the 
first stage depends on the T. brucei subspecies involved and varies from few weeks to 
months in acute T. b. rhodesiense infections, or from several months to years in chronic T. 
b. gambiense infections (Franco et al, 2014). After inoculation, the formation of a 
trypanosomal chancre, characterized by local erythema, oedema, heat, tenderness and a 
lack of any suppuration (Malvy & Chappuis, 2011), arises in about 50% of rhodesiense 
infections, but is rarely formed in gambiense infections. After 3–4 weeks, the chancre 
usually heals with overlying desquamation, sometimes with altered pigmentation (Barrett 
et al, 2003). In T. b. rhodesiense infections, which present poor demarcation between 
stages, pancarditis with congestive heart failure, pericardial effusion, and pulmonary 
oedema can cause fatalities. In contrast, T. b. gambiense infections show a more 
insidious development (Barrett et al, 2003). The first stage is characterised by general 
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malaise, intermittent fever, headache, severe pruritus with scratching, skin lesions, mobile 
or rubbery lymphadenopathies, oedema of the face and extremities and, to a lesser 
extent, myocarditis, splenomegaly or hepatomegaly (Malvy & Chappuis, 2011). In the 
second stage general malaise worsens, headaches become more severe and patient 
sleep pattern is altered. Later this stage culminates in coma, severe organ failure and 
eventually death (Barrett et al, 2003). 
  
6 Parasite life cycle 
 
 Inoculation in the mammalian host of infective metacyclic forms, covered with a 
variant surface glycoprotein (VSG), begins with the bite of an infected tsetse fly vector 
(Figure 3A). Actually, T. brucei parasites change the composition of the insect saliva, in a 
way that increases vector-host contact frequency and enhances the probability of parasite 
transmission (Van Den Abbeele et al, 2010). Once inside the host, the metacyclic 
trypanosomes proliferate at the site of inoculation and then transform into slender forms, 
as they are carried by the draining lymph nodes to the bloodstream, where they replicate 
by binary fission (Vickerman, 1985). When parasitaemia in the host increases, the long 
slender trypomastigotes (proliferative forms) release a soluble factor, stumpy induction 
factor (SIF), via a quorum sensing mechanism, which triggers their differentiation into 
short stumpy forms (non-proliferative forms) (Mony et al, 2014). Stumpy forms, which do 
not divide, are crucial for limiting parasitaemia within the host, and subsequent 
differentiation to procyclic forms when taken into a tsetse vector. During vector blood 
meal, stumpy forms expressing VSG are ingested and primed to differentiate into 
procyclic forms. This priming appears to involve production of a group of carboxylate 
transporters called proteins associated with differentiation (PADs) (Dean et al, 2009). The 
temperature, pH and citrate or cisaconitate in the tsetse midgut seem to trigger for stumpy 
to procyclic differentiation (Brun & Schonenberger, 1981; Czichos et al, 1986). Procyclic 
trypanosomes express a surface coat of procyclic acidic repetitive protein (PARP or 
procyclins) which includes two classes of procyclins, EP (a form of procyclin rich in Glu-
Pro repeats) and GPEET (a form of procyclin rich in Glu-Pro-Glu-Glu-Thr repeats) which 
are developmentally regulated (Vassella et al, 2004). After multiplication in vector midgut, 
procyclic trypomastigotes initiate a migration (Figure 3B), that takes them through the 
peritrophic matrix, along the foregut to the proventriculus, and from there onwards through 
the mouthparts, salivary ducts and finally into the salivary gland (Langousis & Hill, 2014). 
In the proventriculus, procyclic trypomastigotes undergo extensive restructuring, coupled 
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to an asymmetric division to produce one long epimastigote and one short epimastigote 
(Rotureau et al, 2012; Van Den Abbeele et al, 1999). The short epimastigote, coated with 
alanine rich protein (BARP), attaches to epithelial cells following arrival in the salivary 
gland (Urwyler et al, 2007). In order to complete the life cycle, the attached epimastigotes 
undergo a final transformation into free metacyclic trypomastigotes, along with the 
acquisition of the VSG coat, for evasion in the mammalian host (Langousis & Hill, 2014). 
 
 
Figure 3. T. brucei life cycle. (A) Parasite development stages within in the mammalian 
host and the tsetse fly. The dividing forms that replicate via binary fission are indicated 
with a circular arrow. (B) Migration route of procyclic trypomastigotes within the insect. 
The blue line depicts the route taken from the midgut to the salivary gland and the red line 
indicates the route from the salivary gland to the mouthparts. [Adapted from (Langousis & 
Hill, 2014)]. 
 
7 Parasite-host interactions 
 
7.1 Parasite evasion strategies  
 
7.1.1 Variant surface glycoproteins and antigenic variation 
 
 VSGs constitute an important virulence factor throughout the mammalian 
infectious cycle, providing the parasite a wall of protection against the host innate and 
specific immune effectors (Ziegelbauer & Overath, 1993). Consistent with this, is the fact 
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that these molecules are codified by developmentally regulated VSGs genes, being 
silenced in the tsetse fly midgut but activated in the tsetse fly salivary glands and in the 
mammalian host (Tetley et al, 1987). VSGs cover the entire parasite surface. This thick 
coat represent up to 20% of total cell protein and is made of around 107 identical 
molecules with a conserved core structure of glycosylphosphatidylinositol (GPI) anchored 
in the cell membrane and, an exposed proteinacious antigen (Cross, 1975; Vickerman & 
Luckins, 1969) (Figure 4A). During an infection, there may be several million 
trypanosomes within a host, but all express one VSG at the time. The mammal immune 
cells recognize this VSG as foreign molecule and start to produce antibodies, which 
subsequently clear the parasites bearing these VSGs. However, as a result of antigenic 
variation from either homologous gene recombination target to the unique active VSG 
expression site, or of transcriptional switching between the different VSG expression sites 
(Horn, 2014), one “new” VSG offspring appears with a novel VSG coat, thus avoiding the 
specific immune response (Dempsey & Mansfield, 1983). The immune system seems not 
to be the trigger of this molecular mechanism once trypanosomes act in the same way 
even in the absence of a host defense (Doyle et al, 1980). It is currently thought that up to 
30% of an African trypanosome genome is dedicated to archiving up to 2000 VSG genes 
and gene-fragments (Horn, 2014). Therefore T. brucei possess a broad palette of possible 
surfaces, which allow the cycle, of defeating one major trypanosome population with 
concomitant re-establishment of infection by an unrecognized sub-population, to continue 
“forever” leading to the host exhaustion (Baral, 2010). VSG switching operates at a 
frequency of approximately 1 switch/105 cells per population doubling (Horn, 2014). Coat 
exchange appears to be primarily by dilution during rapidly cell division, since recycling off 
and back via coupled endocytosis/exocytosis occurs slower (Seyfang et al, 1990). 
Antibodies clearance, low titer at least, through VSG recycling involves endocytosis at the 
flagellar pocket (Field & Carrington, 2009) and a vigorous directional cell motility mediated 
by the flagellum (Figure 4B) (Engstler et al, 2007). The shedding of VSG by GPI–
phospholipase C (GPI–PLC) in dying cells is considered another strategy to deceived the 
immune system (Sunter et al, 2013; Webb et al, 1997) that will be further discussed.  
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Figure 4. VSGs and host antibodies interaction. (A) Schematic representation of IgG and 
IgM molecules bound to the trypanosome VSG coat (left). VSG homodimer (monomers in 
light blue and purple) attached to the plasma membrane via GPI anchors (right). (B) 
Visualization of antibody removal. Cells were surface labelled with blue-fluorescent 
AMCA-sulfo-NHS and incubated VSG-specific IgG. Anti-VSG antibodies were detected 
with species-specific Alexa Fluor 488-conjugated antibodies (green). Open arrows 
indicate the position of the flagellar pocket, and filled arrows point the lysosome. Scale 
bar, 3 μm. [Adapted from (Engstler et al, 2007)]. 
 
7.1.2 Resistance to trypanosome lytic factors 
 
 Humans and some primates posses in their blood two distinct serum complexes, 
called trypanosome lytic factor 1 (TLF1) and 2 (TLF2), both containing the haptoglobin-
related protein (HPR) and the trypanolytic toxin apolipoprotein L1 (APOL1) (Raper et al, 
1999). These factors after being endocytosed are capable of killing T. b. brucei, but not T. 
b. gambiense or T. b. rhodesiense subspecies (Hajduk et al, 1989; Rifkin, 1978; Uzureau 
et al, 2013). TLF1 uptake occurs after HPR join haemoglobin which are then recognized 
by a specific TLF receptor, the haptoglobin–haemoglobin receptor (TbHpHbR) (Drain et 
al, 2001; Vanhollebeke et al, 2008; Widener et al, 2007), however the mechanism of TLF2 
binding and uptake remains unknown, the hypothesis is that TLF2 enters via nonspecific 
binding to VSGs, and that the recycling of the VSG coat through the flagellar pocket would 
enable its uptake into the endocytic compartment (Pays et al, 2014). 
Chapter I – Human African trypanosomiasis 
 
39 
 
In the case of T. b. brucei infections, the APOL1 acts once the entire TLF particle 
is endocytosed and trafficked to the lysosome. During endolysosomal acidification, 
APOL1 binds to the lysosome membrane compromising membrane integrity through 
anionic-pore formation (Figure 5A) (Perez-Morga et al, 2005). The loss of osmoregulation 
triggers lysosomal swelling, but the specific molecular mechanisms behind parasite death 
are still unknown (Pays et al, 2014). 
 Contrary to T. b. brucei, T. b. rhodesiense and T. b. gambiense overcome TLFs 
through distinct resistant mechanisms (Pays et al, 2014). T. b. gambiense constitutively 
resists normal human serum, whereas T. b. rhodesiense is intrinsically sensitive except 
when inoculated in human blood, where it acquires the ability to resist (Gibson, 2007; 
Xong et al, 1998). In T. b. rhodesiense the resistant mechanism involves a transcriptional 
switching of a given VSG expression site to the expression of an expression site-
associated gene (ESAG), known as serum resistance-associated (SRA) (Xong et al, 
1998). This gene encodes a truncated VSG, which is a GPI-anchored dimer without 
surface-exposed antigenic loops (Campillo & Carrington, 2003), targeted to the 
endolysosomal system (Stephens & Hajduk, 2011), where it binds to APOL1 (Vanhamme 
et al, 2003). This interaction neutralizes APOL1, probably by preventing its membrane 
insertion thus enabling its degradation by lysosomal cysteine proteases (Pays et al, 2014) 
(Figure 5B). T. b. gambiense uses a multifactorial defence mechanism (Figure 5C). The 
VSG-derived T. b. gambiense-specific glycoprotein (TgsGP) plays an essential role by 
preventing the insertion of APOL1 into endolysosomal membranes though membrane lipid 
stiffening. Two additional process, which both reduce intracellular levels of APOL1 are 
necessary for full resistance; a L210S substitution in TbHpHbR reduces APOL1 uptake, 
and a lower pH in early endosomes could enable faster cysteine protease-mediated 
digestion of APOL1 (Capewell et al, 2013; Uzureau et al, 2013).  
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Figure 5. T. brucei response to APOL1. APOL1 trafficking in T. b. brucei (A), T. b. 
rhodesiense (B) and T. b. gambiense (C) subspecies. The boxes represent the endocytic 
compartments, and a colour gradient illustrates the endosomal acidification that takes 
place between the beginning (flagellar pocket), and the end (lysosome) of the endocytic 
pathway. [Adapted from (Pays et al, 2014)]. 
 
7.1.3 Flagellar proteins 
 
Flagellar proteins such, GPI–PLC, calflagins, metacaspase 4 (MCA4) and ESAG4, 
are determinants of host–parasite interactions that modulate virulence in the mammalian 
host (Figure 6A and B). 
GPI–PLC is a metacyclic and bloodstream form specific enzyme, located to an 
external linear array along the flagellum and involved on VSG release. When GPI-
anchored VSG flows across the membrane into the flagellar pocket, the activated enzyme 
cleaves the anchor and releases VSG from the membrane, thus glycosylinositolphosphate 
attached to the shed VSG (GIP-sVSG) become free in blood and tissues (Hanrahan et al, 
2009; Sunter et al, 2013; Webb et al, 1994). This enzyme was shown to be required for 
full virulence of pleomorphic trypanosomes, once mice infected with GPI–PLC null 
mutants have extended survival and control better the parasitaemia than the ones infected 
with control parasites (Webb et al, 1997).  
How calflagins and MCA4 promote pathogenesis remains to be determined. 
Calflagins are Ca2+-binding proteins that are upregulated in bloodstream parasites and 
localize to lipid rafts of the flagellar membrane (Emmer et al, 2009). In vitro these proteins 
are dispensable for proliferation, motility and surface-antibody clearance. However, in vivo 
studies showed attenuated parasitaemia and prolonged survival in mice infected with 
calflagins RNAi-induced monomorphic trypanosomes (Emmer et al, 2010). Also 
monomorphic T. brucei MCA4 null mutants have a striking virulence phenotype, that is 
characterized by multiple parasitaemic waves and prolonged host survival. MCA4 is a 
secreted and flagellum-localized bloodstream form specific protein (Proto et al, 2011).  
ESAG4 is also a bloodstream form specific protein localized in the flagellar 
membrane. It is a member of adenylyl cyclases family that catalyze the conversion of 
adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) (Paindavoine 
et al, 1992). The expression of a dominant-negative ESAG4 mutant showed not to be 
important in vitro, however the reduction in 50% of the cellular cAMP levels, leads to a 
reduced parasitaemia and prolonged mice survival. The proposed model is that, lysed or 
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phagocytosed parasites by host macrophages activate ESAG4 to produce cAMP, which, 
in turn, activates host protein kinase A (PKA) to inhibit trypanotoxic tumour necrosis factor 
alpha (TNF-α) synthesis, which enables trypanosomes to resist the early host innate 
immune response (Salmon et al, 2012).  
 
 
Figure 6. Flagellar proteins contribute to virulence in the mammalian host. (A) Loss of 
GPI–PLC, calflagins and MCA4 decreases parasite virulence and increases mice’s life 
span. (B) T. brucei ESAG4 interferes with host early innate immune response promoting 
parasite virulence and decreases mouse survival. ESAG4 produces cAMP, which 
activates PKA in host macrophages to inhibit TNF-α synthesis. [Adapted from (Langousis 
& Hill, 2014)].  
 
7.2 Host defense  
  
Most of what is known to date on the host immune response directed against HAT, 
is derived from experimental studies, carried out in mice models, which can misrepresent 
what is going on in human hosts. The immune response behind this disease is still 
equivocal, being dependent on the parasite strain, the mouse model, or both. Moreover 
the major immune effectors found in one organ, might be inefficient elsewhere. To 
worsen, the variability of the host genotype has a huge impact on the progression of the 
disease, hindering the scientific community from obtaining definitive answers. 
 
7.2.1 Innate immune response 
 
Concerning the innate immune response against T. brucei, is generally accepted 
that trypanolytic complexes (described above in detail), complement, natural killer cells 
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(NK) and antigen-presenting cells (APC; macrophages and dendritic cells) are the first line 
of defence (Figure 7).  
Although antibody mediated binding of trypanosomes, and their uptake by 
phagocytes does occur in the absence of complement (Ngaira et al, 1983), the latter 
improves the efficacy of parasite and immune-complex removal (Stevens & Moulton, 
1978; Takayanagi et al, 1987). Experimental evidences suggest that both, the classical 
and alternative pathways of complement are activated during trypanosomiasis (Pan et al, 
2006; Russo et al, 1994), however the classical pathway seems to have a more important 
role (Devine et al, 1986; Ferrante & Allison, 1983; Musoke & Barbet, 1977). 
Trypanosomes possess mechanisms to control complement-mediated lysis (Musoke & 
Barbet, 1977; Sheppard et al, 1978). As mentioned above, the removal of immune 
complexes deposited on the parasite surface occurs mainly by a hydrodynamic force 
generated by the parasite motility that results in the transfer of the immune complexes to 
the posterior pole of the cell, in which they are endocytosed (Engstler et al, 2007). 
Moreover, in a lower extent these parasites seem also to escape complement-mediated 
lysis through the shedding of VSG-antibody complexes (Seyfang et al, 1990). The role of 
the mannan binding lectin pathway of complement activation during trypanosome 
infections was never addressed. This pathway may have some relevance considering that 
is triggered by serum lectins and ficolins binding to the mannose residues present in the 
trypanosomes VSG. Moreover, this pathway activation occurs in the absence of specific 
antibodies, and therefore may play a crucial role in parasite clearance during the early 
stage of infection (Namangala, 2012). 
The direct cytotoxic role of activated NK cells remains controversial and poorly 
documented. In resistant mice, NK cells could be one of the sources of interferon-gamma     
(IFN-γ) that activate naϊve macrophages (M) into macrophages type 1 (M1) (also known 
classically activated macrophages, caMϕ), resulting in a type-I response during early 
stage trypanosomiasis (Namangala et al, 2007). NK cells may indirectly, through the 
secretion of cytokines and chemokines, be involved in parasite control, rather than by a 
direct trypanolytic activity (Namangala, 2012). 
  Macrophages and dendritic cells play a central role in the immune response as 
professional APCs. This function includes internalization of pathogen-associated 
molecular patterns (PAMPs) from trypanosomes through phagocytosis, processing of 
parasite antigens in the acidic compartment of the endocytic pathway, and co-stimulation 
and presentation of the immunogenic trypanosome peptides to antigen-specific T helper 
cells (Th cells) in the context of major histocompatibility complex (MHC) Class II 
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molecules (Dagenais et al, 2009; Namangala et al, 2000a; Shi et al, 2007). In an early T. 
brucei infection, macrophages and dendritic cells display a “classical” or pro-inflammatory 
activation profile, which includes production of trypanocidal molecules [reactive oxygen 
species (ROS), reactive nitrogen intermediates (RNI), and TNF-α], pro-inflammatory 
cytokines [(interleukins IL-1, IL-6 and IL-12)], and changes in functional capacity (including 
increased expression of MHC II and co-stimulatory molecules for APC activity) 
(Barkhuizen et al, 2008; Coller et al, 2003; Dagenais et al, 2009; Harris et al, 2006; 
Leppert et al, 2007; Lopez et al, 2008; Magez et al, 2002; Magez et al, 1998; Paulnock & 
Coller, 2001). There is clear evidence that unmethylated CpG deoxyribonucleic acid 
(DNA), released from dead or dying trypanosomes, is recognized by the host innate 
immune system; this toll-like receptor (TLR)-9 ligand is capable of activating macrophages 
in vitro and in vivo (Harris et al, 2006). Nevertheless, GPI residues of the secreted VSG 
are the major contributors for activation of cells of the innate immune system (Magez et al, 
1998; Paulnock & Coller, 2001; Tachado et al, 1997). The GIP-sVSG binds to the type A 
scavenger receptor on the cell membrane (Leppert et al, 2007), and then is internalized 
and processed, initiating a signalling cascade, including activation of nuclear factor kappa-
B (NF-kB) and mitogen-activated protein kinase (MAPK) pathways, and the expression of 
pro-inflammatory genes (Coller et al, 2003; Coller & Paulnock, 2001; Leppert et al, 2007; 
Paulnock & Coller, 2001). An additional key component of macrophage and dendritic cell 
activation is IFN-γ. IFN-γ binds to IFN-γR, generates the formation and phosphorylation 
of signal transducers and activators of transcription 1 (STAT1) homodimers, activating 
downstream pro-inflammatory genes (Leppert et al, 2007). The relative timing of innate 
immune cells exposure to GIP-sVSG and to IFN-γ is critical for the ability of cells to 
become activated for APC functions and, for macrophages, to kill the parasites. If there is 
coincident exposure to significant levels of both IFN-γ and GIP-sVSG (that may occur in 
early infection with activated NK cells releasing IFN-γ in response to IL-12 (not yet 
confirmed experimentally) (Namangala, 2012), or later with IFN-γ derived from T cells 
during activation of the adaptive immune response), increasing cellular activation and 
transcription of pro-inflammatory genes occurs (Coller et al, 2003; Lopez et al, 2008), 
controlling early parasite growth within host tissues. However, if cells are exposed to GIP-
sVSG prior to, or in the absence of sufficient levels of IFN-γ, STAT1 is not phosphorylated 
and the production of trypanocidal factors as well as APC functions are inhibited (Coller et 
al, 2003; Dagenais et al, 2009). These events likely occur as the infection progresses, 
when increasing numbers of parasites release GIP-sVSG prior to sufficient activation of 
new Th1-cell responses for the production of IFN-γ. 
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Therefore, the interplay and timing of parasite and host factors are critical for the 
control of the parasite burden in host tissues and for regulation of host immune 
responses. Nevertheless, during the early stage of infection, type I cytokine responses are 
observed in both susceptible and resistant mice.  
 
7.2.2 Adaptive immune response 
  
The process of innate resistance and acquired immunity are interdependent, in 
which some cells, like macrophages, play a dual role, as initiators of acquired responses 
and as effectors component of cell-mediated immunity (Figure 7). As mentioned before, 
innate immune cells establish an initial pro-inflammatory response at the early stage of the 
infection. These pro-inflammatory molecules activate lymphocytes, mainly cluster of 
differentiation (CD)8+ T cells, to produce IFN-γ, the principal activator of caMϕ. IFN-γ 
production could also result from a direct interaction between parasite products such as 
the trypanosome-derived lymphocyte-triggering factor with CD8+ T cells (Olsson et al, 
1991). Even though, the current paradigm is that VSG-specific Th1 cells and IFN-γ 
regulate the core component of host resistance for this parasitic infection (Schleifer et al, 
1993). Immature CD4+ T lymphocytes are activated by exposure to antigen-MHC II 
complexes on APCs to produce a highly polarized type 1 cytokine response (Dagenais et 
al, 2009; Drennan et al, 2005; Schleifer et al, 1993; Schopf et al, 1998). However, later in 
the disease, the host can set a type 2 immune response to alleviate parasite-elicited 
pathology. The trypanosomes may also induce the production of Th2 cytokines and 
regulatory T-cell activation that results in increased production of IL-10 and transforming 
growth factor beta (TGF-β), both of which suppress an exaggerated protective Th1 
responses and hence promote parasite survival (Magez et al, 2007; Namangala et al, 
2008; Wei & Tabel, 2008). Therefore a type 1 cellular inflammatory response may be 
shifted to a type 2 response, characterized by type 2 cytokines (IL-4, IL-10 and IL-13) 
(produced via CD4+ Th2 cells), which activate macrophages to become alternatively 
activated (aaMφ) and promote B cell maturation into IgG1 (Kaushik et al, 2000; MacLean 
et al, 2001; Namangala et al, 2000b; Sternberg et al, 2005; Uzonna et al, 1999). This 
environment promotes parasite neutralization and allows the infection to proceed into 
chronic phase with minimal pathological manifestations (Baetselier et al, 2001). Actually, 
the activation of an anti-inflammatory response is beneficial for both, the parasite, and at a 
certain time to the host. In one hand there is an increase in arginase activity, leading to 
the production of L-ornithine, a parasite growth factor, on the other hand the depletion of 
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L-arginine (the substrate of NO synthase) leads to a decrease in the levels of cytotoxic 
NO (Vincendeau et al, 2003). Moreover, a control of the host pathology is observed, 
through the control of exacerbated inflammatory response, leading to a longer survival of 
the host and thus increasing parasite transmission probability. In resistant mice model, 
this switch in cytokine profile is described during the late/chronic stages of infection, 
presumably restricting prolonged and exaggerated inflammatory responses (Namangala 
et al, 2009). On the contrary, early mortality in highly susceptible mice is caused by 
enhancement of TNF-α due to exacerbated macrophage activation, excessive INF-γ 
production, and a systemic inflammatory syndrome (Shi et al, 2003; Shi et al, 2006b) 
(Figure 7). 
Regarding the humoral response, T. brucei infection triggers the production of 
immunoglobulin (Ig)M and IgG antibodies. An important feature is the dramatic increase of 
trypanosome-specific and non-specific Ig production induced by cytokine activation of B 
cells (Malvy & Chappuis, 2011). The trypanosome-specific antibodies are protective since 
they mediate parasite clearance, except for the subset of parasites with renewed VSG (as 
described above in detail). Some antibodies are also raised against auto-antigens, 
resulting from aberrant non-specific polyclonal activation of B cells (Hudson et al, 1976; 
Kobayakawa et al, 1979; Williams et al, 1996). These elements contribute to collateral 
tissue damage and immunosuppression. Later in the infection, B-cells become 
suppressed or exhausted, resulting in a total absence of IgG responses and a strongly 
reduced IgM response (Semballa et al, 2004). As the infection progresses, B cell 
lymphopoiesis is shut down in the bone marrow and compensatory extramedullary B 
lymphopoiesis is truncated by apoptosis of transitional B cells thus preventing 
replenishment of mature marginal zone and follicular B cell compartments in the spleen. In 
vitro experiments suggest that living trypanosomes induce cell death in transitional B cells 
through a contact-dependent mechanism, although the mechanism of T. brucei-induced 
transitional B cell depletion in vivo remains to be fully elucidated (Bockstal et al, 2011).  
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Figure 7. A model for induction of protection versus pathogenesis during T. brucei 
infections. Abbreviations: naϊve M cell, naϊve macrophage; M1 or caMϕ, classically 
activated macrophage; M2 (macrophage type 2) or aaMϕ (alternatively activated 
macrophage); TNF/iNOS-producing dendritic cell (Tip-DC), TNF-α and inducible nitric 
oxide synthase producing dendritic cell; NO, nitric oxide; Th, T helper cell. Dotted line, not 
confirmed pathway. [Adapted from (Baetselier et al, 2001; Namangala, 2012)]. 
 
8 Diagnosis 
 
The major reason for diagnosis is the application of appropriate therapeutic and 
prophylactic measures. Other reasons include the need to target and monitor vector 
control or eradication operations, investigations of chemotherapy efficacy and drug 
resistance, and pathophysiological, epidemiological and socio-economic studies. Since 
clinical examinations are not sufficiently specific (Chappuis et al, 2005a; Lejon & Buscher, 
2005), diagnosis relies on laboratory analysis and includes a two-step approach: 
screening and staging (Figure 8).  
Contrary to T. b. rhodesiense infections which typically present higher 
parasitaemia (Pepin & Meda, 2001), and therefore trypanosomes can be identified on a 
peripheral blood smear, in T. b. gambiense infections, the amount of parasites in the 
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bloodstream is generally very low. In T. b. gambiense HAT, the card agglutination test for 
trypanosomiasis (CATT) is the test of choice, once it is a fast and practical serological 
test. Actually is the best-adapted and most efficient screening method, that allows mass 
population screening in endemic areas. This test can be done on serum, capillary blood 
obtained from a finger prick, or blood from impregnated filter papers, and is reported to be 
87–98% sensitive, and 93–95% specific (Brun et al, 2010; Magnus et al, 1978). However 
CATT has limitations, such as the dilutions cut-offs used may lead to false-positive results, 
the cross-reaction events with other parasites which may elicit false positives, and a 
positive result does not constitute an absolute proof of active infection, as CATT can be 
positive three years after treatment. Therefore, after a serological positive result, the 
diagnosis of certitude requires microscopic parasite observation. Once in T. b. gambiense 
infections, parasites detection in blood is very difficult, concentration methods such as the 
microhaematocrit centrifugation (the most used) (Woo, 1970), quantitative buffy coat (the 
most expensive) (Bailey & Smith, 1992), and miniature anion-exchange centrifugation (the 
most sensitive) techniques (Lumsden et al, 1979) should be used. Other highly sensitive 
serological tests, such as immunofluorescence or enzyme-linked immunosorbent assay 
(ELISA), are efficient for T. b. gambiense or T. b. rhodesiense antibody detection, but are 
generally used in non-endemic countries to screen individuals with suggestive clinical 
features or previous exposure (Lejon et al, 1998; Noireau et al, 1988). Polymerase chain 
reaction (PCR) techniques have been used to increase diagnostic accuracy. A 99% of 
sensitivity and a 97.7% specificity was determined for PCR on blood samples (Mugasa et 
al, 2012). This technique is not easily applicable for routine, however the loop-mediated 
isothermal amplification is a more field-adapted PCR that can be used for rapid detection 
of both trypanosome subspecies (Kuboki et al, 2003; Njiru et al, 2008). 
Staging evaluation follows infection confirmation since its crucial to determine early 
or late stage of the disease in order to prescribe proper treatment. Pharmacological 
treatment of CNS disease is far more toxic than early stage drugs (Kennedy, 2008). 
Staging relies on lumbar puncture for detection of trypanosomes in the cerebrospinal fluid 
(CSF) and/or to count white blood cells (WBC). According to WHO criteria, the presence 
of trypanosomes in the CSF or WBC count of more than 5 cells/μl or increased protein 
content (>370 mg/L) defines second-stage disease (WHO, 1998), but there are no clear 
consensus on the cut-offs in WBC counts (Lejon et al, 2003b).  
Present research efforts to improve diagnostic tests and to develop more precise 
staging techniques focus on recombinant or native trypanosome antigens, parasite 
antigens detection methods in blood or CSF, proteomic fingerprinting, low-tech PCR 
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methods, new blood or CSF markers of second-stage disease and alternative              
non-invasive methods for staging (Agranoff et al, 2005; Buguet et al, 2005; Deborggraeve 
et al, 2006; Geiger et al, 2011; Hainard et al, 2009; Hutchinson et al, 2004; Kennedy, 
2010; Lejon et al, 2002; Papadopoulos et al, 2004). Further development and refinement 
of these approaches can be applied in the future, although they must be compared to the 
WHO criteria, made cheap and field adaptable.    
  
 
Figure 8. Decision tree for biological diagnosis and staging of T. b. gambiense HAT, used 
by a research team in Congo, from 2005 to 2009 (Buguet et al, 2009). Villagers were 
submitted to whole blood CATT. CATT positive (Pos) samples were tested for CATT on 
plasma at a 1:4 dilution. CATT plasma 1:4 negative (Neg) people were released. CATT 
positive suspects were examined for the presence of lymph nodes. The lymph nodes were 
punctured, and the fluid was examined microscopically to detect trypanosomes (T). If 
trypanosomes were found (T pos), the suspect was classified as being a patient. In the 
absence of palpable lymph nodes or of trypanosomes in lymph nodes (T neg), blood 
concentration techniques were undertaken. If the capillary centrifugation technique (CTC) 
result was negative, a new blood sample was withdrawn from a forearm vein and passed 
through the miniature anion-exchange centrifugation technique (mAECT). If the latter test 
was also negative, the suspect was released. All patients underwent staging procedures 
consisting of a lumbar puncture and CSF examination. CATT plasma ≥1:16 dilution 
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positive, people are considered as patients, and they undergo lumbar puncture, even if 
they are T neg in the lymph nodes and blood. Three staging possibilities are determined in 
CSF examination: T neg and ≤5 WBC/μL, stage 1; T neg and between 6 and 19 WBC/μL, 
intermediate stage; T pos and/or ≥20 WBC/μL, stage 2. [Adapted from (Bouteille & 
Buguet, 2012)]. 
 
9 Control strategies 
 
 Although more recently the number of HAT cases has been reduced, open 
economy and market globalization, with constantly increasing business travel, immigration 
and worker exchange, along with chances of disease migration, can contribute for HAT 
dissemination. Moreover, population growth, global warming and climate changes can 
modify the geographic distribution of parasites and vectors. The absence of an effective 
vaccine and a chemotherapy far from ideal call up for specific actions like, development of 
approaches to control vectors, identification and validation of new drug targets, 
development of new trypanocidal drugs, improvement in practical diagnostic techniques 
and improvement in understanding HAT pathophysiology (Barrett et al, 2003). Once HAT 
probably will not be defeated in the near future, it is imperative that international, non-
governmental and philanthropic organisations and pharmaceutical companies join forces 
and efforts to fight this disease. 
 
9.1 Tsetse fly control 
 
 Since there is no vaccine against HAT and chemoprophylaxis is not recommended 
due to the toxicity of the drugs, the only preventive measure is the reduction of tsetse fly 
bites. Vector control has been a way to limit rhodesiense HAT although, it was only 
recently applied in gambiense HAT (Solano et al, 2013). During the colonial era, many 
efforts were used to break the tsetse transmission cycle, as large tracts of land were 
cleared of vegetation and wild mammals that could act as a reservoir of T. b. rhodesiense 
were destroyed (Allsopp, 2001; Schofield & Maudlin, 2001). Besides being effective, such 
methods are not employed today. Synthetic insecticides were the next major approach in 
transmission control. Ground and aerial insecticides spraying have had considerable 
success, although ecological considerations now limit indiscriminate use of insecticides 
(Grant, 2001). Moreover these processes are not only costly, but are also labour and 
management intensive. Another useful way of control, but on a much smaller scale, 
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implies tsetse traps and target. The flies are attracted to visual cues provided by large 
expanses of blue or black cloth and chemical clues such as acetone, a tsetse-attracting 
component of cow’s breath that can be used in the traps. Actually, the odour-baited traps 
and the insecticide-coated animal reservoir on which tsetse flies feed, have been very 
useful (Hargrove et al, 2000). More recently, the sterile insect technique (SIT), which 
involves the release of sterile flies into wild populations to compete with natural males, 
was very publicised (Vreysen, 2001). As a matter of fact, this strategy contributed to 
tsetse eradication from the island of Unguja (Zanzibar) in 1994 (Vreysen et al, 2000). The 
enormous costs and the large numbers of irradiated sterile males needed makes this 
control method unfavourable (Rogers & Randolph, 2002). Nowadays, investigations are 
underway to identify factors that influence parasite transmission as a way to intervene at 
the level of the fly. There is still a huge deficit in what is known on tsetse biology, which 
should be overcome with the purpose of bringing new techniques for vector control. 
 
9.2 Vaccines 
   
 Vaccines are unlikely to be developed against HAT as a result of the different      
T. brucei defence strategies. In fact, several attempts have been made to come out with a 
vaccine, but this goal has never been achieved. 
 When VSGs were discovered, as the parasite main protection against the host 
immune system, researchers got excited to have an exposed epitope that they could 
purify, and use to develop a vaccine. Since early, research suggested that the VSG 
repertoire in injected metacyclic trypanosomes was limited to no more than a dozen VSGs 
(Barry et al, 1979; Crowe et al, 1983; Esser et al, 1982; Le Ray et al, 1978), some authors 
propose a vaccine using irradiated metacyclic trypanosomes, which resulted in promising 
preliminary results (Esser et al, 1982). However, the subsequent discovery of the mosaic 
nature of expressed VSGs in bloodstream forms, which is an “illimitable” repertoire (Hall et 
al, 2013; MacGregor et al, 2012; McCulloch & Horn, 2009), and the fact that the main Ig 
response elicited is the short lived IgM isotype, made the exposed antigen vaccination 
programmes fall into disuse. 
 As a consequence of these results, the non-variable antigen-based vaccines were 
begun to be thought as an alternative. In order to bind or uptake exogenous molecules, 
trypanosomes express a number of non- or less-variable surface antigens. The flagellar 
pocket is an organelle that contains conserved receptors and is involved in 
endocytosis/exocytosis, cell division and polarity, and immune evasion. Also, embedded 
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under the VSG coat are multiple copy-number of invariant surface glycoproteins (ISG). 
Trypanosome membrane associated trans-sialidases, that transfer sialic acid from 
sialylated glycoconjugates from the host cell surface to acceptor molecules on the 
parasite’s surface, and cation pumps, important for cation homeostasis, were also taken 
into consideration. Moreover trypanosomes require a highly developed cytoskeleton, 
integral to motility, flexibility and mechanical stability. Thereby, cytoskeleton proteins 
constitute an interesting group of non-variable antigens, such β-tubulin, actin and 
microtubule-associated proteins. All these molecules were thought as possible 
candidates, and have been used in experimental vaccination schemes, however initial 
positive results obtained were a result of a general immune system boost at a nonspecific 
level and did not involved immune memory (Li et al, 2007; Li et al, 2009; Lubega et al, 
2002; Radwanska et al, 2000; Ramey et al, 2009; Rasooly & Balaban, 2004; Silva et al, 
2009). As mentioned above, T. brucei infections compromise host humoral immune 
competence resulting in the loss of B cell responsiveness (Radwanska et al, 2008), 
although human B-cell dysfunction might not be that severe as in mouse models (Lejon et 
al, 2014). This “memory” destruction appears to be permanent, explaining why the large 
majority of vaccines trailed up until now have shown promising initial results, but no long-
term memory. Moreover, this could be a worry, not just for future trypanosome vaccination 
programmes, but also for vaccination programmes against many other infections. 
 The problems encountered with direct anti-trypanosome vaccination could be 
circumvented by alternative approaches such as transmission blocking vaccines (TBVs). 
TBVs can involve a number of strategies, (1) interruption of the parasite life cycle in the 
vector by targeting specific interactions required for parasite development (Maudlin et al, 
1984; Nantulya et al, 1980), (2) reduce vector fitness by reducing the fecundity and 
survival (Kinyua et al, 2005; Nogge & Giannetti, 1980), and (3) block the parasitaemia 
onset in the host by reducing the parasite transmission through immunizing against 
exposed salivary antigens. The feasibility of TBVs is supported by a number of results 
obtained in other infections models (de la Fuente et al, 1998; Outchkourov et al, 2008; 
Saraiva et al, 2006; Willadsen et al, 1995), and therefore may be possible in 
trypanosomiasis. Several antigens have now been proposed as candidates for 
experimental TBV vaccination schemes, but it is still unclear whether TBVs can be 
realistically adapted to the field conditions (Magez et al, 2010).  
 Another alternative strategy to anti-trypanosome vaccination is the so-called anti-
disease vaccine. There is a significant disparity in the disease progression in cattle 
infected with T. congolense, enabling animals to be labelled as trypanosusceptible and 
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trypanotolerant. The main difference between trypanosusceptible and trypanotolerant 
animals is that the latter are able to mount an anti-congopain IgG, an Ig produced by 
leucocytes of the adaptive immune response. Congopain is a cathepsin-L like cysteine 
protease in T. congolense trypanosomes and is under investigation as a vaccine 
candidate for cattle (Lalmanach et al, 2002). Since promising results were achieved, 
congopain is a realistic anti-disease vaccine option against animal trypanosomiasis, 
although it remains to be elucidated if vaccine-induced memory retains its protective 
capacity for prolonged periods of time during infection. A liposome-based GPI-vaccination 
strategy was also developed in order to prevent excessive immune activation upon 
infection. This proposal resulted in parasitaemia control, prolongation of host survival and 
limitation of infection-associated complications like anaemia, weight-loss and impairment 
in locomotion (Stijlemans et al, 2007), but again this response does not appear to involve 
the induction of B cell memory. 
 The technical procedures used during vaccination experiments can lead to 
misleading interpretations; timing between immunization and challenge, number of boosts, 
administration route, infection dose, parasite strain and animal route raise important 
doubts (Magez et al, 2010). Moreover, the absence of an effective vaccine in combination 
with the knowledge of the obstacles in HAT vaccination field, strongly justifies an 
improvement of existent chemotherapy, validation of new targets for drug intervention, 
and the discovery of efficient antiparasitic drugs. 
 
9.3 Chemotherapy  
 
 If untreated, HAT is almost 100% fatal (Jamonneau et al, 2012). Chemotherapy is 
still unsatisfactory and ineffective against both stages of the disease, and for both T. b. 
rhodesiense and T. b. gambiense subspecies. The therapy against HAT is lengthy, costly 
and toxic and requires parenteral administration. There are currently four licensed 
treatment regimes: pentamidine, suramin, melarsoprol and eflonithine (Figure 9). 
Nifurtimox-eflornithine combination therapy besides being used off-license, was placed on 
the WHO list as an essential medicine. Only the mode of action of eflornithine is totally 
understood despite many of these drugs have been around for decades. All anti-
trypanosomal drugs are donated to WHO by Sanofi-Aventis (pentamidine, melarsoprol 
and eflornithine) and Bayer Leverkusen (suramin, nifurtimox) and then distributed in the 
field (Bouteille & Buguet, 2012).  
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9.3.1 Pentamidine 
 
 Pentamidine isethionate (Pentacarinat®) is an aromatic diamidine used against 
first-stage disease caused by T. b. gambiense infection. Pentamidine is unsuitable for 
treatment of advanced disease, in part because serum binding and tissue retention 
reduces blood-brain barrier traversal (Barrett et al, 2011). Nevertheless, effective cases 
were reported against trypanosomiasis during the early phase of CNS involvement (Bray 
et al, 2003; Doua et al, 1996), despite pentamidine that does cross the blood-brain barrier 
is cleared by efflux transporters (Sanderson et al, 2009). It was first used in 1940s, either 
as a prophylactic as well as a curative agent (Bacchi, 1993). Four mg/kg are given daily, 
or on alternate days by intramuscular injection for 7-10 days (Sands et al, 1985). When 
given by intramuscular injection, site pain and transient swelling, abdominal pain and 
gastrointestinal problems, and hypoglycaemia (5–40%) are the most frequently reported 
adverse events. The drug enters principally via the purine transporter 2 (P2) aminopurine 
permease (Carter et al, 1995), however low and high affinity pentamidine transporters 
(LAPT1 and HAPT1, respectively) and a plasma membrane H+ ATPases, HA1-3, also 
contribute to uptake (Alsford et al, 2012; De Koning, 2001). Pentamidine action appears to 
be multifactorial possibly due to the binding to DNA, in regions of the minor groove rich in 
adenine and thymine (Moreno et al, 2010). It is also known to collapse the mitochondrial 
membrane potential, and inhibit the F1F0-ATPase (Lanteri et al, 2008). Consequently, it is 
likely that the antitrypanosomal activity of pentamidine is the result of selective 
accumulation, leading to multiple deleterious effects, rather than effects on a specific 
‘diamidine target’ (Delespaux & de Koning, 2007). Confirmed pentamidine failures are 
rare, likely due to low drug-resistance. Although massive use of pentamidine as a 
chemoprophylactic in the Democratic Republic of Congo may have selected for reduced 
sensitivity to this drug (Kayembe & Wery, 1972). Only recently through genome-scale 
RNA interference target sequencing (RIT-seq) screens, pentamidine loss-of-function was 
linked to melarsoprol-pentamidine cross-resistance (Alsford et al, 2012). The 
aquaglyceroporin 2 (AQP2), a membrane protein that facilitate the transport of water and 
small neutral solutes across membranes in several organisms, was discovered to facilitate 
drug accumulation and is also linked to clinical cases of resistance for both drugs (Baker 
et al, 2012). This was an important finding since the cross-resistance phenotype could not 
be explained based only in P2 and HAPT transporters.  
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9.3.2 Suramin 
 
 Suramin (Germanin®) is a sulphonated naphthylamine used for first-stage T. b. 
rhodesiense disease. It was discovered by Oskar Dressel and Richard Kothe at Bayer in 
1916 (Haberkorn et al, 2001). Suramin is administered by intravenous injections every 3-7 
days for 31 days (20mg/Kg, with a maximum of 1g per injection) (Barrett et al, 2007). 
Adverse drug reaction include acute and late hypersensitivity, nephrotoxicity, peripheral 
neuropathy, and bone marrow toxicity with agranulocytosis and thrombocytopenia 
(Kennedy, 2013). Suramin is selectively concentrated by trypanosomes through receptor-
mediated endocytosis when conjugated with low-density lipoproteins (LDL) 
(Vansterkenburg et al, 1993). However, evidence for a non-LDL uptake in insect-stage 
cells was proposed (Pal et al, 2002). A high-throughput sequencing of a suramin-selected 
RNAi library identified a cohort of proteins contributing to drug efficacy (Alsford et al, 
2012). In a proposed model a 75 kDa ISG (ISG75) acts as a major receptor for suramin 
delivering the drug into the degradative arm of the endocytic pathway. Suramin is 
delivered to the lysosome by either the serum protein carrier being cleaved by cathepsin-L 
upon reaching the lysosome, or by ISG75 being degraded at the late endosome. Once 
free, suramin may inhibit lysosomal enzymes and may also escape into the cytoplasm via 
the major facilitator superfamily transporter (MFST), resulting in inhibition of other cellular 
processes (Alsford et al, 2013). This large negatively-charged polyanion appears to inhibit 
unspecifically many positively-charged enzymes, so it is difficult to conclude which may be 
the determinant of drug action (Wang, 1995). More recently it was shown that this 
compound inhibits a number of glycolytic enzymes (Barrett et al, 2007), such as pyruvate 
kinase by binding the ATP site (Morgan et al, 2011). Resistance to suramin was reported 
in the 1950s (Barrett et al, 2007). The mechanisms for suramin resistance are not yet 
elucidated but may involve changes in ISG75 and in proteins of the endocytic apparatus, 
including AP-1 (adaptin complex-1), GLP-1 (Golgi/lysosomal protein-1), EMP70 
(endosomal membrane protein 70), MFST, p67 (major lysosomal glycoprotein), and 
cathepsin-L (Alsford et al, 2012). 
 
9.3.3 Melarsoprol 
 
 Melarsoprol (Mel B, Arsobal®), a melaminophenyl arsenical synthesised in 1949, is 
still the most powerful trypanocide available to cure both stages of T. b. gambiense and T. 
b. rhodesiense HAT (Friedheim, 1949). However, is the only effective drug against late 
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stage T. b. rhodesiense infections. Melarsoprol is usually administered intravenously and 
the recommended course is 10 days long with daily injections of 2.2 mg/kg (Schmid et al, 
2005). Melarsoprol injections are extremely painful and toxic, and the most important 
reaction is a post-treatment reactive encephalopathy in 10% of patients, half of whom die, 
leading to an overall mortality of about 5% (Blum et al, 2001). Skin reactions, peripheral 
motoric, sensorial neuropathies and thrombophlebitis can also occur (Brun et al, 2010). 
The parasites lyse rapidly when exposed to melarsoprol (Meshnick et al, 1978). It is 
believed that melarsoprol is converted in the host to melarsen oxide, which is then 
transported by P2 transporter. Melarsen oxide acts mainly through the formation of a 
stable adduct with trypanothione [T(SH)2], known as MelT, which is an inhibitor of 
trypanothione reductase (TR), a central enzyme of the parasite thiol/disulfide redox 
balance (Fairlamb, 2003; Fairlamb et al, 1989). Additionally, melarsoprol also formed 
adducts with lipoic acid (Fairlamb et al, 1992) and inhibits glycolysis (Van Schaftingen et 
al, 1987). In some T. b. gambiense HAT areas, melarsoprol treatment failures have 
already reached levels of 30% (Brun et al, 2001; Legros et al, 1999; Stanghellini & 
Josenando, 2001). As mentioned below in the pentamidine section, the cross-resistance 
to melarsoprol was firstly associated with P2 transporter, once Tbat1 gene deletion and 
loss-of-function mutations were described in melarsoprol resistant strains generated in the 
laboratory (Bridges et al, 2007; Maser et al, 1999; Stewart et al, 2010), and the same 
mutations were also found in T. brucei spp. field isolates (Kazibwe et al, 2009; Matovu et 
al, 2001; Nerima et al, 2007). In addition, Tbat1-null trypanosomes were found to have 
lost the adenine-sensitive component of adenosine and melarsoprol-import (Geiser et al, 
2005; Matovu et al, 2003). More recently and as already reported in pentamidine section, 
aquaglyceroporin 2 (AQP2) loss-of-function was linked to melarsoprol-pentamidine cross-
resistance (Alsford et al, 2012). 
 
9.3.4 Eflornithine  
 
 Eflornithine (DL-α-Difluoromethylornithine, DFMO; OrnidylTM) was developed in the 
1970s (Janne et al, 1981). Due to the unacceptable toxicity of melarsoprol, eflornithine is 
the first line treatment for the second stage T. b. gambiense disease (Balasegaram et al, 
2006; Chappuis et al, 2005b; Priotto et al, 2008). The use of this drug against T. b. 
rhodesiense is not advised, because this parasite is innately less susceptible (Iten et al, 
1997). Eflornithine treatment is administered intravenously. The high IC50 and the low   
half-life dictate the use of large quantities of the drug (nearly 4 kg for a 50 kg patient) for 
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the treatment regime of 56 infusions over 14 days (Brun et al, 2010). It is logistically 
difficult to deliver and to administer in the rural areas leading to a continued reliance on 
melarsoprol in impoverished areas. Adverse drug reactions include bone marrow toxicity 
leading to anaemia, leucopenia, and thrombocytopenia (25–50%), gastrointestinal 
symptoms (10–39%), and convulsions (7%) (Burri & Brun, 2003). Eflornithine is the only 
drug with a well understood mode of action, which irreversibly inhibits ornithine 
decarboxylase (ODC) an enzyme of the polyamine pathway (Grishin et al, 1999; Poulin et 
al, 1992). Eflornithine is only active against T. b. gambiense forms of HAT possibly due to 
a reduced rate of ODC turnover in this subspecies (Iten et al, 1997). Surprisingly, it is the 
equal effective inhibition of mammalian ODC. The pronounced differences in turnover 
rates between host and parasite ODC have been invoked to explain selectivity (Heby et 
al, 2003), although and more important, is the fact that mammalian cells are able to 
induce high-affinity polyamine transporters in response to polyamine starvation, whereas 
T. brucei appears to have a limited capacity to scavenge polyamines present in serum 
(Fairlamb, 2003). ODC inhibition by eflornithine leads to an increase in levels of ornithine, 
S-adenosylmethionine (AdoMet) and decarboxylated S-adenosylmethionine (dcAdoMet), 
and a decrease in putrescine, spermidine (Spd) and T(SH)2 (Bacchi & Yarlett, 1993; 
Fairlamb et al, 1987; Xiao et al, 2009). Spd conjugates with two molecules of GSH to form 
T(SH)2, which protects the parasite from oxidative stress. The decrease in Spd and 
consequently in T(SH)2 is therefore harmful for the parasites (Heby et al, 2007; Krauth-
Siegel & Comini, 2008). Downstream of these metabolic changes, a generalized decrease 
in DNA, RNA and protein synthesis, including synthesis of VSG (Bitonti et al, 1988; Yarlett 
& Bacchi, 1988) and morphological and biochemical changes like differentiation into 
stumpy forms can occur (Giffin et al, 1986). The fact that the trypanosomes are unable to 
undergo antigenic variation facilitates the death of the parasites by the host immune 
system (Barrett et al, 2007). Concerning resistance, it appears that eflornithine is 
transported into trypanosomes via an amino acid transporter (TbAAT6) and that the loss 
of this transporter result in eflornithine resistance (Baker et al, 2011; Schumann Burkard 
et al, 2011; Vincent et al, 2010). Whether this mechanism is also used in isolates from the 
field has yet to be established (Barrett et al, 2011).  
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Figure 9. Licensed current therapies against HAT. (A) Structures of drugs used to treat 
early and late stage disease. (B) Table with standard treatment for HAT and main adverse 
reactions. [Adapted from (Brun et al, 2010; Fairlamb, 2003)]. 
 
9.3.5 Eflornithine-nifurtimox combination therapy 
 
 The new nifurtimox/eflornithine combination therapy (NECT) was advanced in 
2009 (Opigo & Woodrow, 2009; Priotto et al, 2009) for the treatment of late-stage T. b. 
gambiense, after showing equivalent to better efficacy than eflornithine alone in clinical 
trials (Yun et al, 2010). NECT has not yet been tested against T. b. rhodesiense (Phillips, 
2012). In combination, nifurtimox is given orally (daily dose of 15 mg/kg, three times a day 
for 10 days) and the eflornithine infusions are reduced in frequency (daily dose of 400 
mg/kg in 14 slow infusions, every 12 hours for 7 days). The administration of the 
combination therapy compared to eflornithine monotherapy is much easier to implement. 
NETC allows the use of lower doses of each drug, being logistically easier to transport 
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due to the lower quantities required and the reduction in refrigeration costs (Yun et al, 
2010). NECT generates adverse events, mainly abdominal pain, vomiting and headache, 
however, the severity of these events is relatively low compared to previous treatments, 
and the majority of patients treated make a good recovery (Alirol et al, 2013; Priotto et al, 
2009). Nifurtimox is a 5-nitrofuran pro-drug that has been used for more than 40 years to 
treat Chagas disease. In trypanosomes the drug must undergo activation by 
nitroreduction, undertaken by NADH-dependent type I nitroreductases (Wilkinson et al, 
2008). Recent evidences on the mode of action of nifurtimox showed the formation of an 
open chain nitrile that cause cellular death due to its interaction with a range of cellular 
targets (Hall et al, 2011). With regard to resistance, a genome-scale RNAi library, to 
screen nifurtimox and eflornithine resistance, confirmed previous findings that 
nitroreductase loss-of-function is the major potential mechanisms of resistance to 
nifurtimox (Baker et al, 2011; Wilkinson et al, 2008). 
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1 Target validation  
 
 Trypanosomes are some of the earliest diverging members of the Eukaryotae and 
share several biochemical peculiarities that have stimulated research to discover new 
drug targets. In addition to the excessive toxicity of the available drugs, there is a steady 
loss of effectiveness due to consistently arising drug resistant parasites. Therefore is 
imperative the discovery and validation of new drug targets. There are some crucial points 
to consider for target selection, such as: absence from the host or substantially different 
so that it can be explored as a target; important for the survival or fitness of the pathogen; 
expressed in a parasite life-cycle stage suitable for drug intervention; and finally, a target 
that can be assayable and druggable (Barrett et al, 1999; Chawla & Madhubala, 2010; 
Pink et al, 2005). Target validation, through genetic and/or biochemical approaches, is the 
starting point of a rational course to chemotherapy. 
 
1.1 Genetic approaches 
 
 The completion of the T. brucei genome project (Berriman et al, 2005) allows 
access to a wealth of information, available at genome databases, like GeneDB 
(http://www.geneDB.org) and TriTrypDB (http://tritrypdb.org). The genome databases 
availability combined with genetic tools, such us generation of null mutants (gene 
knockout) and the RNAi [messenger RNA (mRNA) knockdown, shown to occur in T. 
brucei (Ngo et al, 1998)], has allowed the discovered and validation of new drug targets.  
 
1.1.1 Gene knockout 
 
 The gene knockout strategy requires the introduction into the parasite, usually by 
electroporation, of a linear DNA construct containing an antibiotic resistance gene, flanked 
by 5’ and 3’ DNA sequences from the targeted gene. The replacement of the natural gene 
occurs via homologous recombination. The transgenic parasites are selected through 
antibiotic resistance (Figure 10A) (Barrett et al, 1999). In T. brucei, selective gene 
replacement can be performed directly on procyclic forms (insect stage) or on 
bloodstream forms (mammalian stage). It is important to guarantee that any phenotype 
observed results from the deletion of the gene of interest. This is confirmed when the 
phenotype is restored upon target gene reintroduction (genetic complementation). Gene 
knockout strategies are usefull when: (1) genes can be deleted from the parasite, which 
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remain viable in all life-cycle stages, (2) genes can be deleted from the parasite, with little 
effect on viability, however switching conditions, such as changing the availability of 
nutrients and growth factors, can lead to cell death, (3) genes can be deleted from one 
life-cycle stage with little or no effect on viability but are found to be essential in another 
life-cycle stage, and finally (4) genes cannot be deleted from any life-cycle stage. In the 
latter, removal of the second copy would be lethal to the parasite, therefore a conditional 
knockout (cKO) can be a solution; after the first allele has been knocked out, a 
tetracycline (tet) regulatable copy of the gene coding sequence is inserted in the 
ribossomal RNA intergenic locus prior to the removal of the second endogenous allele 
(Figure 10B). Meaning that the second allele is effectively removed only in the presence of 
tet. The parasite death upon removal of tet (which represses transcription of the 
regulatable allele) proves undoubtedly that the gene is essential (Merritt & Stuart, 2013).  
 In contrast, there are other genes in which this procedure can be misleading: (1) 
genes that encode a protein that activates a pro-drug, (2) genes that encode a protein 
whose activation by a drug is toxic, (3) genes that encode an enzyme whose activity is 
unimportant but that is an essential building block of an essential enzyme complex (gene 
deletion would be lethal, but enzyme inhibition would have no significant effect), and lastly 
(4) gene that encode an enzyme whose autocatalytic processing is inhibited by a drug, 
leading to the lethal accumulation of the pro-protein (Barrett et al, 1999).  
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Figure 10. Gene knockout strategies. Transfection scheme to create null cell lines (A) and 
conditional null cell lines (B). [Adapted from (Merritt & Stuart, 2013)].  
 
1.1.2 RNA interference 
 
 In 1998, T. brucei was the first protozoan parasite in which RNAi was shown to be 
functional (Ngo et al, 1998). RNAi purpose has been proposed to promote genome 
stability by silencing mobile elements and repeats (Kolev et al, 2011). The RNAi 
machinery comprises two dicer-like enzymes, DCL1 (cytoplasmic) and DCL2 (nuclear), 
which process long double-stranded RNAs (dsRNAs) into small sections of small 
interfering RNAs (siRNAs) (of approximately 25 nucleotides) in the cytoplasm and the 
nucleus, respectively (Figure 11). Nuclear TbDCL2 initiates the process by targeting 
dsRNAs of sense and antisense transcripts from retroposons and repeats (Shi et al, 
2006a). Cytoplasmic TbDCL1 targets the dsRNA molecules produced by TbDCL2 and 
any nucleic or cytoplasmic dsRNA still unprocessed (Roberts et al, 1972). RNA 
Interference Factor 5 (TbRIF5) was very recently demonstrated to act in partnership with 
TbDCL1 and to be necessary for cytoplasmic and not nuclear RNAi (Barnes et al, 2012). 
T. brucei first Argonaute protein (TbAGO1) targets siRNAs products from both Dicers 
(Durand-Dubief & Bastin, 2003; Shi et al, 2009; Shi et al, 2004a; Shi et al, 2004b). Duplex 
siRNAs were shown to increase and avoid association with TbAGO1 in the absence of 
TbRIF4 (Barnes et al, 2012). AGO1 unwound the siRNAs fragments to form single-
stranded RNAs (ssRNAs). The ssRNAs display amenable sequences that recognize 
specific mRNAs, which are then targeted and degraded by the RNAi-induced silencing 
complex (RISC). In the very beginning, it was disappointing to discover that the effect on 
the downregulation of the target mRNA achieved was only transient and lasted about one 
cell cycle. The great evolution of T. brucei RNAi technology was driven not only by the 
knowledge of the RNAi endogenous components, but also by the development of vectors 
for inducible and heritable expression of dsRNAs (Inoue et al, 2002; Wirtz & Clayton, 
1995; Wirtz et al, 1999). RNAi is greatly used to knockdown the expression of a specific 
mRNA in African trypanosomes for examining the function of its protein (Inoue et al, 
2002). When RNAi is used as a tool, dsRNA induces sequence-specific silencing of a 
query gene through degradation of the complementary RNA in the cell (Owino et al, 
2008). Indeed, it circumvents the necessity of generating double knockout (dKO), which is 
a requirement for such studies in diploid organisms; hence it is a simpler and faster 
method. RNAi has been shown to occur in T. brucei (Ngo et al, 1998), Trypanosoma 
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congolense (Inoue et al, 2002) and Leishmania subgenus Viannia (Lye et al, 2010) but not 
in Trypanosoma cruzi (T. cruzi) (DaRocha et al, 2004) and Leishmania subgenera 
Leishmania and Sauroleishmania (Robinson & Beverley, 2003). However, since T. cruzi 
and Leishmania spp. share 76% of genes with T. brucei (El-Sayed et al, 2005), some data 
obtained from RNAi in T. brucei can be extrapolated to those organisms. Besides RNAi 
proved to be a great tool, it is important to keep in mind all the limitations inherent to this 
technique (Owino et al, 2008): (1) the "background" expression from the "repressed" 
promoters affects selection of suitable transformants (Alibu et al, 2005; Chen et al, 2003; 
Wang et al, 2000; Wirtz et al, 1998), (2) the development of RNAi revertants (Chen et al, 
2003), (3) the variation in regulation of constructs expression due to availability of various 
sites for integration (Alsford et al, 2005; Biebinger et al, 1996), (4) the difficulty in 
generating recombinant bloodstream forms (Alsford et al, 2005), (5) the possible 
integration of the constructs in unanticipated regions, rather than the transcriptionally 
inactive rDNA locus affecting more than one protein (Motyka et al, 2004), and (6) the 
inability to achieve a complete abolishment of gene function (Motyka et al, 2004). Indeed, 
RNAi-silenced gene can elicit phenotypes similar to those of genetic null mutants, 
however for some cases only the full ablation of all copies can warrant the complete 
disruption of gene function. This is particularly true for abundant proteins or for enzymes 
with activity that is difficult to silence completely (Balana-Fouce & Reguera, 2007). 
Despite these limitations, researchers have been expanding and improving RNAi 
technology; from testing individual genes, passing to small-scale and genome wide RNAi 
screen, to finally ending up with RIT-seq (Alsford et al, 2011; Morris et al, 2002; 
Subramaniam et al, 2006; Wurst et al, 2009). Other milestones in RNAi technology are in 
vivo mRNA knockdown within a infection mouse model (Abdulla et al, 2008) and RNAi 
complementation, through introduction of an ectopic copy of a protein with the same 
biological function but having no more than 13 nucleotide stretches of identity 
(Sienkiewicz et al, 2010).    
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Figure 11. RNAi pathway in T. brucei. The two dicer-like enzymes, cytoplasmic DCL1 and 
nuclear DCL2, process dsRNAs into siRNAs duplexes in the cytoplasm and the nucleus, 
respectively. AGO1 is programmed with single stranded “guide” siRNA, following siRNA 
strand separation, loading and modification to form the RISC, which then cleave and 
degrade the target mRNA. [Adapted from (Balana-Fouce & Reguera, 2007; Kolev et al, 
2011)]. 
 
1.2 Biochemical approaches 
 
  A successful protein biochemical characterization and validation has to comply 
with multiple factors. The expression and purification of the target protein in a soluble and 
active form is required in a biochemical assay. In vitro biochemical characterization 
studies require a large quantity of highly pure protein. Escherichia coli (E. coli) is the most 
widely used prokaryotic organism for protein production (Khow & Suntrarachun, 2012). In 
addition, fusion tags coupled to recombinant proteins have enabled purification of almost 
any protein, enhancing protein yield and solubility as well as promoting proper folding of 
the target protein (Arnau et al, 2006; Esposito & Chatterjee, 2006). The most frequently 
used fusion tags are the affinity tags; exogenous residues that bind strongly to a chemical 
ligand or antibody. This high affinity enables a high degree of purification of the target 
protein. Proteins in which native purification strategies cannot be achieved, denaturing 
purification conditions have to be used. However the protein’s native state and its 
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functional capacity is not always achieved subsequent to denaturation, as a result of 
insufficient refolding (Kathir et al, 2005). The acquisition of the active protein is followed by 
the development and optimization of a functional assay to determine the best working 
conditions for the target (Sidoli et al, 2006). After the establishment of a functional assay, 
biochemical assays are used for kinetic studies (Cleland, 1967). The fundamental concept 
of enzyme kinetics is conveyed by Michaelis-Menton, which allows the measure of the 
catalytic constants (Km, Vmax and kcat) (Cleland, 1967). This can in turn be used to 
characterize the type of inhibition by which a drug inhibits the enzyme activity 
(competitive, uncompetitive and non-competitive inhibition), and to determine the 
inhibitory constant (Ki) and the inhibitory concentration that reduces enzyme activity by 
50% (IC50) (Robertson, 2005; Swinney, 2004). Confirmed enzyme inhibitory compounds 
are subsequently tested for cytotoxicity in the cells, before a compound is regarded as a 
good lead. The value of the inhibitor can be limited by the lack of understanding how and 
where it binds to the target protein. Without these data, it can be difficult to improve 
potency, evaluate specificity, and fully explain cellular phenotypes resulting from drug 
treatment. Methods to identify the binding site of the inhibitor include structural studies (X-
ray crystallography (Hassell et al, 2007), nuclear magnetic resonance (NMR) 
spectroscopy (Pellecchia et al, 2008), computational docking (Mobley & Dill, 2009), and 
photo-crosslinking (Robinette et al, 2006)). Mutagenesis studies are frequently used to 
validate the binding sites suggested by the methods described above (Claustre et al, 
2002). The high throughput screening of chemical libraries, was a huge step to speed the 
finding of inhibitors and allows a rapidly screen of existing compounds. With the latter, 
financial constrains involved in drug development are reduced, which is frequently cited as 
a major reason for not pursuing drug development programmes against diseases of 
developing world (Barrett et al, 1999).  
 
2 Targeting attractive metabolic pathways 
 
 The overall metabolism in eukaryotes is considerable conserved, however a 
substantial variability can be noted in enzymatic characteristics, pathways, cellular 
compartments and regulatory mechanisms when species are compared. Notably, T. 
brucei presents a number of features that are distinct/absent from those seen in other 
organisms, including mammalian cells. T. brucei has appealing metabolic pathways and 
unusual biological features that have been studied for drug target validation and to 
rationally design therapeutic drugs (Gull, 2002).  
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2.1 Polyamine metabolism  
 
The enzymes belonging to the polyamine pathway are required for polyamines 
synthesis, which play pivotal roles in protein/nucleic acid synthesis and cell 
proliferation/differentiation, and in the synthesis of the unique redox-cofactor, T(SH)2, 
crucial for the antioxidant defenses of parasites (Willert & Phillips, 2008). ODC catalyzes 
the first step in the polyamines biosynthesis, through decarboxylation of ornithine to 
putrescine (Figure 12). S-Adenosylmethionine decarboxylase (AdoMetDC) generates 
dcAdoMet, which serves as the aminopropyl group donor for Spd and spermine (Spm) 
synthesis. The latter reactions are catalyzed by Spd synthase (SpdSyn) and Spm 
synthase (SpmSyn), respectively. Interestingly, T. brucei has different features compared 
to human polyamine metabolism; (1) ODC and AdoMetDC have long half-lives, (2) 
appears to lack SpmSyn, and (3) exhibits negligible putrescine and uptake capacity (Heby 
et al, 2007; Heby et al, 2003) (Figure 12). T. brucei ODC knockout cell lines require 
exogenous putrescine for proliferation (Li et al, 1996). When null mutants of bloodstream 
forms were injected into mice, the parasites were unable to multiply and were quickly 
cleared from the blood (Li et al, 1998). Not surprisingly, was that ODC knockdown also led 
to cell death (Xiao et al, 2009). Nowadays, ODC is used in the field as drug target against 
HAT. As mentioned in the chemotherapy section, eflornithine interacts irreversibly with 
ODC and is the reference drug for the neurological stage of T. b. gambiense HAT (Grishin 
et al, 1999; Poulin et al, 1992). AdoMetDC is protein is activated by heterodimer formation 
with a catalytically dead homolog termed prozyme, found only in trypanosomatids (Willert 
et al, 2007). The generation of inducible AdoMetDC RNAi and prozyme cKOs in the 
mammalian blood stage led to a reduction in Spd and T(SH)2 pools, and parasite death 
(Willert & Phillips, 2008). Inhibitors of AdoMetDC have also been shown to be potent 
trypanocidals (Bacchi et al, 1996). The functional importance of SpdSyn was also 
disclosed in bloodstream forms, using a tetracycline-inducible RNAi system. Down-
regulation of the corresponding mRNA correlated with a decrease in intracellular Spd 
levels and cessation of growth (Taylor et al, 2008; Xiao et al, 2009). All these results show 
undoubtedly that the polyamine metabolism is a very appealing pathway for drug 
development. Comparative modeling and site-directed mutagenesis studies indicate that 
sufficient differences exist in the structures of the polyamine biosynthetic enzymes. 
Therefore it is possible to design structure-based inhibitors that will selectively kill the 
parasites while exerting minimal or at least tolerable effects on mammalian host (Heby et 
al, 2007). 
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Figure 12. Human host cell and T. brucei polyamine pathways. (A) Polyamine pathway in 
mammalian cells. (B) Polyamine and T(SH)2 biosynthetic pathway in T. brucei parasites. 
Abbreviations: ARG, arginase; AdoMet, S-adenosylmethionine; AdoMetDC, S-
adenosylmethionine decarboxylase; SAT, N1-acetyltransferase specific for spermidine and 
spermine; dcAdoMet, decarboxylated S-adenosylmethionine; MTA, methylthioadenosine; 
AcSpd, acetylated spermidine; AcSpm, acetylated spermine; ODC, ornithine 
decarboxylase; PAO, polyamine oxidase; Put, putrescine; Spd, spermidine; SpdSyn, 
spermidine synthase; Spm, spermine; SpmSyn, spermine synthase; GSH, glutathione; 
GSS, glutathionylspermidine synthase; ROS, reactive oxygen species; TryR, 
trypanothione reductase; TryS, trypanothione synthetase. [Adapted from (Heby et al, 
2007)].  
 
2.2 Thiol metabolism 
 
 In most eukaryotic organisms the glutathione (GSH)/glutathione reductase (GR) 
and thioredoxin (Trx)/thioredoxin reductase (TrxR) systems, maintain the intracellular thiol 
redox homeostasis (Lillig & Holmgren, 2007; Shelton et al, 2005). T. brucei genome 
sequencing project revealed absence of genes encoding for GR and TrxR (Berriman et al, 
2005). Nevertheless, redox homeostasis in T. brucei is efficiently regulated since they can 
successfully withstand the oxidative burst during host infection and perfectly adapt to the 
different metabolic and environmental conditions imposed by their digenetic life-cycle 
(Krauth-Siegel & Comini, 2008). Actually, this microorganism possesses a unique redox 
metabolism that is based on T(SH)2 (Fairlamb et al, 1985) and nicotinamide adenine 
dinucleotide phosphate hydrogen (NADPH)-dependent TR (Fairlamb & Cerami, 1992; 
Chapter II - Discovery of targets against human African trypanosomiasis 
69 
 
Krauth-Siegel et al, 2003). T. brucei trypanothione synthetase (TryS) catalyzes the entire 
synthesis of T(SH)2 from GSH and Spd (Oza et al, 2003). The absence of the T(SH)2 
system in mammals, the lack of a functional redundancy within the parasite thiol system 
together with the sensitivity of trypanosomes against oxidative stress render the 
components of this metabolism attractive drug targets (Krauth-Siegel & Comini, 2008). 
The relevance of the T(SH)2 system has been corroborated genetically [e.g. TR cKO 
caused increased hydroperoxide sensitivity, arrest of proliferation and loss of virulence 
(Krieger et al, 2000), and TryS suppression through RNAi and cKO, decreases T(SH)2 
levels concomitant with impairment of parasite proliferation and viability (Comini et al, 
2004; Wyllie et al, 2009)]. Chemical validation studies regarding this pathway can also be 
seen in the literature. As an example, TR inhibitors were identified and did not block the 
closest mammalian homolog, the GR (Eberle et al, 2009; Eberle et al, 2011; Spinks et al, 
2009). However, their efficacy in infection models turned out to be disappointing because 
redox metabolism of the parasite was not affected at all, unless TR was titrated down to 
less than 5% of normal (Krieger et al, 2000), a residual activity that is hard to permanently 
sustain in vivo by any reversible inhibitor. Therefore, recent efforts focus on irreversible 
TR inhibitors, which may raise concerns regarding the pronounced selectivity that is 
mandatory for this kind of inhibition (Flohe, 2012). Nevertheless, TR inhibition has been 
used in the field for the treatment of late stage T.b. rhodesiense infection, through the use 
of melarsoprol (Fairlamb et al, 1989). TryS chemical validation was achieved with 
inhibitors obtained from a high-throughput screening, leading to predictive metabolic 
impairments and parasites death (Torrie et al, 2009). 
 
 
Figure 13. Simplistic representation of GSH and T(SH)2 mediated redox homeostasis in 
mammalian host and T. brucei parasites. Detoxification of ROS is accomplished by a 
cascade derived from T(SH)2/TR and GSH/GR in parasites and mammalian host, 
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respectively, with NADPH as the primary electron source. [Adapted from (Paul et al, 
2014)]. 
 
2.3 Glycosomes and energy metabolism   
 
 T. brucei compartmentalize several important metabolic systems such as 
glycolysis, pentose phosphate pathway (PPP), fatty acids beta-oxidation, and ether-lipid, 
isoprenoid and purine/pyrimidine biosynthesis in their peroxisomes which are designated 
glycosomes (Michels et al, 2006). The enzymatic content of these organelles may vary 
considerably within the life-cycle, in particular, during differentiation between bloodstream 
and procyclic forms (Michels et al, 2006). This unique glycosome compartmentalization 
and their large phylogenetic distance with the mammalian hosts provides the parasite with 
unique features (Chawla & Madhubala, 2010). The glycolytic enzymes 
compartmentalization within the glycosome was shown to be essential (Bakker et al, 
2000; Furuya et al, 2002). Contrary to other organisms in which glycolysis has negative 
feedback loops to prevent the autocatalytic pathway from losing control [e.g., inhibition of 
hexokinase (HK) by glucose 6-phosphate (Newsholme et al, 1967) and 
phosphofructokinase (PFK) by phosphoenolpyruvate (Blangy et al, 1968)], T. brucei lacks 
feedback regulation (Nwagwu & Opperdoes, 1982). Without compartmentalisation, ATP 
produced in the latter steps of the pathway would be accessible in the first steps causing a 
turbo explosion within the pathway and death by accumulation of toxic intermediates 
(Haanstra et al, 2008). In fact, the rate of glucose transport is the main regulator of 
glycolysis (Haanstra et al, 2011). In contrast to procyclic forms, which contain an extended 
glycolytic pathway catalyzing the aerobic fermentation of glucose to succinate (Figure 14) 
(Bochud-Allemann & Schneider, 2002; Coustou et al, 2003), in bloodstream forms, 
glycolysis of host glucose provides the sole source of carbon for ATP production (Clayton 
& Michels, 1996; Michels et al, 2006; Tielens & Van Hellemond, 1998). In bloodstream 
forms, not only the glycolytic enzymes have structural differences compared with their 
mammalian counterparts, but also the exclusively dependence on glycolysis for ATP 
production due to a reduced mitochondrial function, present a series of targets for 
potential therapeutic development (Coley et al, 2011) (Figure 14). Indeed, plasma 
membrane glucose transporter, as well as the pyruvate transporter that is responsible for 
the efflux of the trypanosome’s glycolytic end-product into the blood, have been 
chemically validated as drug targets (Bakker et al, 1999; Seyfang & Duszenko, 1991; 
Wiemer et al, 1995). The genetic validation as drug targets, has been obtained by RNAi 
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and cKO experiments for the following glycosomal enzymes, HK (Albert et al, 2005; 
Chambers et al, 2008), PFK (Albert et al, 2005; Kessler & Parsons, 2005), fructose-1,6-
bisphosphate aldolase (ALD) (Caceres et al, 2010), triosephosphate isomerase (TPI) 
(Helfert et al, 2001), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Caceres 
et al, 2010), as well as for the other enzymes involved in glycolysis but not present in the 
glycosomes, such as phosphoglycerate mutase (PGAM) (Albert et al, 2005), enolase 
(ENO) (Albert et al, 2005) and phosphoglycerate kinase (PYK) (Albert et al, 2005). Also 
chemical validation has been pursued for several enzymes of the glycolytic pathway, such 
as HK1 (Chambers et al, 2008; Dodson et al, 2011; Sharlow E, 2011; Sharlow et al, 2010; 
Willson et al, 2002), PFK (Brimacombe et al, 2014; Nowicki et al, 2008; Walsh et al, 
2010), ALD (Azema et al, 2006), GAPDH (Aronov et al, 1999), PYK (Drew et al, 2003) 
and ENO (de A S Navarro et al, 2007).  
 
 
 
Figure 14. The energy metabolism of bloodstream (a) and procyclic (b) T. brucei foms. 
Enzymes: 1, hexokinase; 2, glucose-6-phosphate isomerase; 3, phosphofructokinase; 4, 
aldolase; 5, triosephosphate isomerase; 6, glyceraldehyde-3-phosphate dehydrogenase; 
7, phosphoglycerate kinase; 8, glycerol-3-phosphate dehydrogenase; 9, glycerol kinase; 
10, phosphoglycerate mutase; 11, enolase; 12, pyruvate kinase; 13, glycerol-3-phosphate 
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oxidase; 14, phosphoenolpyruvate carboxykinase; 15, L-malate dehydrogenase; 16, 
fumarase; 17, fumarate reductase; 18, pyruvate phosphate dikinase; 19, pyruvate 
dehydrogenase complex; 20, acetate:succinate CoA transferase; 21, proline oxidase; 22, 
Δ'-pyrroline-5-carboxylate reductase; 23, glutamate semialdehyde dehydrogenase; 24, 
glutamate dehydrogenase; 25, α-ketoglutarate dehydrogenase; 26, succinyl CoA 
synthetase; 27, FAD-dependent glycerol-3-phosphate dehydrogenase. Abbreviations: AA, 
amino acid; AcCoA, acetyl-CoA; 1,3-BPGA, 1,3- bisphosphoglycerate; c, cytochrome c; 
Citr, citrate; DHAP, dihydroxyacetone phosphate; Fum, fumarate; G-3-P, glyceraldehydes 
3-phosphate; Glu, glutamate; Gly-3-P, glycerol 3-phosphate; KG, α-ketoglutarate; Mal, 
malate; OA, 2-oxoacid; Oxac, oxaloacetate; PEP, phosphoenolpyruvate; 3-PGA, 3-
phosphoglycerate; Succ, succinate; Succ-CoA, succinyl CoA; UQ, ubiquinone. Substrates 
and secreted end-products are indicated in green and red boxes. Enzymes involved in 
reactions represented by dashed lines are present, but experiments indicated that no 
significant fluxes occurred through these steps. [Adapated from (Hannaert et al, 2003a)].  
 
2.4 Lipid metabolism 
 
The uniqueness of parasites lipid metabolism provides a number of enzymes that 
have been proven to be valid targets for the development of novel chemotherapeutics 
(Lee et al, 2007; van Hellemond & Tielens, 2006). T. brucei has two ways to supply itself 
with fatty acids: acquire fatty acids from the host or synthesize its own fatty acids de novo 
(Smith & Butikofer, 2010). There is a significant difference between the energy required 
for fatty acid synthesis compared to uptake, explaining why uptake is likely preferred over 
fatty acid synthesis pathway. However, when the host fatty acid supply is insufficient, the 
parasite must then synthesize its own fatty acids (Lee et al, 2006). Fatty acid synthesis in 
trypanosomes comprises at least two pathways, the fatty acid elongase pathway of the 
endoplasmic reticulum that serves as the major pathway for synthesis (Lee et al, 2006), 
and a minor pathway in the mitochondria that catalyzes the synthesis of mitochondrial 
fatty acids (Guler et al, 2008; Stephens et al, 2007). A number of well-known fungi lipid 
metabolism inhibitors appeared to be also effective against T. brucei, as thiolactomycin 
(and its derivatives) was shown to inhibit type II fatty acid biosynthesis (Jones et al, 2004).  
 Particularly important to the parasite is phosphatidylinositol, which is a ubiquitous 
phospholipid that functions as a precursor for cell signaling molecules and provides the 
basic building block used in GPI anchor biosynthesis. As mentioned before GPI-anchored 
proteins form a surface coat, known as VSG, which protects the parasite from host 
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immune response (Hong & Kinoshita, 2009). Some enzymes involved in 
phosphatidylinositol and GPI synthesis were already validated as targets (Martin & Smith, 
2006; Smith et al, 2001). Also a number of natural products that inhibit fatty acid 
biosynthesis in other parasites have been shown to kill T. brucei in vitro (Karioti et al, 
2007; Tasdemir et al, 2005; Tasdemir et al, 2007). Myristate is a key component of the T. 
brucei GPI-anchor, and is synthesized by a set of elongase enzymes. The essentiality of 
these enzymes was demonstrated using RNAi (Lee et al, 2006). N-myristoyltransferase, 
an enzyme responsible for attachment of myristate to the GPI anchor, showed to be 
essential for parasite viability based on the same knockdown approach (Price et al, 2003). 
Homology modelling using crystallographic information from fungal N-myristoyltransferase 
inhibitors, which also inhibited the trypanosomal enzyme (Bowyer et al, 2008; 
Panethymitaki et al, 2006), was employed to rational design new T. brucei selective 
inhibitors (Sheng et al, 2009). More recently, pyrazole sulfonamides constituted lead 
compounds for N-myristoyltransferase inhibition (Frearson et al, 2010).  
The synthesis of sphingolipids within the fatty acid metabolism was shown to be 
critical to T. brucei viability. The sphingolipid content and biosynthetic capabilities of 
parasitic protozoa have drawn attention due to the potential for new chemotherapeutic 
targets. A key enzyme of sphingolipid biosynthesis pathway is sphingolipid synthase, 
which has recently been identified and shown to be essential for T. brucei survival by 
RNAi and by chemical inhibition using aureobasidin A (Mina et al, 2009; Sheng et al, 
2009). Intracellular degradation of sphingomyelin, which is the main sphingolipid in T. 
brucei, is achieved by sphingomyelinases. T. brucei conditional null mutant demonstrates 
that the neutral sphingomyelinase activity is essential for growth and survival, causing 
VSG trafficking to be impaired (Young & Smith, 2010). 
Protein prenylation through the attachment of farnesyl to proteins is an important 
regulatory mechanism for signal transduction. The enzyme responsible for this process, 
protein farnesyltransferase was shown to be a good target (Ali et al, 1999) and was used 
in screening efforts to identify leads for medicinal chemistry, including a series of 
tetrahydroquinolines active against T. brucei (Eastman et al, 2006). 
 
2.5 Folate metabolism 
 
 Folate is an essential cofactor in the biosynthesis of DNA and aminoacids. The 
inhibition of its metabolism leads to alterations of cell replication and function. T. brucei 
parasites do not have a de novo pathway for the synthesis of pteridines (folate and 
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biopterins) and rely on salvage from the host (Ferrari et al, 2013). They depend on 
specific transporters for folate and biopterin and in enzymes involved in the biosynthesis 
of reduced folate, [thymidylate synthase (TS), dihydrofolate reductase (DHFR), and 
pteridine reductase 1 (PTR1)], which is an essential cofactor for the synthesis of the 
deoxythymidine-monophosphate (dTMP) necessary for DNA synthesis (Figure 15). TS 
catalyzes the reductive methylation of deoxyuridine-monophosphate (dUMP) to dTMP, 
using the cofactor N5,N10-methylene tetrahydrofolate as a carbon donor and reducing 
agent. DHFR restores the tetrahydrofolate (H4F) pool through the NADPH dependent 
reduction of the dihydrofolate (H2F) previously produced. In higher plants and protozoa, 
such as in T. brucei, the DHFR and TS activities are achieved by a single bifunctional 
enzyme, dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Gamarro et al, 1995). 
PTR1 belongs to the family of short-chain dehydrogenases/reductases, and reduces both 
folate and biopterin (Robello et al, 1997). Therefore, bifunctional DHFR-TS is specific for 
folate, while PTR1 reduces both folate and biopterin (Figure 15). DHFR-TS has been 
chemically and genetically validated as key drug targets (Sienkiewicz et al, 2008). 
Although a clear chemical scaffold, for a focused lead discovery, have not been yet 
identified, validation data is sufficiently compelling to warrant efforts to exploit T. brucei 
DHFR as a target (Jacobs et al, 2011). PTR1 knockdown resulted in T. brucei loss of 
viability and virulence in cultures and animal models (Sienkiewicz et al, 2010). Chemical 
studies attempting to screen PTR1 inhibitors are present in the literature. 
Aminobenzothiazole and aminobenzimidazole were identified as PTR1 selective inhibitors 
but showed limited ability to inhibit T. brucei growth in vitro (Mpamhanga et al, 2009). 
Apparently other studies have also failed to obtain highly potent PTR1 inhibition and 
trypanocidal activity in culture (Spinks et al, 2011; Tulloch et al, 2010). Discover the basis 
for this limitation will be essential to any future efforts. It has been suggested that the 
inhibition of both enzymes, DHFR-TS and PTR1, would fully arrest the pathway's 
metabolic function, and the structural differences between trypanosomatids PTR1/DHFR-
TS and their mammalian congeners are pronounced enough to enable selective inhibition 
towards an efficacious and safe therapy (Ferrari et al, 2013). 
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Figure 15. Folate and biopterin reduction in T. brucei. (A) Folate reduction catalyzed by 
both DHFR and PTR1 enzymes. DHFR-TS [Protein Data Bank (PDB) code 2H2Q] is 
shown in the center of the cycle with DHFR and TS domains colored blue and red, 
respectively. (B) Two-stage reduction of biopterin catalyzed by PTR1. [Adapted from 
(Tulloch et al, 2010)]. 
 
3 Exploiting the pentose phosphate pathway 
 
 As already mentioned, glucose is the only energy source for T. brucei bloodstream 
forms. Besides glycolysis, glucose is also metabolized by PPP. Despite less investigated 
than glycolysis, it is becoming clear that PPP plays a crucial role in the metabolism of 
many parasitic protozoa and in their relationship with the host's (Barrett, 1997). In most 
organisms, the PPP is localized in the cytosol, however in trypanosomatids, including T. 
brucei this pathway can be splited between the cytosol and the glycosomes (Hannaert et 
al, 2003a). PPP takes part of the carbohydrate metabolism and is important to maintain 
carbon homeostasis, to provide precursors for nucleotide and amino acid biosynthesis 
and to supply reducing molecules to defeat oxidative stress. PPP is divided into an 
oxidative and a non-oxidative branch (Figure 16). The oxidative PPP is considered 
unidirectional, and converts glucose-6-phosphate into ribulose 5-phosphate (Ru5P) and 
NADPH, whereas the bidirectional non-oxidative branch metabolizes glycolytic 
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intermediates yielding R5P (Stincone et al, 2014). The enzymes belonging to this pathway 
present marked differences from human enzymes, either in structure and/or kinetics, 
which make them suitable candidates as targets and allow the design of specific inhibitors 
(Comini et al, 2013).  
 
3.1 Oxidative branch 
 
 The oxidative branch includes three steps for the synthesis of Ru5P, with the 
concomitant production of two moles of NADPH per mole of glucose 6-phosphate 
consumed  (Figure 16) (Barrett, 1997).  
 Glucose-6-phosphate dehydrogenase (G6PDH; EC1.1.1.49) catalysis the first step 
of the PPP; glucose 6-phosphate is oxidised to 6-phospogluconolactone, while 
nicotinamide adenine dinucleotide phosphate (NADP+) is reduced to NADPH (Glaser & 
Brown, 1955). G6PDH from trypanosomatids share about 50% identity with the human 
ortholog (Comini et al, 2013). This enzyme is predominantly distributed in the cytosol with 
a minor fraction compartmentalized in glycosomes (Duffieux et al, 2000; Heise & 
Opperdoes, 1999; Opperdoes & Szikora, 2006). RNAi mediated reduction of the G6PDH 
level in bloodstream forms validates genetically this enzyme as a drug target, due to the 
deleterious phenotype observed [growth arrest and reduced tolerance to hydrogen 
peroxide (H2O2)]. The steroids dehydroepiandrosterone (DHEA) and epiandrosterone (EA) 
were found to inhibit the enzyme with Ki values about 6-fold lower than those reported for 
the human enzyme. Moreover viability assays confirmed the toxic effect of both steroids 
on cultured T. brucei bloodstream forms (Cordeiro et al, 2009). The specific action of 
steroids against G6PDH was confirmed recently using transgenic cell lines (Gupta et al, 
2011).  
 In the second step, the enzyme 6-phosphogluconolactonase (6-PGL; EC3.1.1.31) 
hydrolyses 6-phospogluconolactone into 6-phosphogluconate (Duffieux et al, 2000; Miclet 
et al, 2001). About 85% of 6-PGL is found in the cytosol and 15% in the glycosomes, thus 
showing a dual localization (Duclert-Savatier et al, 2009). T. brucei 6-PGL crystal structure 
has been recently resolved, in the absence and presence of ligands (Delarue et al, 2007; 
Duclert-Savatier et al, 2009), which allows a detailed mechanistic characterization of the 
enzyme. The low amino acid identity (below 20%) with the human ortholog predicts 
important structural differences (Comini et al, 2013), however the essentiality of 6PGL has 
not yet been addressed.   
Chapter II - Discovery of targets against human African trypanosomiasis 
77 
 
 Lastly, 6-phosphogluconate is oxidised and decarboxylated to Ru5P by 6-
phosphogluconate dehydrogenase (6-PGDH; EC1.1.1.44), while again reducing NADP+ to 
NADPH (Dickens & Glock, 1951). This protein is predominantly cytosolic, with a small 
glycosomal component in procyclics (Heise & Opperdoes, 1999). 6-PGDH from 
kinetoplastids exhibits low amino acid sequence identity (less than 35%) with its 
mammalian counterpart (Barrett, 1997; Comini et al, 2013). T. brucei 6-PGDH three-
dimensional structure has been determined and compared against the sheep liver enzyme 
(Phillips et al, 1998). Despite the low protein sequence identity between both enzymes, a 
high conservation in the overall structure and in the residues directly engaged in substrate 
and coenzyme binding was observed. Several secondary residues surrounding the 
substrate-binding site and others bridging the C-terminal tail on the coenzyme binding 
site, differed significantly in identity and in structural arrangement and were proposed to 
account for the different affinities of substrate/coenzyme and inhibitors (Adams et al, 
1994; Comini et al, 2013). Deletion of T. brucei 6-PGDH, leads to the accumulation of 6-
phosphogluconate which inhibits phosphoglucose isomerase and consequently glycolysis 
(Hanau et al, 2004). The relevance of 6-PGDH for T. brucei was first revealed through 
cytotoxic studies using several substrate and cofactor analogues, as well as high-energy 
intermediates and transition-state analogues in inhibition studies (Dardonville et al, 2004; 
Dardonville et al, 2003). Some hydroxamate derivatives of D-erythronic acid, analogues of 
the high-energy intermediate, were found to be potent and selective inhibitors of the 
parasite enzyme (Dardonville et al, 2004). From this study the compound 2,3-o-
isopropylidene-4-erythrono hydroxamate showed to be a potent inhibitor, however does 
not have trypanocidal activity due to its poor membrane permeability. Therefore 
phosphate prodrugs have been developed to circumvent this aspect. The class of aryl 
phosphoramidate prodrugs of 2,3-o-isopropylidene-4-erythrono hydroxamate showed high 
trypanocidal activity and a good correlation between activities with their stability in mouse 
blood (Ruda et al, 2010b). More recently, a novel “virtual fragment screening” approach, in 
which the structure of the Lactococcus lactis 6-PGDH (almost identical to T. brucei) was 
used as docking template, allowed the discovery of some compounds with good IC50 
against T. brucei 6-PGDH (Ruda et al, 2010a).  
 To sum up, the oxidative branch is therefore crucial once it supplies cells with 
Ru5P, a precursor of the non-oxidative PPP, and with NADPH an essential reducing 
agent involved not only in many biosynthetic reactions, including de novo lipid synthesis, 
but also in protecting cells against oxidative stress by regenerating GSH (Comini et al, 
2013). 
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3.2 Non-oxidative branch 
 
 In the non-oxidative part, the formed Ru5P can be converted either to R5P or to 
xylulose 5-phosphate. Thereafter two enzymes, transketolase (TKT) and transaldolase 
(TAL), are responsible for the relative complex interconversion reactions between 
R5P/xylulose 5-phosphate and glycolytic intermediates glyceraldehyde 3-
phosphate/fructose 6-phosphate via reshuffling of monophosphate sugars (Figure 16) 
(Stincone et al, 2014). Through the sharing of these intermediates, TKT and TAL act as a 
bridge between glycolysis and the PPP. Moreover they connect to sedoheptulose 7-
phosphate which is synthesized also by other sources, thus representing a glycolysis-
independent entry and exit point into/from the non-oxidative PPP (Stincone et al, 2014).   
Rpi (EC 5.3.1.6) converts Ru5P into R5P and the other way around. This enzyme 
is classified into type A (distributed in mammals, fungi and some bacteria) or B (restricted 
to some bacteria and protozoa). The absence of type B Rpi in mammalians and the 
significant structural divergence between both enzymes have raised interest on 
trypanosomal RpiB. Both T. cruzi and Leishmania donovani (L. donovani) Rpi have been 
suggested as potential drug targets, although genetic and chemical validation are still 
lacking (Kaur et al, 2012; Stern et al, 2007). The competitive inhibitor analogous of the 
isomerization intermediate, 4-phospho-D-erythronohydroxamic acid (4-PEH), was shown 
to be the best inhibitor against RpiB (Roos et al, 2005; Stern et al, 2007). However, it also 
strongly inhibits type A enzyme (Roos et al, 2005) and its antiparasitic activity is still 
unclear. 
The ribose 5-phosphate epimerase (RPE; EC 5.3.1.4) interconverts Ru5P and 
xylulose 5-phosphate. In T. brucei RPE activity was detected in procyclics, but not in 
parasites isolated from mice (Cronin et al, 1989), which therefore does not qualify as 
potential target against HAT.  
TKT (EC 2.2.1.1) is an enzyme capable of catalysing two distinct reversible 
reactions that involved the transfer of two carbon atoms: (i) from xylulose 5-phosphate to 
R5P, producing glyceraldehyde 3-phosphate and sedoheptulose 7-phosphate, and (ii) 
from xylulose 5-phosphate to erythrose 4-phosphate to generate glyceraldehyde 3-
phosphate and fructose 6-phosphate, using thiamine diphosphate as a cofactor (Schenk 
et al, 1998). The structure of the human TKT was determined (Mitschke et al, 2010), and 
at least two residues involved in the binding of the cofactor and substrate (Gln189 and 
Lys260) are not conserved in trypanosomatids (Comini et al, 2013). Although, TKT null 
procyclics showed a remarkable alteration in the metabolic profile, did not exhibit any in 
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vitro growth or morphological phenotype (Stoffel et al, 2011). Additionally, TKT activity 
was shown repressed in bloodstream stages (Cronin et al, 1989), suggesting TKT is not a 
good drug target.  
TAL (EC 2.2.1.2) transfer a three-carbon fragment, dihydroaxyacetone, from 
sedoheptulose 7-phosphate to glyceraldehyde 3-phosphate, producing fructose 6-
phosphate and erythrose 4-phosphate. The backward reaction is also catalyzed by this 
enzyme (Comini et al, 2013). TAL was detected in the cytosol of T. brucei bloodstream 
forms (Cronin et al, 1989), however its role was never addressed. Once these forms 
present a defective non-oxidative branch, including an absence of TKT activity whose 
products constitute substrates for TAL, TAL protein can be disregarded as a drug target 
candidate (Comini et al, 2013).     
In resume, the non-oxidative PPP has recently started to receive more attention, 
and in fact deserves further investigation once supplies parasites with R5P, to form the 
RNA and DNA backbone, and erythrose 4-phosphate, a precursor of aromatic amino 
acids and vitamin B6 (Stincone et al, 2014). 
 
 
Figure 16. Scheme of the PPP in T. brucei: components, biological relevance, and 
inhibitors. The substrates and products of the PPP that are shared with other metabolic 
pathways are labelled with a green dot. Characterized enzyme inhibitors are shown in red. 
The enzymes of the oxidative and non-oxidative phase of the PPP are in orange and blue, 
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respectively. Salvage pathways for R5P are in lilac. Enzymes absent in infective T. brucei 
are marked with red dot. Enzymes of proved indispensability are indicated with yellow dot. 
[Adapted from (Comini et al, 2013)].  
 
4 Exploiting asparagine metabolic pathway 
 
 Asparagine is a non-essential amino acid, meaning it can be synthesized from 
central metabolic pathway intermediates and is not required in the diet. This amino acid is 
frequently involved in protein active or binding sites (Snijder et al, 2001; Vernet et al, 
1995) and additionally, asparagine (N)-linked glycosylation of proteins is a fundamental 
and extensive post-translational modification that results in the covalent attachment of an 
oligosaccharide onto asparagine residues of polypeptide chains (Schwarz & Aebi, 2011). 
Asparagine has a high nitrogen/carbon ratio and it is therefore linked to nitrogen 
homeostasis and protein biosynthesis. Moreover, the removal of this amino acid by L-
asparaginase is widely used in chemotherapeutic protocols for treatment of acute 
lymphoblastic leukemia (Richards & Schuster, 1998). All these facts explain the growing 
biochemical and genetic studies of enzymes related with asparagine metabolism. 
 Two major pathways called tRNA-dependent and independent are involved in 
asparagine metabolism. In addition, organisms may also uptake asparagine from the 
exterior (Min et al, 2002) (Figure 17). Different environmental and physiological conditions 
can modulate the synthesis and import of asparagine (Benko et al, 1969; Hunter & Segel, 
1971; Hunter & Segel, 1973; Pall, 1970; Zheng & Haselkorn, 1996). Actually some cells 
rely on extracellular asparagine to reach the total requirements of this amino acid. 
Examples of cells that must import asparagine, include asparagine auxotrophs (usually 
not found in nature and result from genetic manipulation, being unable to growth in 
minimal medium unless asparagine is added to the culture (Jones, 1978; Min et al, 2002; 
Qian et al, 2013; Reitzer & Magasanik, 1982; Willis & Woolfolk, 1975)), and leukemia cells 
which exhibit a particularly low level of asparagine and therefore are sensitive to 
exogenous asparagine depletion (Rizzari et al, 2013). 
Very few data is available in literature concerning asparagine metabolism and 
transport in T. brucei. The ever-changing environments during T. brucei life cycle leads to 
a variable repertoire of transporters on their surfaces (Berriman et al, 2005; Besteiro et al, 
2005). Trypanosomes have in their flagellar pockets a high rate of endo and exocytosis, 
and of transporters required for the uptake of many essential nutrients (Field & Carrington, 
2009). RNAi against T. brucei AATP1 characterized this protein as a transporter of small 
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neutral amino acids, with the following order of affinity: L-threonine > L-serine > glycine > 
L-alanine > L-cysteine > L-asparagine (Ebikeme, 2007). Asparagine is the only TbAATP1 
specific amino acid with a hydrophilic side group and, consequently is the least specific, 
however, its side group is small enough to be recognised by this transporter. Nevertheless 
the apparent high level of redundancy in amino acid transporters suggests that blocking 
them would not cause detriment to the parasites (Ebikeme, 2007).  
 
4.1 t-RNA dependent reactions 
  
 Aminoacyl-tRNA synthetases are central enzymes in protein translation, providing 
the charged tRNAs needed for appropriate construction of peptide chains. These 
enzymes catalyze a two-step reaction whereby an ATP and amino acid molecule enter the 
active site, forming an aminoacyl-adenylate intermediate followed by the esterification of 
the amino acid to the end of the tRNA, forming the final ‘charged’ aminoacyl-tRNA (Pham 
et al, 2014). The synthesis of Asn-tRNAAsn is made through direct and/or indirect tRNA 
aminoacylation reactions of the tRNA dependent pathway (Figure 17A). In the presence of 
a discriminating asparaginyl-tRNA synthetase, (EC 6.1.1.22) a canonical aminoacylation 
occurs forming Asn-tRNAAsn (Min et al, 2002). However, half of the prokaryotes, including 
bacteria and archaea do not use a full complement of 20 canonical aminoacyl-tRNA 
synthetases enzymes to synthesize aminoacyl-tRNA for protein synthesis (Blaise et al, 
2011). In these cases, a non-discriminating aspartyl-tRNA synthetase (EC 6.1.1.23) 
generates the misacylated Asp-tRNAAsn species which are amidated to the correctly 
charged Asn-tRNAAsn by the Asp-tRNAAsn amidotransferase (EC 6.3.5.6), using 
preferentially glutamine over asparagine or ammonium chloride as amide donor (Blaise et 
al, 2011; Tumbula et al, 2000). Non-discriminating forms are most commonly found in 
organisms lacking asparaginyl-tRNA synthetase, therefore the combination of non-
discriminating aspartyl-tRNA synthetase and Asp-tRNAAsn amidotransferase provides the 
sole route for Asn-tRNAAsn biosynthesis (Curnow et al, 1998; Roy et al, 2003). Rarely, a 
given bacterium will encode for both discriminating and non-discriminating forms (e.g. 
Thermus thermophilus and Deinococcus radiodurans) (Becker & Kern, 1998; Curnow et 
al, 1998). Phylogenetic and experimental analysis suggest that asparaginyl-tRNA 
synthetase evolved from an ancestral aspartyl-tRNA (Figure 17B) (Feng et al, 2005; 
Raczniak et al, 2001; Roy et al, 2003; Shiba et al, 1998; Tumbula-Hansen et al, 2002; 
Woese et al, 2000; Wolf et al, 1999). The evolutionary trend appears that horizontal gene 
transfer has allowed some indirect pathways to be supplanted by direct ones, and not the 
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reverse (Szathmary, 1999), which might in part be due to the arguably greater efficiency 
of the direct pathways. As a matter of fact, selectivity is a major issue because the human 
genome encodes for 36 aminoacyl-tRNA synthetases that have eukaryotic and bacterial 
origins (Pham et al, 2014). It is a challenge to avoid potential cytotoxicity in aminoacyl t-
RNA synthetase inhibition. Strategies to circumvent host toxicity include exploitation of 
bacterial-type aminoacyl-tRNA synthetase where the human homologue is divergent, as is 
the case of Leishmania asparaginyl t-RNA synthetase (Gowri et al, 2012), or exploitation 
of parasite-specific modifications (Bour et al, 2009). Asparaginyl-tRNA synthetase has 
been a long-standing drug target in Brugia malayi, a nematode which causes lymphatic 
filariasis (Pham et al, 2014). In T. brucei mammalian stage parasites, the knockdown of 
mRNA encoding asparaginyl-tRNA synthetase (Tb927.4.2310) resulted in a severe in vitro 
growth defect showing that this enzyme is essential for the parasite, however drugability 
studies are not yet available (Kalidas et al, 2014).  
 
4.2 t-RNA independent reactions 
 
 AS catalyzes direct reactions of asparagine synthesis within the t-RNA 
independent pathway, performing the ATP-dependent conversion of aspartic acid to 
asparagine, employing either glutamine or ammonia as the nitrogen source (Figure 17A). 
There are two unlinked genes, asnA and asnB, that encode for mechanistically distinct 
enzymes (Nakamura et al, 1981; Scofield et al, 1990).  
 The asnA gene encodes type A enzyme (EC 6.3.1.1; putative Tb927.7.1110 in T. 
brucei) in prokaryotes, archaea and protozoan parasites (Blaise et al, 2011; Blattner et al, 
1997; Gowri et al, 2012; Nakamura et al, 1981; Reitzer & Magasanik, 1982; Sugiyama et 
al, 1992). AS-A forms asparagine through two steps: the β-carboxylate group of aspartate 
is first activated by ATP to form an aminoacyl-AMP, before its amidation by a nucleophilic 
attack with an ammonium ion (Blaise et al, 2011). This type A enzyme is considered 
strictly ammonia-dependent (Cedar & Schwartz, 1969a; Cedar & Schwartz, 1969b; 
Reitzer & Magasanik, 1982). Structural studies (Blaise et al, 2011; Nakatsu et al, 1998), 
coupled with sequence analysis (Wolf et al, 2001), site-directed mutagenesis experiments 
(Gatti & Tzagoloff, 1991; Hinchman et al, 1992), phylogenetic and biochemical data 
(Blaise et al, 2011; Roy et al, 2003) show that AS-A derives from the aspartyl t-RNA 
synthetase ancestor (Figure 17B). It was hypothesized that aspartyl t-RNA synthetase 
ancestor gene duplicated, with one copy leading to the archaeal aspartyl t-RNA 
synthetase and the other undergoing a second gene duplication. One gene of this second 
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duplication gave rise to asparaginyl-tRNA synthetase, while the second copy evolved to 
the archaeal AS-A. To do so, the latter, firstly lost its anticodon binding domain and 
secondly rearranged its catalytic site, leading to loss of capacity to aminoacylate tRNAAsp 
while acquiring the ability to activate the β-carboxylate of aspartate. Archaeal AS-A was 
then horizontally transferred from archaea to bacteria, where it evolved into the current 
AS-A (Blaise et al, 2011). Till now AS-A was suggested as a drug target against L. 
donovani parasites (Gowri et al, 2012; Manhas et al, 2014), in T. brucei remains to be 
studied. 
 AS-B (EC 6.3.5.4; putative Tb927.3.4060 in T. brucei), encoded by asnB gene, is 
present not only in prokaryotes (Humbert & Simoni, 1980; Reitzer & Magasanik, 1982), 
but also in eukaryotes, including mammalian cells (Andrulis et al, 1987; Andrulis et al, 
1989), yeasts (Ramos & Wiame, 1980), algae (Merchant et al, 2007), and higher plants  
(Coruzzi, 2003). The N-terminal of AS-B catalyzes the conversion of glutamine into 
glutamic acid and ammonia, and aspartate reacts with ATP in the C-terminal site, 
generating the intermediate β-aspartyl-AMP (Boehlein et al, 1998; Luehr & Schuster, 
1985). The ammonia released in the N-terminal domain of the enzyme travels through an 
intramolecular tunnel connecting the active sites, and reacts with the reactive 
acyladenylate intermediate to produce asparagine (Huang, 2001). Glutamine is the 
preferred source of nitrogen for AS-B (Boehlein et al, 1994; Duff et al, 2011; Horowitz & 
Meister, 1972; Patterson & Orr, 1968; Ramos & Wiame, 1979; Reitzer & Magasanik, 
1982), except for human enzyme that has similar affinity for glutamine and ammonia 
(Ciustea et al, 2005). The larger size of type B enzyme compared with A, and the 
additional ability of type B to use either glutamine or ammonia as the nitrogen donor have 
led to the speculation that asnB was formed by the fusion of an ancestral glutamine 
amidotransferase gene with an ancestral ammonia-dependent asn gene homologous to 
asnA (Gaufichon et al, 2013). Moreover phylogeny studies also showed homologs of 
glutamine-dependent AS within bacterial, eukaryal, and archaeal lineages, therefore 
suggesting that type B enzyme evolved before the segregation of organisms into the 
modern cell types (Min et al, 2002).  AS-B is regarded as a potential therapeutic target in 
the treatment of pancreatic, ovarian, hepatic and breast tumours (Dufour et al, 2012; 
Lorenzi et al, 2008; Lorenzi et al, 2006; Yang et al, 2014). It is also generally accepted 
that the role of AS-B in leukaemic cells regarding resistance to L-asparaginase treatment 
may vary among genetic subtypes (den Boer et al, 2005; Stams et al, 2005), due to 
different AS expression. Therefore AS-B inhibition together with L-asparaginase 
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administration might be a new strategy for the treatment of tumours patients with high AS 
expression.  
 Regarding studies on AS inhibition, a transition state analogue of cysteine 
sulfoximine, N-adenylated S-methyl-L-cysteine sulfoximine was synthesized and showed 
to be an extremely potent slow binding inhibitor of E. coli type A enzyme (Koizumi et al, 
1999).  This inhibitor was also found to effectively inhibit type B enzymes (Boehlein et al, 
2001; Gutierrez et al, 2006).  
 Alternative asparagine synthetic pathways were described, but apparently are not 
present in T. brucei. In higher plants and bacteria, β-cyanoalanine is hydrolyzed into 
asparagine by β-cyanoalanine hydratase (EC 4.2.1.65) (Brysk et al, 1969; Castric et al, 
1972; Castric & Strobel, 1969; Piotrowski & Volmer, 2006), and in mouse (Maul & 
Schuster, 1986), rat liver (Cooper, 1977), and in plants (Ireland & Joy, 1983; Zhang et al, 
2013), asparagine-oxo-acid transaminase (EC 2.6.1.14) catalysis the reverse reaction 
of L-asparagine and α-2-oxo-carboxylate, to produce 2-oxosuccinamate and an amino 
acid (Meister & Fraser, 1954). 
 Asparaginases (EC 3.5.1.1) catalyze the hydrolysis of asparagine into aspartate 
and ammonium ion. Firstly, the nucleophilic threonine attacks the carbonyl of the amide 
substrate to generate an acyl-enzyme intermediate, releasing ammonia. In the second 
step, water attacks the acyl-enzyme intermediate to produce L-aspartate (Michalska & 
Jaskolski, 2006). In some infections asparaginase constitutes a virulence factor, like in the 
case of Campylobacter jejuni (Hofreuter et al, 2008), Helicobacter pylori (Scotti et al, 
2010; Shibayama et al, 2011), Salmonella typhimurium (Kullas et al, 2012) and 
Mycobacterium tuberculosis (Gouzy et al, 2014). Asparaginase takes part of therapeutic 
strategies against cancer metabolism, rather than a therapeutic target (Rizzari et al, 
2013). In T. brucei, asparaginase does not seems to be present (Ginger, 2007). 
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Figure 17. Enzymes involved in asparagine metabolism. (A) Asparagine consumption, 
synthesis and uptake. Enzymes involved in tRNA-dependent and independent pathways 
within asparagine metabolism are depicted. (B) Hypothetical scenario for asparaginyl-
tRNA (AsnRS) and archeal AS (AS-AR) evolution. AsnRS and AS-AR derives from the 
same ancestor aspartyl-tRNA (AspRS). The gene of the AspRS ancestor duplicated, with 
one copy leading to archaeal/eukaryal AspRS and the other undergoing second gene 
duplication. One gene of this second duplication gave rise to AsnRS, while the second 
copy evolved to AS-AR through loss of the anticodon binding domain and mutations in the 
catalytic site. Thereafter AsnRS and AS-AR were horizontally transferred from archaea to 
other phylae. [Adapted from (Blaise et al, 2011)]. 
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1 Scope of the thesis 
 
 HAT caused by T. brucei parasite continues to exact a huge burden on people’s 
lives and economy in African developing countries. Disease control is dependent on drug 
therapy due to the absence of a human vaccine. Nevertheless the current available drugs 
are of inefficient delivery, insufficient efficacy and of excessive toxicity. Moreover, the 
increasing resistance against the present chemotherapy imposes the discovery and 
validation of new drug targets to reach novel compounds (Babokhov et al, 2013). The 
genome sequence availability (Berriman et al, 2005) offers a unique avenue for 
identification of novel therapeutic targets. By using an in silico subtractive genomic 
approach, several hits came out as potential targets. AS-A and RpiB were selected based 
on the following criteria: i) absence of a human homologue, ii) commitment in more than 
one metabolic pathway, iii) “workable” size of the gene and protein, iv) availability of 
homologous 3D structures, and v) availability of theoretical inhibitors. The selection of a 
target, based on a genomic screening, implies its chemical and/or genetic validation. 
Therefore, the main purpose of this thesis was to evaluate genetically the functional 
significance of AS-A and RpiB for parasites survival and infectivity. Moreover, proteins 
were biochemically characterized and their subcellular localization and expression within 
the parasite life cycle investigated. Results section is divided in two main parts. The first 
part is on AS-A, an enzyme that uses ammonia as nitrogen donor for the conversion of 
aspartate into asparagine, which is important in nitrogen homeostasis and protein 
biosynthesis (Richards & Schuster, 1998). The second part provides results of RpiB, an 
enzyme of the non-oxidative PPP that interconverts Ru5P and R5P, playing crucial roles 
in carbohydrate metabolism and acid nucleic synthesis (Stincone et al, 2014). In order to 
functional characterize the two candidate targets, AS-A and RpiB, the specific objectives 
of this thesis were: 
 
i. In silico analysis of the theoretical 3D protein structures; 
ii. Biochemical characterization of the recombinant proteins; 
iii. Study the effect of theoretical inhibitors on the enzymes activity; 
iv. Analyze protein expression profiles between different parasite life cycle stages; 
v. Define proteins subcellular localization; 
vi. Analyze the in vitro and in vivo phenotypes of RNAi transgenic parasites. 
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2 Results 
 
2.1 Knockdown of asparagine synthetase A renders Trypanosoma brucei 
auxotrophic to asparagine 
 
 Asparagine synthetase (AS) catalyzes the ATP-dependent conversion of aspartate 
into asparagine using ammonia or glutamine as nitrogen source. There are two distinct 
types of AS, asparagine synthetase A (AS-A), known as strictly ammonia-dependent, and 
asparagine synthetase B (AS-B), which can use either ammonia or glutamine. The 
absence of AS-A in humans, and its presence in trypanosomes, suggested AS-A as a 
potential drug target that deserved further investigation. We report the presence of 
functional AS-A in Trypanosoma cruzi (TcAS-A) and Trypanosoma brucei (TbAS-A): the 
purified enzymes convert L-aspartate into L-asparagine in the presence of ATP, ammonia 
and Mg2+. TcAS-A and TbAS-A use preferentially ammonia as a nitrogen donor, but 
surprisingly, can also use glutamine, a characteristic so far never described for any AS-
A. TbAS-A knockdown by RNAi didn't affect in vitro growth of bloodstream forms of the 
parasite. However, growth was significantly impaired when TbAS-A knockdown parasites 
were cultured in medium with reduced levels of asparagine. As expected, mice infections 
with induced and non-induced T. brucei RNAi clones were similar to those from wild-type 
parasites. However, when induced T. brucei RNAi clones were injected in mice 
undergoing asparaginase treatment, which depletes blood asparagine, the mice exhibited 
lower parasitemia and a prolonged survival in comparison to similarly-treated mice 
infected with control parasites. Our results show that TbAS-A can be important under in 
vivo conditions when asparagine is limiting, but is unlikely to be suitable as a drug target. 
 
Reprinted from PLoS Negl Trop Dis. 2013 Dec 5;7(12):e2578. doi: 10.1371/journal.pntd.0002578.  
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Supplementary Figures 
 
 
 
Figure S1 
 
Figure S1.  RNAi vectors used to generate RNAi-mediated TbAS-A downregulation. 
(A) pHD1144 vector for stem-loop cloning (pSP72 vector with a stuffer fragment); (B) 
pHD1145 inducible polymerase I vector for insertion of ready-made stem-loops (pHD677 
vector without a T7 promoter and with an inducible EP1 promoter and hygromycin 
resistance cassette, insertion into ribosomal spacer). 
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Figure S2 
 
Figure S2. Validation of antibodies against TbAS-A. Immunofluorescence analysis 
of T. brucei wt or a representative AS RNAi clone grown in the presence or absence of 
tetracycline. RNAi induced and uninduced cells were grown for 48h, then fixed and probed 
with rat polyclonal anti-TbAS-A (A) or rabbit polyclonal anti-TbAS-A (B) antibody and co-
stained with DAPI. Bars, 5μm. Quantification of TbAS-A fluorescence levels in induced 
cells (AS RNAi tet(+), n = 30) and uninduced cells (AS RNAi tet(-), n = 30), using the rat 
and the rabbit polyclonal anti-TbAS-A antibodies (C). Data representative of two 
independent experiments using two different clones. ImageJ software (version 1.43u) was 
used for fluorescence quantification. p value was calculated by Student's t test (*** p ≤ 
0.001 and ** p ≤ 0.01). 
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Figure S3 
 
Figure S3. TbAS-A cellular localization in T. brucei bloodstream forms. 
Immunofluorescence analysis by confocal microscopy of TbAS-A (red) in bloodstream 
forms. Aldolase (glycosome marker), GRASP (golgi marker), BiP (endoplasmic reticulum 
marker) and MitoTracker (labels mitochondria) are in green. DAPI locate nuclear and 
kinetoplast mitochondrial DNA (blue). Bars, 5 μm. Images are maximal Z-projections of 50 
contiguous stacks separated by 0.1 μm. 
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2.2 T. brucei ribose 5-phosphate isomerase B as a promising drug target 
 
2.2.1 Ribose 5-phosphate isomerase B knockdown compromises Trypanosoma 
brucei bloodstream form infectivity 
 
Ribose 5-phosphate isomerase is an enzyme involved in the non-oxidative branch 
of the pentose phosphate pathway and catalyzes the inter-conversion of D-ribose 5-
phosphate and D-ribulose 5-phosphate. Trypanosomatids, including the agent of African 
sleeping sickness namely Trypanosoma brucei, have a type B ribose-5-phosphate 
isomerase. This enzyme is absent from humans, which have a structurally unrelated 
ribose 5-phosphate isomerase type A, and therefore has been proposed as an attractive 
drug target waiting further characterization. In this study Trypanosoma brucei ribose 5-
phosphate isomerase B showed in vitro isomerase activity. RNAi against this enzyme 
reduced parasites in vitro growth and more importantly bloodstream forms infectivity. Mice 
infected with induced RNAi clones exhibited lower parasitaemia and a prolonged survival 
compared to control mice. Phenotypic reversion was achieved by complementing induced 
RNAi clones with an ectopic copy of Trypanosoma cruzi gene. Our results present the first 
functional characterization of Trypanosoma brucei ribose 5-phosphate isomerase B, and 
show the relevance of an enzyme belonging to the non-oxidative branch of the pentose 
phosphate pathway in the context of Trypanosoma brucei infection. 
 
Reprinted from PLoS Negl Trop Dis. 2015 Jan 8; 9(1): e3430. doi:10.1371/journal.pntd.0003430 
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Supplementary Figures 
 
Figure S1 
 
Figure S1. Sequence alignment and ribbon representation of RpiB protein from 
trypanosomes. (A) ClustalW alignment of RpiB from T. cruzi CL Brener Esmeraldo-like 
(Tc00.1047053509199.24; PDB accession code 3K7S), T. cruzi CL Brener Non-
Esmeraldo-like (Tc00.1047053508601.119) and T. brucei (Tb927.11.8970). The residues 
are colored according to ALSCRIPT Calcons (Aline version 011208) using a predefined 
colour scheme (red: identical residues; orange to blue: scale of conservation of amino 
acid properties; white: dissimilar residues). Secondary structure of TcRpiB 
crystallographic model (PDB code 3K7S) (grey) and the theoretical homology models 
TcRpiB (Tc00.1047053508601.119) (purple) and TbRpiB (Tb927.11.8970) (blue) are 
depicted above the alignment. Black circles indicate R5P binding residues. (B) 
Ribbon representation of TcRpiB  Esmeraldo-like (PDB code 3K7S) colored according to 
the sequence similarity with TcRpiB Non-Esmeraldo-like and TbRpiB as shown in (A). (C) 
Superposition of TcRpiB structure (PDB code 3K7S) (grey) with TcRpiB 
(Tc00.1047053508601.119) (purple) and TbRpiB (Tb927.11.8970) (blue) homology 
models. Ligand color scheme: R5P is shown in yellow (oxygen, pink; phosphorous 
orange). 
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Figure S2 
 
Figure S2. Biochemical properties of TcRpiB (Tc00.1047053508601.119) expressed 
in E. coli. (A) 10 μg of TcRpiB recombinant protein analyzed by SDS-PAGE and 
Coomassie blue staining. Mw, molecular weight marker. Western blot analysis of his-
tagged recombinant protein probed with rabbit anti-histidine monoclonal antibody 
(MicroMol-413) (1:1000). (B) Kinetic parameters of direct (R5P to Ru5P) and inverse 
(Ru5P to R5P) reaction. The values are the means ± standard deviation obtained from 3 
independent experiments. (C) Inhibition (%) of TcRpiB activity by 4PEH. (D) Plot of 
Kmapp/Vmax versus 4PEH concentrations; Ki corresponds to the symmetric value of the X-
axis intersection. (E) Plot showing the effect of different 4PEH concentrations on the 
inverse of the initial velocity versus the inverse of several concentrations of R5P. (C-E) 
The values correspond to the means ± standard deviation of two replicates, and data is 
representative of three independent experiments. 
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Figure S3 
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Figure S3. Validation of antibodies against TbRpiB. Immunofluorescence analysis 
of T. brucei wt or a representative Rpi RNAi clone in the presence or absence of 
tetracycline (tet). RNAi induced and uninduced cells were grown for 48h, then fixed and 
probed with rat polyclonal anti-TbRpiB (A) or rabbit polyclonal anti-TbRpiB (B) antibody 
and co-stained with DAPI. Bars, 5μm. (C) Quantification of TbRpiB fluorescence levels in 
induced cells [Rpi RNAi tet(+), n=30] and uninduced cells [Rpi RNAi tet(-), n=30], using 
the rat and the rabbit polyclonal anti-TbRpiB antibodies. Data representative of two 
independent experiments using two different clones. ImageJ software (version 1.43u) was 
used for fluorescence quantification. p value was calculated by Student's t test (*** 
p≤0.001, for both p<0.001). (D, E) Whole membrane resulting from Western blot analysis 
of RpiB levels, in T. brucei wt or a representative Rpi RNAi clone, in the presence or 
absence of tet. The membrane was probed with rat anti-TbRpiB (1:100) (D) or rabbit anti-
TbRpiB (1:1000) (E), and after membrane stripping, with rabbit anti-aldolase (1:5000) for 
loading control. 
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2.2.2 Unsuccessful attempts to generate Trypanosoma brucei ribose 5-phosphate 
isomerase B double knockout 
 
Ribose 5-phosphate isomerase catalyzes the interconversion of ribulose 5-
phosphate and ribose 5-phosphate within the non-oxidative branch of the pentose 
phosphate pathway. There are two types of ribose 5-phosphate isomerases, namely A 
and B. Trypanosomatids including Trypanosoma brucei, the agent of Human African 
trypanosomiasis, have a type B ribose 5-phosphate isomerase. This enzyme represents a 
potential drug target since it is absent from humans, which instead have a type A ribose 5-
phosphate isomerase. We have recently shown using RNAi that ribose 5-phosphate 
isomerase B confers bloodstream forms optimal growth in vitro and more important, is 
detrimental for mice infectivity. To further evaluate ribose 5-phosphate isomerase 
essentiality we tried to engineer a double knockout cell line. While single knockout cell 
lines can be generated in a first attempt, null mutants were never obtained. As expected, 
infections with the single knockout lines showed a reduced infectivity in vivo. In 
conclusion, our data reinforces ribose 5-phosphate isomerase B as a promising drug 
target against T. brucei and demonstrates the need of using a conditional knockout 
system to ultimately prove its essentiality. 
 
Unpublished data. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV – Objectives and results 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV – Objectives and results 
133 
 
SHORT COMMUNICATION 
 
Unsuccessful attempts to generate Trypanosoma brucei ribose 5-phosphate 
isomerase B double knockout 
 
Inês Loureiro1, Joana Tavares1†* & Anabela Cordeiro da Silva1,2†* 
 
1 Parasite Disease Group, Instituto de Biologia Molecular e Celular da Universidade do 
Porto, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal 
2 Departamento de Ciências Biológicas, Faculdade de Farmácia da Universidade do 
Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal 
 
†These authors contributed equally to this work. 
*corresponding authors e-mail: cordeiro@ibmc.up.pt; jtavares@ibmc.up.pt  
 
Abstract 
Ribose 5-phosphate isomerase catalyzes the interconversion of ribulose 5-
phosphate and ribose 5-phosphate within the non-oxidative branch of the pentose 
phosphate pathway. There are two types of ribose 5-phosphate isomerases, namely A 
and B. Trypanosomatids including Trypanosoma brucei, the agent of Human African 
trypanosomiasis, have a type B ribose 5-phosphate isomerase. This enzyme represents a 
potential drug target since it is absent from humans, which instead have a type A ribose 5-
phosphate isomerase. We have recently shown using RNAi that ribose 5-phosphate 
isomerase B confers bloodstream forms optimal growth in vitro and more important, is 
detrimental for mice infectivity. To further evaluate ribose 5-phosphate isomerase 
essentiality we tried to engineer a double knockout cell line. While single knockout cell 
lines can be generated in a first attempt, null mutants were never obtained. As expected, 
infections with the single knockout lines showed a reduced infectivity in vivo. In 
conclusion, our data reinforces ribose 5-phosphate isomerase B as a promising drug 
target against T. brucei and demonstrates the need of using a conditional knockout 
system to ultimately prove its essentiality. 
 
Introduction  
The pentose phosphate pathway (PPP) takes part of the carbohydrate metabolism 
and is divided into an oxidative and a non-oxidative branch. The oxidative PPP is 
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considered unidirectional and converts glucose 6-phosphate into ribulose 5-phosphate 
and NADPH, whereas the bidirectional non-oxidative branch metabolizes glycolytic 
intermediates yielding ribose 5-phosphate [1]. The importance of the non-oxidative branch 
is mainly attributed to the production of ribose 5-phosphate (R5P), a precursor for nucleic 
acids biosynthesis [2]. Within the non-oxidative PPP, ribose-5-phosphate isomerase (Rpi) 
catalyzes the interconversion of ribulose 5-phosphate into ribose 5-phosphate. There are 
two distinct forms of Rpi, termed A and B. The type B enzyme is present in 
Trypanosomatids, including in Trypanosoma brucei (T. brucei) parasites, while type A 
exists in humans. Although both enzymes catalyze the same reaction, they show no 
sequence or overall structural homology [3], which open up the possibility of considering 
T. brucei ribose 5-phosphate isomerase B (TbRpiB) as a new potential drug target against 
Human African trypanosomiasis. This disease relies exclusively on chemotherapy for 
control since vaccines are unlike to be suitable [4,5]. Moreover, we showed recently that 
TbRpiB mRNA knockdown through RNAi, is detrimental for parasites infectivity in mice [6], 
supporting the idea of a very promising therapeutic target. To further dissect the 
importance and role of RpiB in T. brucei parasites, targeted gene-disruption experiments 
were performed.  
 
Materials and methods 
 
Parasite growth  
T. brucei brucei Lister 427 bloodstream forms were cultivated in HMI-9 medium, as 
previously described [7]. 
 
Generation of DNA constructs and transfection 
Three different DNA cassettes were generated (Figure 1). The DNA fragments 
consisted in open reading frames (ORF) of the resistance genes (hygromycin, bleomycin 
and neomycin), flanked by the same 5’ and 3’ untranslated regions (UTRs) that flank the 
TbRPIB gene. 
For the generation of single knockout (sKO) mutants, the plasmid used was 
the pGL345-HYG plasmid [8,9] modified with the 5′ (924 bp) and 3’ (997 bp) RPIB flanks 
obtained through PCR from T. brucei genomic DNA template. PCR conditions were as 
follows: initial denaturation (2 min at 94ºC),  35 cycles of denaturation (15s at 94ºC), 
annealing (30s at 59ºC), elongation (1 min at 72ºC) and a final extension step (10 min at 
72ºC). The primers contained HindIII/SalI and SmaI/BgIII restriction sites (Table 1) were 
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used for cloning into the appropriately pre-digested pGL345-HYG (Figure 1). Thereafter 
the final plasmid was digested with HindIII and BglII to obtain the final DNA fragment for 
transfection. The transfection [10], using the 10 μg of DNA, resulted in stable hygromycin-
resistant parasites selected with 7.5 μg/ml of hygromycin. 
To remove the second allele, pGL345-BLEO or pGL345-NEO plasmids were 
constructed by replacing the hygromycin with bleomycin or neomycin resistance gene 
ORF, respectively, in the plasmid used to obtain the sKOs, employing SpeI/BamHI 
restriction enzymes (Figure 1). Ten micrograms of the final constructs, again obtained by 
digestion with HindIII and BglII restriction enzymes, were then transfected for double 
knockout (DKO) mutants achievement. The dose of 7.5 μg/ml, 0.2 μg/ml and 5 ug/ml of 
hygromycin, bleomycin and neomycin, respectively were used to select the resistant 
parasites. 
 
 
Figure 1. Graphic representation of the three constructs used for targeted 
disruption of TbRPIB. Drawings of the HYG fragment [used in the first attempt to 
generate single knockouts (sKO) (top)], of the BLEO fragment [used in the first two 
attempts to generate double knockouts (DKO) (center)], and NEO fragment [used in the 
third and fourth tries to obtain DKOs (bottom)] are depicted. Restriction enzymes used to 
insert the selectable marker (SpeI and BamHI), the 5’ UTR (HindIII and SalI) and 3’ UTR 
(SmaI and BglII) are charted. 
 
PCR analysis  
DNA was extracted using DNAzol reagents (Invitrogen) from wt and sKO cells 
lines. For sKO mutants resistant to hygromycin, PCR analysis was conducted using a 
forward primer complementary to a region 51-71 bp upstream the HindIII restriction site of 
the 5’ UTR of TbRPIB, and a reverse primer complementary to a region 61-82 bp 
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downstream the ATG of the hygromycin ORF (Table 1). PCR products were run in 1% 
(w/v) agarose gel. PCR conditions were as follows: initial denaturation (2 min at 94ºC), 35 
cycles of denaturation (30s at 94ºC), annealing (30s at 63ºC), elongation (2 min at 72ºC) 
and a final extension step (10 min at 72ºC). For sKO mutants resistant to neomycin PCR 
analysis was conducted using a forward primer complementary to a region 51-71 bp 
upstream the HindIII restriction site of the 5’ UTR of TbRPIB, and a reverse primer 
complementary to a region 2347 bp downstream the ATG of the bleomycin ORF (Table 
1). PCR products were run in 1% (w/v) agarose gel. PCR conditions were as follows: 
initial denaturation (2 min at 94ºC), 35 cycles of denaturation (30s at 94ºC), annealing 
(30s at 62ºC), elongation (2 min 30s at 72ºC) and a final extension step (10 min at 72ºC). 
 
Table 1. Primers used to amplify 5’ and 3’ RPIB flanks.  
 5’ UTR 
Primer F 5’ - CGAAGCTTTAAGCGGTGATTGAGCGT - 3’ 
Primer R 5’ - CGGTCGACTGTTGATTGTAAAAGGA - 3’ 
 3’ UTR 
Primer F 5’ - CGCCCGGGATATTTGGTAAATGATAATC - 3’ 
Primer R 5’ - CGAGATCTGCATACGTTCAGTGGTTGTT - 3’ 
 PCR analysis (HYH cassette) 
Primer F 5’ - AACATGCCCCACCCCTCCCC - 3’ 
Primer R 5’ - GCTGCATCAGGTCGGAGACGC - 3’ 
 PCR analysis (NEO cassette) 
Primer F 5’ - AACATGCCCCACCCCTCCCC - 3’ 
Primer R 5’ - GTGGTCGAATGGGCAGGTAG - 3’ 
 
Southern blot analysis 
The 3′ UTR of TbRPIB was amplified by PCR (using the primers previously 
described) and labelled using the Kit Amersham AlkPhos Direct Labeling and Detection 
System with CDP-Star (GE Healthcare). The resulting labelled product was used as a 
probe. Genomic DNA preparations (10 μg) from wt and TbRPIB sKO cells were digested 
with BspHI and separated in a 0.8% (w/v) agarose gel. The DNA fragments were 
transferred onto Hybond-N+ positively charged nylon membrane (GE Healthcare). 
Membrane hybridization, washes, and chemiluminescent detection were done according 
to the kit manufacture instructions. 
 
Western blot analysis 
 For Western blotting, 107 of wt and sKO parasites were resolved in 12% Tris-
Glycine SDS/PAGE, and then transferred on to a nitrocellulose Hy-bond ECL membrane 
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(Amersham Biosciences). The membrane was blocked in 5% (w/v) non-fat dried skimmed 
milk in PBS/0.1% Tween-20 (blocking solution), followed by incubation with a combination 
of rabbit anti-TbRpiB (1:1000) [6] with rabbit anti-aldolase (1:5000) (kindly provided by 
Christine Clayton, ZMBH, University of Heidelberg, Germany) antibodies in blocking 
solution at 4ºC overnight, respectively. Blots were washed with PBS/0.1% Tween-20 (3 
times, 15 min). Horseradish peroxidase-conjugated goat anti-rabbit IgG (Amersham) 
(1:5000 for 1h, at room temperature) was used as the secondary antibody. The 
membranes were developed using SuperSignal WestPico Chemiluminescent Substrate 
(Pierce). ImageJ software (version 1.43u) was used for protein bands semi-quantification. 
 
In vitro and in vivo analysis of TbRPIB sKO 
For in vitro growth curves, cell lines were seeded at 105 parasites/ml of complete 
HMI-9 medium, after 48h in the absence of selective drugs. Every 24h, until day 10, cell 
growth was monitored microscopically. For in vivo infections, after 48h in the absence of 
selective drugs, 104 wt and sKO parasites were inoculated intraperitoneally in 6–8 weeks 
old BALB/c mice (n=3). Parasitaemia was measured at fourth, fifth and sixth day post-
infection through tail blood extraction. 
 
Results and discussion 
To obtain TbRPIB null mutants, sKO lines were firstly generated and were 
achieved right in the first attempt. After HYG cassette transfection, one TbRPIB wt allele 
was replaced through homologous recombination by the hygromycin selectable marker, 
giving rise to TbRPIB single-allele (null/+) knockout mutants. PCR and Southern blot 
confirmed the correct insertion of the cassette (Figure 2A and B, respectively), and 
Western blot shows a decrease in TbRpiB protein levels of approximately 50% in sKO cell 
lines compared to wt lines (Figure 2C). No significant differences were found on the in 
vitro growth of TbRPIB sKO bloodstream forms compared to wt (Figure 2D). This differs 
from our previous results where a statistically significant difference on the in vitro 
cumulative growth of induced versus non-induced RNAi TbRpiB cell lines was seen after 
day 4 [6]. The higher levels of RpiB down-regulation achieved with RNAi might explain the 
different phenotypes. When used to infect mice, TbRPIB sKO showed as expected, 
reduced infectivity evaluated by the parasitaemia (Figure 2E) and by the increase of mice 
life span (Figure 2F) when compared to wt parasites. Again, the defective phenotype 
observed in vivo was less pronounced when compared to the one achieved with RNAi [6]. 
Chapter IV – Objectives and results 
138 
 
Nevertheless, our data shows that 50% of RpiB down-regulation is sufficient to 
compromise parasites infectivity. 
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Figure 2. Analysis of bloodstream TbRPIB sKO (HYG marker). (A) PCR analysis of 
parental wt and two sKOs to evaluate hygromycin cassette integration on the RPIB 
genomic locus. The amplified 2025 bp region is depicted. A PCR mix without genomic 
DNA, was used as a negative control. (B) Southern blot analysis of BspHI digested 
genomic DNA (≈10 μg) from wt cells and two TbRPIB sKO clones (HYG selectable 
marker) probed with 3’ UTR of TbRPIB. (C) Western blot analysis of whole-cell extracts 
from wt and two sKO clones. Proteins were detected with rabbit anti-TbRpiB antibody. 
Aldolase was used as loading control. (D) Growth curve of a wt versus a representative 
sKO cell line. Black and grey squares represent wt and sKO growth, respectively. 
Cumulative cell numbers (product of cell number and total dilution) are plotted. Values 
represent averages from two independent experiments using one representative sKO 
clone and ± error bars indicate standard deviation. (E) Groups of mice (n=3) were infected 
intraperitoneally with 104 control wt (black squares) or a representative sKO clone (grey 
squares). Parasitaemias of each group are shown from 4th to 6th day post-infection. Values 
are means and errors bars indicate + standard deviation. 5×104 trypanosomes/ml of blood 
is the detection limit. For TbRPIB sKO, the mean of parasitaemia at day 6 was below the 
detection limit and therefore not seen in the graphic. Mice were culled when parasitaemia 
reached 108 cells/ml. (F) Kaplan–Meier survival analysis of mice infected with wt versus a 
representative sKO clone (black and grey line, respectively). Parasitaemias and survival 
curve are representative of two independent experiments using two different sKO clones. 
 
For the generation of TbRPIB double-allele knockout mutants, the hygromycin-
resistant cell line was subjected to a second round of transfection using a construct with a 
different selectable marker (bleomycin). Two attempts to cultivate transfectants in the 
presence of both hygromycin and bleomycin, did not result in the outgrowth of cells 
resistant to both antibiotics. In a third attempt, the construct was modified. The selectable 
marker was changed to neomycin. Again, cells resistant to both antibiotics did not grow. 
The neomycin construct reliability was assessed by simultaneous transfection of wt and 
sKO cell line. Resistant parasites were only obtained for the wt but not for the sKO cell 
line (Figure 3). This result strongly suggests that a functional copy of TbRPIB gene is 
essential for parasites survival.  
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Figure 3. Analysis of bloodstream TbRPIB sKO (NEO marker). (A) PCR analysis of 
parental wt and sKO to evaluate neomycin cassette integration in the RPIB genomic 
locus. The amplified 2347 bp region is depicted. A PCR without genomic DNA (-), was 
used as a negative amplification control. 
 
To ultimately prove the gene essentiality, a TbRPIB conditional knockout should be 
pursued. Using this system, parasites are engineered to express a regulatable allele of 
the gene and a gene is proved essential when parasites die upon removal of tetracycline 
(which represses transcription of the regulatable allele in null mutants) [11].  
With our results RpiB gains strength as a potential therapeutic target against T. 
brucei infections.  
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1 Asparagine synthetase A 
 
1.1 Trypanosomatids asparagine synthetase A peculiarities 
 
 Asparaginyl-tRNA synthetases and non-discriminating aspartyl-tRNA synthetases 
are involved in asparagine metabolism and have been subjected to a considerable 
number of studies (Becker & Kern, 1998; Blaise et al, 2011; Min et al, 2002; Pham et al, 
2014; Raczniak et al, 2001; Roy et al, 2003) however, very few have been done in 
trypanosomatids (Gowri et al, 2012; Kalidas et al, 2014). AS-A is a tRNA synthetase 
paralog containing only the synthetase domain to perform asparagine biosynthesis (Gowri 
et al, 2012). While ASB genes are reported from all the three domains of life, ASA genes 
have been reported from prokaryotes (Nakamura et al, 1981), archaea (Blaise et al, 
2011), and more recently from eukaryotic pathogens including, Trypanosomatids, 
Trichomonas vaginalis, Entamoeba histolytica and Cryptosporidium spp (Gowri et al, 
2012; Heinz et al, 2012). In trypanosomatids, such T. cruzi, T. brucei and L. donovani, the 
ASA gene encodes a functional AS-A enzyme (Loureiro et al, 2013; Manhas et al, 2014). 
 Several AS-A 3D structures are available, including from E. coli (PDB 11AS and 
12AS), Pyrococcus abyssi (PDB 3P8T, 3P8V, 3P8Y, 3REX, 3REU and 3RL6), and of an 
AS-A peptide from Pyrococcus furiosus (PDB 1NNH) (Blaise et al, 2011; Nakatsu et al, 
1998) and more recently, also from T. brucei (Manhas et al, 2014). Analysis of EcAS-A 
crystal structure reveals a class II catalytic core of aminoacyl tRNA synthetases (Nakatsu 
et al, 1998). Structure-based sequence comparison of EcAS-A with the catalytic domain of 
yeast aspartyl tRNA synthetase showed a high conservation of catalytic residues. Despite 
the substrates of these two enzymes are the same, the activation of carboxyl groups on 
the aspartyl residues is different. Saccharomyces cerevisiae aspartyl tRNA synthetase 
activates the α carboxyl group of the substrate while EcAS-A activates the β carboxyl 
group (Nakatsu et al, 1998). The recent crystal structure of archaeal Pyrococcus abyssi 
AS-A helped to uncover how the active site of ancestral aspartyl-tRNA synthetase 
rearranged throughout evolution to transform an enzyme activating α carboxyl group into 
an enzyme that is able to activate the β carboxyl group and can react with ammonia 
instead of tRNA (Blaise et al, 2011). Trypanosomes AS-A have the highest amino acid 
sequence identity with EcAS-A and a sequence-based phylogenetic analysis followed by 
structural modeling suggests close evolutionary origin of kinetoplastid AS-A with the 
prokaryotic rather than the archael enzyme (Gowri et al, 2012; Loureiro et al, 2013). The 
crystal structure of apo-TbAS-A was solved by molecular replacement using EcAS-A 
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(PDB code 11AS) as the search model (Manhas et al, 2014). Expectedly, the overall fold 
of TbAS-A was hence very similar to EcAS-A. This appears also to happen for the other 
trypanosomatids, T. cruzi and L. donovani. Interestingly, it still remains unclear the 
functional and structural significance of the small divergent region present in 
trypanosomatids enzymes but absent in EcAS-A and archaeal AS-A (Manhas et al, 2014). 
Also interesting is the fact that these residue insertions seem to have little sequence 
conservation between trypanosomes and L. donovani AS-A (LdAS-A); in TbAS-A 
sequence this insertion is: QVVFPRTSKPIPTMNSLSS; in TcAS-A is: 
DITFPCGDPTMNSLAS, and in LdAS-A is: KIGFPTADDEKPSVNTIMS). The apo form of 
TbAS-A structure shows no significant deviation from its E. coli counterpart except a ~9Å 
displacement near α-helices 6 and 7 (Manhas et al, 2014). This study also confirmed that 
the active site residues involved in L-asparagine and AMP recognition are conserved 
between EcAS-A, TbAS-A and LdAS-A. Nevertheless, small different features within the 
active sites, like the Y218 residue in EcAS-A though conserved, is disordered in TbAS-A 
and can be exploited to screen specific inhibitors that can selectively target parasite 
enzymes. In this line, and as predicted by the initial bioinformatics analysis, the amino 
acid sequence and structure similarity between trypanosomes AS-A and human AS-B 
showed to be very low. It was determined less than 15% of sequence identity (clustalw) 
(Larkin et al, 2007), and using Dali program (Holm & Rosenstrom, 2010), we were not 
able to structurally superimposed trypanosomes sequences with human AS-B. The 
common AS-A protein active sites present in the three trypanosomatids sequences are 
different from those found in human AS-B protein, therefore, it is theoretically possible to 
design a common inhibitor that will act against these and not against human protein. 
AS type A enzymes are known for catalyzing the ATP dependent conversion of 
aspartate into asparagine, using strictly ammonia as the nitrogen source (Cedar & 
Schwartz, 1969a; Cedar & Schwartz, 1969b; Reitzer & Magasanik, 1982). AS type B 
enzymes detain the ability of using both ammonia and glutamine as substrates, with 
remarkable preference for the second (Boehlein et al, 1994; Ciustea et al, 2005; Duff et al, 
2011; Horowitz & Meister, 1972; Patterson & Orr, 1968; Ramos & Wiame, 1979) (except 
for human enzyme which has similar affinity for glutamine and ammonia) (Ciustea et al, 
2005). We have demonstrated that recombinant TbAS-A and TcAS-A have in vitro AS 
type A activity, as proteins were able to generate asparagine using aspartate, ATP and 
ammonia, in the presence of magnesium, which is an essential cofactor. To our 
knowledge, we reported for the first time, AS type A enzymes able to use not only 
ammonia but also glutamine as a nitrogen donor, however with preference for ammonia 
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(Loureiro et al, 2013). This hybrid activity was only previously demonstrated for type B 
enzymes (Boehlein et al, 1994; Ciustea et al, 2005; Duff et al, 2011; Horowitz & Meister, 
1972; Patterson & Orr, 1968; Ramos & Wiame, 1979). In agreement with our study, a 
more recent paper also shows that L. donovani is capable of using glutamine as nitrogen 
source (Manhas et al, 2014). It is important to point that papers about AS-A biochemical 
characterization from bacteria are old papers, which resorted to technology available at 
that time (Cedar & Schwartz, 1968; Cedar & Schwartz, 1969a; Reitzer & Magasanik, 
1982). Gene fusion technology and affinity chromatography is now widely used for the 
improvement of soluble protein production and/or purification in E. coli, which were not 
available at that time. The background activity seen in the absence of substrates 
corroborates some level of contamination in the purified enzymes, which may have led to 
misleading results (Cedar & Schwartz, 1969a). Therefore, the paradigm that AS-A 
enzymes are strictly ammonia dependent should be reevaluated. Nevertheless, the hybrid 
activity of trypanosomatids AS-A was detected using enzymes expressed on heterologous 
systems. Ideally this activity should be also demonstrated using the enzymes purified 
directly from parasites extracts. Another important aspect is the fact that, despite the 
residues involved in the binding of aspartate/asparagine and ATP/AMP are well described 
in type A enzymes, where and when does ammonia bind remains unknown (Blaise et al, 
2011). In trypanosomatids AS-A, this issue also arises for glutamine. Unless the 
crystallographic structure is solved at very high resolution (~1Å), the hydrogen atoms are 
generally not visible in the electron density maps, and the ammonia nitrogen atom is not 
easily distinguishable from the oxygen atom in a water molecule. Thus, 
the cocrystallization of AS-A enzymes with ammonia will probably not allow the 
unambiguous determination of the ammonia binding site. The cocrystallization 
of trypanosomatids enzymes with glutamine, although difficult, may give information about 
the nitrogen donor binding site, therefore should be pursued. 
In Klebsiella aerogenes, the nitrogen enrichment or impoverishment of the medium 
was proved to trigger the expression of AS-A or AS-B respectively (Reitzer & Magasanik, 
1982). Trypanosomatids AS-A ability to use either ammonia or glutamine as nitrogen 
donors may reflect parasites need to adapt to changes in nitrogen content and availability 
(Loureiro et al, 2013; Manhas et al, 2014). Interestingly, the difference on affinity found in 
TbAS-A and TcAS-A for both substrates, ammonia or glutamine (1.5 and 2 folds 
difference, respectively), is lower than the difference found in most AS-B type enzymes 
(except for human AS-B, as mentioned above) (Ciustea et al, 2005; Duff et al, 2011; 
Horowitz & Meister, 1972; Patterson & Orr, 1968; Ramos & Wiame, 1979).  
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1.2 The promising T. brucei asparagine synthetase A is unlikely to be suitable as a 
drug target against human African trypanosomiasis 
  
Our genetic studies showed that TbAS-A is unlikely to be used as a target for the 
development of HAT new chemotherapeutic drugs. Parasites with down regulated levels 
of AS-A were able not only to growth as the wt in vitro, but also to equally infect mice. A 
defective growth phenotype and cell cycle arrest in G0/G1 was only observed when 
parasites with downregulated levels of AS-A were grown on asparagine-free medium. This 
phenotype was reverted when exogenous asparagine was added to the medium (Loureiro 
et al, 2013). Other studies also established a link between low levels of asparagine and in 
vitro cell cycle arrest. Helycobacter pylori L-asparaginase induces cell-cycle arrest in vitro 
of fibroblasts and gastric cell lines, in an extent that correlates with asparagine synthetase  
levels (Scotti et al, 2010). Moreover, removal of L-asparagine from the culture of L5178Y 
leukemia cells (lack a functional asparagine synthetase), by E. coli L-asparaginase leads 
to DNA fragmentation, cells cycle arrest in G1 phase, and apoptosis (Ueno et al, 1997). 
Similarly to in vitro experiments, the infectivity of bloodstream forms with reduced levels of 
AS-A was only affected when mice were simultaneously treated with E. coli L-
asparaginase. The appearance of RNAi revertants, both in vitro and in vivo experiments, 
was a powerful sign of a stressful situation for the parasites. T. brucei can become 
irresponsive to tetracycline induction and consequently resume a normal growth efficiency 
through the deletion of the integrated target gene fragment and apparently by other 
unclear mechanisms, such as mutations at the T7 promotor/tetracyclin operator (Chen et 
al, 2003). Overall, our results suggest that bloodstream parasites rely on two major 
sources of asparagine to ensure normal proliferation: uptake from the extracellular 
medium and biosynthesis by AS-A. More importantly, parasites growth is only significantly 
affected when both sources of asparagine are compromised (Loureiro et al, 2013). 
Its noteworthy to mention that in trypanosomes genome there is a second open 
reading frame (Tb927.3.4060) coding for a putative AS domain. However, this is 
apparently not a classical AS, despite the presence of a good Pfam AS domain (PF0073) 
at the C-terminus. A BLASTp search using the T. brucei sequence revealed a variety of 
proteins of unknown function that aligned not only across the AS domain, but also in the 
N-terminal region, which contains N-terminal aminohydrolase domains. Best matches 
originate from extremely diverse eukaryotes including a plant, an alga, a member of the 
fungi and an amoeba. BLASTp against the Saccharomyces cerevisiae predicted proteome 
yielded YML096W, and the reciprocal BLASTp on the trypanosome genome indeed gave 
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Tb927.3.4060 as best match. The function of YML096W is not known. Moreover, our 
results indirectly suggest that this protein may have no significant contribution for 
asparagine biosynthesis at least in T. brucei bloodstream forms (Loureiro et al, 2013). 
Based on our results, a therapy that simultaneously inhibits T. brucei asparagine 
synthetase activity A, by using a AS-A specific inhibitor, and abrogates asparagine 
uptake, through L-asparaginase which decrease asparagine blood levels or through an 
asparagine transporter inhibitor which prevents the parasite to uptake extracellular 
asparagine, might be an option. Interfering with asparagine levels in the blood, through 
the administration of L-asparaginase, is currently used on the treatment of acute 
lymphoblastic leukemia (Pieters et al., 2011). These therapies rely on the fact that some 
malignant cells are dependent on exterior supplies of L-asparagine, because on their own 
exhibit a particular low level of AS expression (Asselin & Kurtzburg, 2003; Rizzari, 2003), 
and are also incapable of a rapid AS protein up-regulation response. Both aspects make 
these cells highly sensitive to L-asparaginase (Aslanian et al, 2001; Su et al, 2008). In 
contrast to leukemic cells which die when deprived of exogenous asparagine, most solid 
tumors express AS-B and synthesize asparagine de novo (Balasubramanian et al, 2013), 
therefore L-asparaginase alone has not proven to be an effective therapy. AS-B inhibition 
together with L-asparaginase administration might be a new strategy for the treatment 
pancreatic, ovarian, hepatic and breast tumours with high AS expression (Dufour et al, 
2012; Lorenzi et al, 2008; Lorenzi et al, 2006; Yang et al, 2014). But still, L-asparaginase 
treatment requires parenteral administration and leads to serious adverse events, such as 
pancreatitis, severe hyperlipidaemia, altered liver function, severe allergic reactions, and 
thrombosis (Appel et al, 2008; Cohen et al, 2010; van den Berg, 2011). Once the actual 
chemotherapy against HAT is already highly toxic and expensive for developing countries, 
we need to developed new non-toxic and cheaper therapies of easy administration, rather 
than parenteral. Therefore is questionable the benefit of the suggested combination 
therapy over the existing HAT therapies. With regard to the second strategy, the functional 
redundancy in amino acid transporter repertoire, does not offer much of viable drug 
targets (Ebikeme, 2007). However exceptions exist, a recent study showed that in 
Francisella tularensis infection, the depletion of an amino acid transporter (AnsP) involved 
in asparagine and aspartate transport, lead to a severe intracellular growth defect and 
impact systemic dissemination of bacteria in mice. Remarkably, the intracellular growth 
and in vivo virulence defect of the mutants were fully and specifically reversed when 
asparagine, asparagine-containing dipeptides or simultaneous aspartic acid and 
ammonium were added at high concentrations and alternative amino acid permeases 
Chapter IV – Discussion and conclusions 
150 
 
assured their transport. These facts confirmed that the multiplication defect of the null 
ansP mutants is due to an asparagine uptake defect when the bacteria are localized in the 
cytosol of infected cells. Thus it is reasonable to assume that in these cases transporters 
can constitute attractive targets (Gesbert et al, 2014). However, interfering with 
asparagine uptake in T. brucei is unlikely to be achievable, once a family of 46 genes 
encoding amino acid transporters is present in the T. brucei genome making it the largest, 
and most diverse, family of transporters encoded in the genome (Ebikeme, 2007).  
 
1.3 The controversy on the essentiality of asparagine synthetase A in 
trypanosomatids 
 
In T. brucei bloodstream forms immunolocalization studies indicate AS-A is 
localized in the cytosol (Loureiro et al., 2013). In contrast, in L. donovani promastigotes 
AS-A was localized not only in the cytosol but also in the mitochondria of parasites 
engineered to express an episomal GFP-tagged AS-A. Indeed in this work, protein 
localization studies were performed on AS-A overexpressing parasites, an artificial 
condition that may have an impact on the protein distribution (Manhas et al, 2014). L. 
major AS-A appears to have a mitochondrial (PSORT II) and cytosolic (MARSPred) 
localization prediction however, mitochondria targeting signal peptide sequences and 
cleavage sites could not be predicted by computational tools (Manhas et al, 2014). These 
aspects combined with a poor and inaccurate mitochondria labeling warrant new AS-A 
localization studies in Leishmania. The same study also describes ASA as an essential 
gene for Leishmania based on failed attempts to delete the second copy of the gene 
(Manhas et al, 2014). However, to be fully convincing, attempts to remove the second 
allele should have been made in complemented parasites that are then left in culture 
without drug. The maintenance of the episomal copy in complemented null mutants 
cultured without drug pressure is the ultimate proof the gene is essential since in 
Leishmania no cKOs are yet possible. The authors mentioned that chromosomal null 
mutants could not be obtained as the double transfectant mutants showed aneuploidy, but 
experimental data regarding ploidy levels was not shown (Manhas et al, 2014). A slight 
growth delay in vitro was shown for LdASA sKOs compared to wt parasites, however this 
difference was not proved to be statistically significant (Manhas et al, 2014). Experiments 
to analyze the infectivity of sKO parasites would be also important and already indicative 
of AS-A relevance, since authors argue that this protein is a therapeutic target. Overall, 
the conclusion of Leishmania ASA as an essential gene requires a careful reevaluation. 
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1.4 Does the function of asparagine synthetase and its product, asparagine, goes 
beyond protein biosynthesis in T. brucei? 
 
Depletion of any individual or several amino acids in the cells triggers the 
activation of the amino acid response (AAR) pathway (Gong et al, 1991; Hutson & Kilberg, 
1994). Within this pathway, amino acid deprivation causes an increased abundance of the 
corresponding uncharged tRNA that binds to and activates the general control non-
depressible 2 (GCN2) kinase (Kilberg et al, 2009) which in turns phosphorylates the 
eukaryotic translation initiation factor-2 alpha (eIF2α). The eIF2α is a general sensor of 
exogenous and endogenous stress signals and therefore a substrate for several other 
kinases, which are in turn activated by several stress events and that are summarized on 
figure 18. Phosphorylated eIF2α signals down-regulate global protein synthesis by 
repressing translation initiation (Baird & Wek, 2012), but simultaneously, up-regulate the 
translation of a subset of mRNA molecules involved in stress response, including the 
activating transcription factor 4 (ATF4) (Kilberg et al, 2009). Consequently ATF4 activates 
specific genes via C/EBP-ATF response element (CARE), including AS gene (Kilberg et 
al, 2009). The magnitude of the up-regulation of various ATF4 transcriptional targets, 
including AS, vary depending on the amino acid and on the cell line (Fomina-Yadlin et al, 
2014). Reduced translation conserves energy and nutrients, allowing time for the cell to 
adapt appropriately to the stress conditions.  
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Figure 18. Phosphorylation of eIF2α is mediated by different kinases that respond to 
specific environmental stresses: 1) GCN2 which is activated during amino acid starvation; 
2) protein kinase R (PKR), which plays a key role in the cellular anti-viral response; 3) 
protein kinase RNA-like endoplasmic reticulum kinase (PERK), which responds to protein 
misfolding in the endoplasmic reticulum; and 4) HRI that limits protein synthesis during 
heme-deficiency. Phosphorylated eIF2α suppresses global translation, but leads to a 
paradoxical increase in translation of specific mRNA species, such as that for ATF4, 
which consequently enhanced AS transcription, one of the hundreds of ATF4 target 
genes. [Adapted from (Balasubramanian et al, 2013; Kilberg et al, 2009)]. 
 
The activation of the GCN2-eIF2-ATF4 signalling pathway, leading to increased 
expression of AS was proved to be a component of solid tumor adaptation to nutrient 
deprivation and/or hypoxia (Ye et al, 2010). What is curious in this study, is the fact that 
supplementation of small hairpin ATF4-expressing tumor cells with asparagine, but no 
other amino acid, reversed the increased apoptosis and authophagy leading to increased 
cell survival. Moreover, another study proposed that the function of AS up-regulation in 
response to low glucose is to protect pancreatic cancer cells from apoptosis. In addition to 
greater tolerance for glucose limitation, pancreatic cancer cells over-expressing AS 
exhibited increased resistance to apoptosis induced by cisplatin (Cui et al, 2007).  
AS protein’s name directs the focus to its function, the synthesis of asparagine, 
however the reaction impact the cellular levels of glutamine as well (Scofield et al, 1990). 
Given the critical function of glutamine as an oxidizable energy source, a key nitrogen 
carrier, and a mammalian target of rapamycin (mTOR) regulator, glutamine homeostasis 
should also be considered when evaluating the impact of the activity of these enzymes. 
With respect to deprivation of glutamine, curiously a very recent paper using SV40-
transformed mouse embryonic fibroblasts, neuroblastoma and human glioblastoma cell 
lines demonstrated that suppression of citrate synthase, the first tricarboxylic acid cycle 
(TCA) cycle enzyme, prevented glutamine-withdrawal-induced apoptosis, which was a bit 
surprising once many cancer cells consume large quantities of glutamine to maintain TCA 
cycle anaplerosis and cell survival (Zhang et al, 2014). Citrate synthase suppression 
reduced TCA cycle activity and diverted oxaloacetate into production of aspartate, and 
ultimately asparagine (Figure 19).  
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Figure 19. Citrate synthase knockdown redirects oxaloacetate to aspartate and 
asparagine biosynthesis. Abbreviations are as follows: Glc, glucose; Pyr, pyruvate; Ac-
CoA, acetyl-CoA; CS, citrate synthase; Gln, glutamine; Glu, glutamate; Cit, citrate; a-KG, 
a-ketoglutarate; Suc, succinate; Fum, fumarate; Mal, malate; OAA, oxaloacetate; Asp, 
aspartate; Asn, asparagine. [Adaped from (Zhang et al, 2014)]. 
 
Subsequent experiments within this study demonstrated that asparagine can maintain the 
viability of glutamine-deprived cells without restoration of anaplerosis or the levels of other 
nonessential amino acids. The rescue of survival by asparagine was specific to depletion 
of the nonessential amino acid, glutamine, once exogenous asparagine had no effect on 
cell death induced either by depletion of essential amino acids, including leucine, 
threonine, or phenylalanine, or by glucose depletion or DNA topoisomerase inhibition. 
Interestingly, while sustained levels of asparagine promote cellular adaptation to depletion 
of glutamine and other nonessential amino acids, intracellular depletion of asparagine 
through AS knockdown, induces apoptosis even in the face of an abundant supply of 
glutamine and other nonessential amino acids, only being reversed by addition of 
exogenous asparagine. Surprisingly, only the addition of asparagine can specifically 
suppress that apoptosis through the suppression of CHOP induction without altering the 
upstream signaling cascade, including eIF2a phosphorylation and ATF4 accumulation. 
Zhang J et al. (2014) results showed that exogenous asparagine had no effect on cell 
death induced by glucose depletion contradicting the study above from Cui H at el. (2007). 
Nevertheless,all together the data proposes an unexpected role of AS-A and/or 
asparagine in regulating cell survival. Protein synthesis seems too simplistic, as other 
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amino acid synthesis pathways are not as highly regulated, and other amino acids do not 
appear to play as critical a role. 
The response to stress via phosphorylation of eIF2α is conserved from yeast to 
mammals and plays a significant role when cells must respond to environmental stresses 
(Murguia & Serrano, 2012). Previous work indicated that trypanosomes encode three 
potential eIF2 kinases (eIF2K1-K3) being one of them, TbeIF2K1, a possible GCN2 
orthologue. T. brucei TbeIF2K2, was able to phosphorylate yeast and mammalian eIF2α. 
It also phosphorylates an unusual form of eIF2α found in trypanosomes (Moraes et al, 
2007). Phosphorylation of eIF2α has been shown to mediate translational control in 
response to nutritional stress and underlie cell differentiation in protozoan parasites. In 
Toxoplasma gondii, phosphorylation of eIF2α by different stress stimulus results in the 
differentiation into quiescent stages, which are responsible for microbial persistence and 
latent infection (Narasimhan et al, 2008). Also, phosphorylation of Plasmodium 
falciparum eIF2α is required in the formation of sporozoites in the salivary gland of the 
insect vector (Zhang et al, 2010). In the case of Leishmania, promastigotes with impaired 
eIF2α phosphorylation upon ER stress, showed delayed differentiation into amastigotes 
either within axenic cultures or macrophages (Chow et al, 2011). In T. cruzi differentiation 
of epimastigotes into the infective form, trypomastigotes, requires the inhibition of 
translation by phosphorylation of eIF2α that is triggered by nutritional deprivation (Chow et 
al, 2011). Unfortunately, neither of the above studies determined whether an increase of 
AS protein levels or asparagine occurs in stresses stimulus-response. 
All these facts suggest that key features of eIF2-signalling pathway are probably 
conserved in parasites and raised a relevant question: is it possible that AS or asparagine 
serves another role, perhaps as a signaling molecule in T. brucei? In our study, 
bloodstream forms with down-regulated levels of AS-A had growth defects only in limiting 
asparagine environments suggesting that asparagine production is the main function of 
TbAS-A. However, an involvement of AS-A in a stress-response signaling pathway can’t 
be completely excluded since residual levels of AS-A upon RNAi induction might be 
sufficient for that potential function. 
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2 Ribose 5-phosphate isomerase B  
 
2.1 Ribose 5-phosphate isomerase B has a critical role in T. brucei infectivity in 
mice  
 
The PPP is an important pathway that branches from glycolysis and uses glucose-
6-phosphate in reactions that ultimately produce NADPH and R5P. The connections 
between glycolysis, amino acid/lipid biosynthesis, and sugar/redox metabolism, place 
PPP central to the metabolic network. Involved in the non-oxidative branch of PPP, RpiB 
has been pointed in several pathogens as a potential therapeutic target (Edwards et al, 
2011; Kaur et al, 2012; Roos et al, 2008; Stern et al, 2007; Wang & Yang, 2013) due to 
the very low sequence identity with its human counterpart RpiA. Presumably, both 
enzymes represent an example of convergent evolution as RpiA occur in most eukaryotes 
and some bacteria, while RpiB exist almost exclusively in prokaryotes, with few 
exceptions in lower eukaryotes, including trypanosomatids, other parasitic protozoa, and 
some fungi (Stern et al, 2011). In organisms where both genes are found, such as E. coli, 
RpiA plays the main role in the isomerazation of R5P and Ru5P (Skinner & Cooper, 1974) 
while RpiB might be involved on the isomerization of a different sugar phosphate, like D-
allose-6-phosphate (Roos et al, 2008). Interestingly, E. coli RpiB is slightly worse at 
catalyzing the isomerization of D-allose-6-phosphate than R5P suggesting that if for some 
reason RpiA stops functioning, RpiB can take over its activity (Roos, 2007). Structural 
studies explained why larger 6-carbon sugar phosphate could be accommodated by E. 
coli RpiB and not by Mycobacterium tuberculosis (M. tuberculosis) RpiB enzyme. In the 
latter the active site has no space for a linear 6-carbon compound (Roos et al, 2008). 
Moreover since this sugar is extremely rare in nature, the reason why E. coli has an 
operon devoted to allose metabolism remains a mystery. In trypanosomes and other 
organisms where only an RpiB is encountered, the role of this enzyme must be mainly of 
R5P and Ru5P isomerization. 
To date, the crystal structures of RpiB enzymes from E. coli (PDB 1NN4 and 
2VVR) (Becker & Kern, 1998; Zhang et al, 2003), M. tuberculosis (PDB 2VVP, 2VVQ, 
2VVO, 2BET, 2BES and 1USL) (Becker & Kern, 1998; Curnow et al, 1998; Roos et al, 
2005), Coccidioides immintis (PDB 3QD5, 3SDW and 3SGW) (Min et al, 2002), 
Anaplasma phagocytophilum (PDB 4EM8), Clostridium thermocellium (PDB 3PH3, 3PH4 
3HEE, and 3HE8) (Jung et al, 2011), Giardia lamblia (PDB 3S5P), T. cruzi (PDB 3K7P, 
3M1P, 3K7O, 3K8C and 3K7S) (Stern et al, 2011), and Thermotoga maritima (1O1X) 
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(Gatti & Tzagoloff, 1991) have been determined. Multiple sequence alignment and 
structural superposition showed a huge similarity within the TcRpiB (CL Brener Esmeraldo 
like strain), TcRpiB (CL Brener Non-Esmeraldo like strain) and TbRpiB sequences 
(Loureiro et al, 2015). Sequence and structure similarities between trypanosomes and 
human RipA enzymes were confirmed to be very low (<15%). Thus, it should be possible 
to design compounds that only bind to RpiB enzymes.  
From X-ray structures and site-directed mutagenesis studies, it is consensual a 
main role for His102 in the furanose ring opening step, and was suggested Glu75 in the 
M. tuberculosis enzyme, Cys66 from E. coli, and Cys69 in T. cruzi as the catalytic base for 
the isomerization (Roos et al, 2004; Roos et al, 2005; Stern et al, 2007; Zhang et al, 
2003). Additionally, His10 in E. coli and His11 in T. cruzi were proposed to be important in 
the stabilization of the protein (Stern et al, 2007; Zhang et al, 2003). The complete 
conservation of crucial amino acid residues in TbRpiB warrants the in vitro RpiB activity. 
As in TcRpiB (Stern et al, 2007), T. brucei enzyme detains the ability of using both R5P 
and Ru5P as substrates, with remarkable preference for the second (Loureiro et al, 2015).  
As far as we know a rpiB knockout was only described in E. coli. But in this case 
both type A and B are equally efficient in catalyzing the isomerization step and therefore 
the construction of double mutants was needed to fully prevent this reaction. The Rpi dKO 
lacking both rpiA and rpiB showed severely impaired growth phenotype (Sorensen & 
Hove-Jensen, 1996). In contrast and as already mentioned, T. brucei lacks RpiA, 
therefore Rpi activity is very likely confined to the type B enzyme.  
RNAi was firstly performed for TbRpiB genetic validation. In vitro RNAi induction 
leads to a significant decrease of bloodstream forms proliferation after day 4. Most 
important is when RNAi was induced in vivo, and the infectivity of induced RNAi cells was  
substantially affected leading to a decrease in parasitaemia and a prolonged mice 
survival. Mice infected with RNAi induced parasites eventually die due to the emergence 
of  RNAi revertants. The occurrence of any off target effect was excluded since in vitro 
and in vivo phenotypes were reverted in TcRpiB complemented parasites (Loureiro et al, 
2015). To further investigate if bloodstream forms deleted of RpiB are completely cleared 
in mice, we tried to generate knockout parasites. Despite several attempts we did not 
succeed to obtain null mutants suggesting the need of using a cKO system to 
unequivocally prove TbRpiB essentiality. Studies conducted with sKO lines were in 
agreement with the previous RNAi results. Expectedly in vivo phenotypes, including 
parasitaemia and mice life span, were not so strong as the ones obtained in RNAi. A 
possible explanation is due to differences on the level of RpiB downregulation, which was 
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higher in RNAi than in the sKO clones (Loureiro et al, unpublished). To better understand 
why mice infected with sKO parasites had reduced parasitaemias and increased survival 
compared to wt, we propose to follow infections in mice using live imaging system and 
bioluminescent wt and sKO parasites.  
 
2.2 Inquiries on the role of pentose phosphate pathway in T. brucei  
 
An enhanced PPP activity has been reported in highly proliferative cells, such as 
pluripotent stem cells and cancer cells. In stem cells, an up-regulation of gene-products 
involved in glucose uptake and glucose phosphorylation to glucose 6-phosphate was 
observed comparatively to somatic cells. However, the expression levels of some genes 
coding glycolytic enzymes downstream glucose 6-phosphate were reduced, while the 
level of genes involved in the non-oxidative PPP (RPIA and TKT) increased (Prigione et 
al, 2011; Varum et al, 2011). Also, not only G6PDH is increased in various human cancer 
types when compared to the respective benign control tissue (Bezwoda et al, 1985; 
Pedersen, 1975; Zampella et al, 1982), but also an enhanced PPP activity occurs in the 
human breast cancer cell line MCF7 when compared to non-transformed mammary 
epithelial cells (Meadows et al, 2008). Therefore, the role of the PPP is particularly evident 
in cells or tissues that undergo proliferation. The fact that RPE and TKT enzymes are not 
detected in T. brucei bloodstream forms (Cronin et al, 1989) suggests that in these highly 
proliferative forms, the PPP is constrained to the production of NADPH and R5P (Comini 
et al, 2013). During proliferation, it is predictable that cells restructure their central carbon 
metabolism in order to adapt to the rise in metabolic demands. In our study we observed a 
stronger phenotype in vivo than in vitro which can be explained by the fact that, contrary 
to culture conditions, in vivo parasites may do not have access to essential nutrients, 
which are usually available in culture media. Moreover, parasites need to deal with 
pressure from the host immune response. To prevent a collapse of the metabolic network, 
parasites need to adapt their metabolism in order to ensure proper functionality upon 
environmental changes. A paradigm example of a transcriptional regulation of the PPP is 
the case of G6PDH in yeast. In a deficient NADPH producing yeast, due to zwf1 (codes 
G6PDH) deletion, the NADPH-producing role of G6PDH is compensated by other NADP-
oxidizing enzymes under normal growth conditions. On the other hand, the 
NADP+/NADPH ratio collapses upon H2O2 exposure, rendering G6PDH null cells highly 
oxidant sensitive (Nogae & Johnston, 1990). The PPP plays pivotal roles in response to 
anabolic intermediates needs and in counteracting oxidative stress. It is mainly implicated 
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in (1) maintaining metabolic and redox homeostasis via NADP+ to NADPH reduction, (2) 
synthesizing R5P used in nucleotide biosynthesis (increased synthesis is required upon 
DNA damage stress), and (3) activating stress-responsive gene expression (Figure 20) 
(Stincone et al, 2014).  
 
 
Figure 20. Induction of glycolysis/PPP transition during oxidative stress. In a stress 
situation, activity of the PPP is increased through orchestrated allosteric/post-translational 
and transcriptional regulation. The fastest response is made through oxidative inhibition of 
GAPDH and consequently forward glycolytic reactions, while PPP remains active. This 
process is also supported by post-translational modifications that increase G6PDH 
activity, a process comparatively slower but that allows cellular adaptation to stress in a 
long(er)-term response. [Adapted from (Stincone et al, 2014)].  
 
It was previously demonstrated that the main role of PPP in Plasmodium spp. 
erythrocytic stages seems to be the NADPH supply, once R5P can be obtained from the 
uptake and degradation of host purines (Preuss et al, 2012). In T. cruzi, oxidative stress 
not only regulates kinetically, but also increases its protein level (Igoillo-Esteve & Cazzulo, 
2006). In T. brucei G6PDH RNAi leads to growth arrest and reduced tolerance to H2O2, 
and in L. mexicana PPP flux increases when parasites were exposed to the oxidative 
stress inducer methylene blue (Maugeri et al, 2003). Also kinetic models of glycolysis and 
PPP reactions in T. brucei corroborated the importance of PPP in response to oxidative 
stress (Achcar et al, 2012; Albert et al, 2005; Kerkhoven et al, 2013). Additionally, 6PGDH 
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knockout (enzyme from the oxidative branch) leads to a lethal phenotype (Barrett, 1997) 
while in contrast, procyclics TKL null mutants (enzyme from the non-oxidative branch) do 
not have any effect on cell growth (Stoffel et al, 2011). Taken together, these results 
indicate that also in trypanosomatids, including T. brucei, the main role of the PPP 
appears to be in the defence against oxidative stress. Once NADP+/NADPH take part of 
the oxidative PPP, supposedly the NADPH-dependent PPP antioxidant response will not 
be affected upon RpiB downregulation. However, it was already proposed in other 
organisms the occurrence of a NADPH-independent PPP antioxidant response, in which 
the underlying molecular mechanism is still unknown. This was based on the observations 
that: (1) in yeast double mutant deleted for both the oxidative PPP enzyme G6PDH (zwf1) 
and the non-oxidative PPP enzyme TAL (tal1) was more sensitive to H2O2 than the parent 
mutants deleted for either zwf1 or tal1 alone (Kruger et al, 2011), (2) also in yeast an 
increased oxidant resistance was obtained when the metabolite load of the non-oxidative 
pathway was augmented due to expression of the mammalian sedoheptulokinase (Kardon 
et al, 2008; Kruger et al, 2011); and (3) in Entamoeba histolytica, which has an alternative 
PPP pathway absent of G6PDH, 6PGDH and TAL, when exposed to oxidative stress, 
metabolites of the non-oxidative PPP increased (Husain et al, 2012). These facts impose 
the following question: does T. brucei parasite have an equal antioxidant response when 
the non-oxidative branch PPP is disturbed but the oxidative PPP remains fully active?  
The detrimental effect of RpiB downregulation in vivo is most likely due to the 
inability of the parasite to respond to a much higher requirement of R5P for proliferation 
and/or DNA repair under host pressure. It is now crucial to understand if the quantity of 
R5P decreases in induced TbRpiB RNAi relative to non-induced parasites, and if in fact in 
vivo the non-oxidative PPP flux into R5P does not operate. To measure oxidative relative 
to non-oxidative PPP flux into R5P, one possible method involves separate feeding 
experiments with, 1-13C-glucose and 6-13C-glucose and the measure of R5P labelling by 
mass spectrometry. Indeed, R5P produced via oxidative PPP is labelled with 6-13C but not 
with 1-13C-glucose (Fan et al, 2014). Another possibility involves feeding with 1,2-13C-
glucose and look for single versus double labelled R5P, with the former made by the 
oxidative PPP and the latter by the non-oxidative PPP (Lee et al, 1998) (Figure 21). 
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Figure 21. Glucose labelled on the sixth, first and both first and second carbons can be 
used to determine relative flux through the oxidative and non-oxidative PPP by 
assessment of singly, doubly and non-labelled downstream intermediates. [Adapted from 
(Fan et al, 2014; Metallo & Vander Heiden, 2013)]. 
 
In the case of in vivo experiments, mass spectrometry based methods are not applicable. 
Recently a new described NMR technique, termed hyperpolarization (Ardenkjaer-Larsen 
et al, 2003), can be used to measure PPP flux in vivo but the major limitation of the 
technique is the relatively short life time of the spin polarization, which means that only 
relatively rapid metabolic processes can be imaged (Stincone et al, 2014).  
 
2.3 Do “alternative pathways” to generate ribose 5-phosphate exist?  
 
A well described ribose transport is the one present in E. coli being taken by the 
rbsACB gene product (Figure 22A) (Roos, 2007). Phosphorylation of ribose by ribokinase 
is the first reaction in the metabolism of exogenous ribose and is required for keeping 
ribose inside the cell. Once phosphorylated it is trapped within the cell due to added 
negative charge, which prevents it from leaking back across the membrane. In T. brucei, a 
specific transport system for ribose was not yet identified, even though this parasite has a 
ribokinase gene (Kerkhoven et al, 2013). Interestingly, a previous study knockdown the 
ribokinase levels on T. brucei and no growth defect was observed. However attempts to 
generate null mutants failed in spite of numerous rounds of transfection. The cKO was 
generated with inducible expression of an exogenous copy of the ribokinase gene, but 
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again no growth phenotype could be observed, even if the ectopic copy was switched off. 
It was therefore concluded that ribokinase activity is essential but that residual levels in 
RNAi and leaky expression in the cKO were sufficient to fulfil its essential role. Therefore, 
if ribose can be uptaken by a not yet described transporter, ribokinase activity might be an 
alternative way of generating R5P. 
As mentioned above Plasmodium spp. parasites are able to and depend on the 
uptake of host purines via an equilibrative nucleoside transporter (Figure 22B). The 
nucleosides can subsequently be degraded by nucleoside phosphorylases yielding ribose-
1-phosphate, which might be isomerized by phosphoglucomutase to R5P (Downie et al, 
2008).  This alternative route does not appear to exist in T. brucei since the latest enzyme 
is absent (Bandini et al, 2012). 
Both the non-oxidative PPP and the Calvin cycle share some important reactions. 
While the classical non-oxidative PPP uses TAL to make sedoheptulose 7-phosphate, the 
Calvin cycle uses the glycolytic enzyme ALD to convert erythrose 4-phosphate plus 
dihydroxyacetone phosphate into sedoheptulose 1,7-bisphosphate, which in turn is 
hydrolysed by the enzyme sedoheptulose-1,7-bisphosphatase to yield sedoheptulose 7-
phosphate. This hydrolysis step provides the thermodynamic driving force, pushing the 
Calvin cycle towards R5P, and ultimately Ru5P (Figure 22C). Until recently, 
sedoheptulose-1,7-bisphosphatase enzymatic activity was thought to be specific of 
photosynthetic organisms, however metabolomic screening of yeast strains lacking genes 
of unknown function, revealed a strain with elevated sedoheptulose 1,7-bisphosphate. 
The associated gene was subsequently shown to encode an enzyme with sedoheptulose-
1,7-bisphosphatase activity involved in a novel variant of the non-oxidative PPP that 
follows yet more closely the Calvin cycle reaction sequences (Figure 22D) (Clasquin et al, 
2011). This variant of the non-oxidative PPP is termed riboneogenesis. R5P biosynthesis 
via riboneogenesis can be used when demand for ribose exceeds that for NADPH. In 
such cases, it is presumably advantageous to have a thermodynamically driven 
alternative to the standard oxidative towards non-oxidative PPP, and to avoid an over-
reduction of the NADPH pool. Till now, sedoheptulose-1,7-bisphosphatase activity was 
proved to have a role only in plant and yeast metabolisms. In T. brucei, the presence of 
sedoheptulose-1,7-bisphosphatase coding gene was already confirmed (Hannaert et al, 
2003b). Sequence alignment of trypanosome with plant and algal sequences indicated 
that all residues essential for catalysis have been conserved, suggesting that T. brucei 
encodes a functional protein, however it remains to be demonstrated. Also remains to be 
elucidated if this alternative non-oxidative PPP can constitute a salvage pathway for R5P. 
Chapter IV – Discussion and conclusions 
162 
 
 
 
Figure 22. Alternative pathways to generate R5P bypassing the oxidative PPP. (A) The 
path from D-ribose to R5P in E. coli. RbsA a cytoplasmic ATPase, RbsC a membrane 
permease, RbsB the periplasmic ribose binding protein, RbsD is a mutarotase, that 
converts the pyranose form of ribose to the furanose form, and RbsK or ribokinase binds 
specifically the α-furanose form of ribose for its phosphorylation leading to R5P. (B) 
Ribose-1P synthesis within Plasmodium infected erythrocytes. (C) The light-independent 
reactions of carbon fixation in the Calvin cycle share enzymes and reactions with the PPP 
and glycolysis. (D) Yeast Shb17 feeds carbon into the non-oxidative PPP. The cells were 
fed with glucose labelled selectively at the 6-position with carbon 13 (6-13C-glucose). Flux 
through Shb17 into S7P can be measured using [6-13C1]-glucose. [6-
13C1]-glucose leads to 
[7-13C1]-S7P when S7P is made via the oxidative PPP or the non-oxidative PPP. However, 
when S7P is produced from SBP via Shb17, a fraction of the S7P pool is doubly labelled: 
[1,7-13C2]-S7P. This labelling pattern was observed preferentially when yeast cells were 
grown on media that decreased their need for NADPH (e.g. by providing them with lipids). 
Abbreviations: G6P, glucose-6-phosphate; F6P, frutose 6-phosphate; FBA or fba, fructose 
biphosphate aldolase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GAP, 
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glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; TPI, triosephosphate 
isomerase; E4P, erythrose 4-phosphate; SBP, sedoheptulose-1,7-bisphosphate; S7P, 
sedoheptulose 7-phosphate; shb17 or SH17BPase, sedoheptulose-1,7-bisphosphatase; 
tal, transaldolase; TK or tkl, transketolase; RPI or rki1,  ribose phosphate isomerase; rpe1, 
ribose phosphate epimerase; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosphate; 
Xu5P, xylulose 5-phosphate; PGK, phosphoglycerate kinase; PRK, phosphoribulokinase; 
hPNP, human purine nucleoside phosphorylase; PfPNP, purine nucleoside 
phosphorylase; Ino, inosine; Hxt, hypoxanthine; RBC, red blood cell; PV, parasitophorous 
vacuole; MTI, methylthioinosine. [Adapted from (Clasquin et al, 2011; Downie et al, 2008; 
Roos, 2007; Stincone et al, 2014)].  
 
2.4 Challenges on T. brucei ribose 5-phosphate isomerase B druggability   
 
 Despite genetic studies demonstrated TbRpiB as a highly promising drug target 
(Loureiro et al, 2015); Loureiro et al, unpublished), two important aspects concerning 
inhibition studies and possible RpiB redundancy should be kept in mind. 4-PEH is the 
strongest inhibitor described against RpiB enzymes (Roos et al, 2005; Stern et al, 2007), 
being also active against the T. brucei enzyme (Loureiro et al, 2015). However, 4-PEH 
mediated inhibition of TbRpiB not only requires concentrations on the milimolar range 
(Loureiro et al, 2015) but also lacks selectivity, since it also inhibits the spinach type A 
enzyme (Roos et al, 2005). Future structure-based drug design studies are needed to 
design potent and selective inhibitors. Another concern, despite speculative, is that under 
drug pressure, “alternative pathways” to generate R5P may overcome the detrimental 
effect of RipB inhibition.  
 In conclusion, there is still a long way until RipB is considered an ideal drug target 
against HAT. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter V 
Publications outside the scope of the thesis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter V - Publications outside the scope of the thesis  
167 
 
 
 
Chapter V - Publications outside the scope of the thesis  
168 
 
 
 
Chapter V - Publications outside the scope of the thesis  
169 
 
 
 
Chapter V - Publications outside the scope of the thesis  
170 
 
 
 
Chapter V - Publications outside the scope of the thesis  
171 
 
 
 
Chapter V - Publications outside the scope of the thesis  
172 
 
 
 
Chapter V - Publications outside the scope of the thesis  
173 
 
 
 
Chapter V - Publications outside the scope of the thesis  
174 
 
 
 
Chapter V - Publications outside the scope of the thesis  
175 
 
 
 
Chapter V - Publications outside the scope of the thesis  
176 
 
 
 
Chapter V - Publications outside the scope of the thesis  
177 
 
 
 
Chapter V - Publications outside the scope of the thesis  
178 
 
 
 
Chapter V - Publications outside the scope of the thesis  
179 
 
 
 
Chapter V - Publications outside the scope of the thesis  
180 
 
 
 
Chapter V - Publications outside the scope of the thesis  
181 
 
 
 
Chapter V - Publications outside the scope of the thesis  
182 
 
 
 
Chapter V - Publications outside the scope of the thesis  
183 
 
 
 
Chapter V - Publications outside the scope of the thesis  
184 
 
 
 
Chapter V - Publications outside the scope of the thesis  
185 
 
 
Chapter V - Publications outside the scope of the thesis  
186 
 
 
 
Chapter V - Publications outside the scope of the thesis  
187 
 
 
 
Chapter V - Publications outside the scope of the thesis  
188 
 
 
 
Chapter V - Publications outside the scope of the thesis  
189 
 
 
 
Chapter V - Publications outside the scope of the thesis  
190 
 
 
 
Chapter V - Publications outside the scope of the thesis  
191 
 
 
 
Chapter V - Publications outside the scope of the thesis  
192 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
193 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
194 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
195 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
196 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
197 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
198 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
199 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
200 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
201 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
202 
 
 
 
 
Chapter V - Publications outside the scope of the thesis  
203 
 
 
Chapter V - Publications outside the scope of the thesis  
204 
 
 
Chapter V - Publications outside the scope of the thesis  
205 
 
 
Chapter V - Publications outside the scope of the thesis  
206 
 
 
Chapter V - Publications outside the scope of the thesis  
207 
 
 
Chapter V - Publications outside the scope of the thesis  
208 
 
 
Chapter V - Publications outside the scope of the thesis  
209 
 
 
Chapter V - Publications outside the scope of the thesis  
210 
 
 
Chapter V - Publications outside the scope of the thesis  
211 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI 
Bibliography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI - Bibliography 
215 
 
Abdulla MH, O'Brien T, Mackey ZB, Sajid M, Grab DJ, McKerrow JH (2008) RNA interference of 
Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS 
neglected tropical diseases 2: e298 
 
Achcar F, Kerkhoven EJ, SilicoTryp C, Bakker BM, Barrett MP, Breitling R (2012) Dynamic modelling 
under uncertainty: the case of Trypanosoma brucei energy metabolism. PLoS computational 
biology 8: e1002352 
 
Adams MJ, Ellis GH, Gover S, Naylor CE, Phillips C (1994) Crystallographic study of coenzyme, 
coenzyme analogue and substrate binding in 6-phosphogluconate dehydrogenase: implications 
for NADP specificity and the enzyme mechanism. Structure 2: 651-668 
 
Agranoff D, Stich A, Abel P, Krishna S (2005) Proteomic fingerprinting for the diagnosis of human 
African trypanosomiasis. Trends in parasitology 21: 154-157 
 
Albert MA, Haanstra JR, Hannaert V, Van Roy J, Opperdoes FR, Bakker BM, Michels PA (2005) 
Experimental and in silico analyses of glycolytic flux control in bloodstream form Trypanosoma 
brucei. The Journal of biological chemistry 280: 28306-28315 
 
Ali BR, Pal A, Croft SL, Taylor RJ, Field MC (1999) The farnesyltransferase inhibitor manumycin A is 
a novel trypanocide with a complex mode of action including major effects on mitochondria. 
Molecular and biochemical parasitology 104: 67-80 
 
Alibu VP, Storm L, Haile S, Clayton C, Horn D (2005) A doubly inducible system for RNA 
interference and rapid RNAi plasmid construction in Trypanosoma brucei. Molecular and 
biochemical parasitology 139: 75-82 
 
Alirol E, Schrumpf D, Amici Heradi J, Riedel A, de Patoul C, Quere M, Chappuis F (2013) 
Nifurtimox-eflornithine combination therapy for second-stage gambiense human African 
trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 56: 
195-203 
 
Allsopp R (2001) Options for vector control against trypanosomiasis in Africa. Trends in 
parasitology 17: 15-19 
 
Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, Turner DJ, Field MC, Berriman 
M, Horn D (2012) High-throughput decoding of antitrypanosomal drug efficacy and resistance. 
Nature 482: 232-236 
 
Alsford S, Field MC, Horn D (2013) Receptor-mediated endocytosis for drug delivery in African 
trypanosomes: fulfilling Paul Ehrlich's vision of chemotherapy. Trends in parasitology 29: 207-212 
 
Alsford S, Kawahara T, Glover L, Horn D (2005) Tagging a T. brucei RRNA locus improves stable 
transfection efficiency and circumvents inducible expression position effects. Molecular and 
biochemical parasitology 144: 142-148 
 
Chapter VI - Bibliography 
216 
 
Alsford S, Turner DJ, Obado SO, Sanchez-Flores A, Glover L, Berriman M, Hertz-Fowler C, Horn D 
(2011) High-throughput phenotyping using parallel sequencing of RNA interference targets in the 
African trypanosome. Genome research 21: 915-924 
 
Andrulis IL, Chen J, Ray PN (1987) Isolation of human cDNAs for asparagine synthetase and 
expression in Jensen rat sarcoma cells. Molecular and cellular biology 7: 2435-2443 
 
Andrulis IL, Shotwell M, Evans-Blackler S, Zalkin H, Siminovitch L, Ray PN (1989) Fine structure 
analysis of the Chinese hamster AS gene encoding asparagine synthetase. Gene 80: 75-85 
 
Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R (2008) L-Asparaginase and the effect 
of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thrombosis and 
haemostasis 100: 330-337 
 
Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, 
Golman K (2003) Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. 
Proceedings of the National Academy of Sciences of the United States of America 100: 10158-
10163 
 
Arnau J, Lauritzen C, Petersen GE, Pedersen J (2006) Current strategies for the use of affinity tags 
and tag removal for the purification of recombinant proteins. Protein expression and purification 
48: 1-13 
 
Aronov AM, Suresh S, Buckner FS, Van Voorhis WC, Verlinde CL, Opperdoes FR, Hol WG, Gelb MH 
(1999) Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid 
glyceraldehyde-3-phosphate dehydrogenase. Proceedings of the National Academy of Sciences of 
the United States of America 96: 4273-4278 
 
Aslanian AM, Fletcher BS, Kilberg MS (2001) Asparagine synthetase expression alone is sufficient 
to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. The Biochemical journal 
357: 321-328 
 
Asselin BL, Kurtzburg J (2003) Asparaginase Treatment of Acute Leukemias: Humana Press 
 
Azema L, Lherbet C, Baudoin C, Blonski C (2006) Cell permeation of a Trypanosoma brucei aldolase 
inhibitor: evaluation of different enzyme-labile phosphate protecting groups. Bioorganic & 
medicinal chemistry letters 16: 3440-3443 
 
Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF, Iriemenam NC (2013) A current 
analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. 
Pathogens and global health 107: 242-252 
 
Bacchi CJ (1993) Resistance to clinical drugs in African trypanosomes. Parasitol Today 9: 190-193 
 
Bacchi CJ, Brun R, Croft SL, Alicea K, Buhler Y (1996) In vivo trypanocidal activities of new S-
adenosylmethionine decarboxylase inhibitors. Antimicrobial agents and chemotherapy 40: 1448-
1453 
 
Chapter VI - Bibliography 
217 
 
Bacchi CJ, Yarlett N (1993) Effects of antagonists of polyamine metabolism on African 
trypanosomes. Acta tropica 54: 225-236 
 
Baetselier PD, Namangala B, Noel W, Brys L, Pays E, Beschin A (2001) Alternative versus classical 
macrophage activation during experimental African trypanosomosis. International journal for 
parasitology 31: 575-587 
 
Bailey JW, Smith DH (1992) The use of the acridine orange QBC technique in the diagnosis of 
African trypanosomiasis. Trans R Soc Trop Med Hyg 86: 630 
 
Baird TD, Wek RC (2012) Eukaryotic initiation factor 2 phosphorylation and translational control in 
metabolism. Advances in nutrition 3: 307-321 
 
Baker N, Alsford S, Horn D (2011) Genome-wide RNAi screens in African trypanosomes identify 
the nifurtimox activator NTR and the eflornithine transporter AAT6. Molecular and biochemical 
parasitology 176: 55-57 
 
Baker N, Glover L, Munday JC, Aguinaga Andres D, Barrett MP, de Koning HP, Horn D (2012) 
Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African 
trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 
109: 10996-11001 
 
Bakker BM, Mensonides FI, Teusink B, van Hoek P, Michels PA, Westerhoff HV (2000) 
Compartmentation protects trypanosomes from the dangerous design of glycolysis. Proceedings 
of the National Academy of Sciences of the United States of America 97: 2087-2092 
 
Bakker BM, Walsh MC, ter Kuile BH, Mensonides FI, Michels PA, Opperdoes FR, Westerhoff HV 
(1999) Contribution of glucose transport to the control of the glycolytic flux in Trypanosoma 
brucei. Proceedings of the National Academy of Sciences of the United States of America 96: 
10098-10103 
 
Balana-Fouce R, Reguera RM (2007) RNA interference in Trypanosoma brucei: a high-throughput 
engine for functional genomics in trypanosomatids? Trends in parasitology 23: 348-351 
 
Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U (2006) Melarsoprol 
versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. 
Bulletin of the World Health Organization 84: 783-791 
 
Balasubramanian MN, Butterworth EA, Kilberg MS (2013) Asparagine Synthetase: Regulation by 
Cell Stress and Involvement in Tumor Biology. American journal of physiology Endocrinology and 
metabolism 
 
Balmer O, Beadell JS, Gibson W, Caccone A (2011) Phylogeography and taxonomy of Trypanosoma 
brucei. PLoS neglected tropical diseases 5: e961 
 
Bandini G, Marino K, Guther ML, Wernimont AK, Kuettel S, Qiu W, Afzal S, Kelner A, Hui R, 
Ferguson MA (2012) Phosphoglucomutase is absent in Trypanosoma brucei and redundantly 
substituted by phosphomannomutase and phospho-N-acetylglucosamine mutase. Molecular 
microbiology 85: 513-534 
Chapter VI - Bibliography 
218 
 
 
Baral TN (2010) Immunobiology of African trypanosomes: need of alternative interventions. 
Journal of biomedicine & biotechnology 2010: 389153 
 
Barkhuizen M, Magez S, Ryffel B, Brombacher F (2008) Interleukin-12p70 deficiency increases 
survival and diminishes pathology in Trypanosoma congolense infection. The Journal of infectious 
diseases 198: 1284-1291 
 
Barnes RL, Shi H, Kolev NG, Tschudi C, Ullu E (2012) Comparative genomics reveals two novel RNAi 
factors in Trypanosoma brucei and provides insight into the core machinery. PLoS pathogens 8: 
e1002678 
 
Barrett MP (1997) The pentose phosphate pathway and parasitic protozoa. Parasitol Today 13: 
11-16 
 
Barrett MP, Boykin DW, Brun R, Tidwell RR (2007) Human African trypanosomiasis: 
pharmacological re-engagement with a neglected disease. British journal of pharmacology 152: 
1155-1171 
 
Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S (2003) The 
trypanosomiases. Lancet 362: 1469-1480 
 
Barrett MP, Mottram JC, Coombs GH (1999) Recent advances in identifying and validating drug 
targets in trypanosomes and leishmanias. Trends in microbiology 7: 82-88 
 
Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E (2011) Drug resistance in human 
African trypanosomiasis. Future microbiology 6: 1037-1047 
 
Barry JD, Hajduk SL, Vickerman K, Le Ray D (1979) Detection of multiple variable antigen types in 
metacyclic populations of Trypanosoma brucei. Trans R Soc Trop Med Hyg 73: 205-208 
 
Becker HD, Kern D (1998) Thermus thermophilus: a link in evolution of the tRNA-dependent 
amino acid amidation pathways. Proceedings of the National Academy of Sciences of the United 
States of America 95: 12832-12837 
 
Benko PV, Wood TC, Segel IH (1969) Multiplicity and regulation of amino acid transport in 
Penicillium chrysogenum. Archives of biochemistry and biophysics 129: 498-508 
 
Berrang-Ford L, Berke O, Sweeney S, Abdelrahman L (2010) Sleeping sickness in southeastern 
Uganda: a spatio-temporal analysis of disease risk, 1970-2003. Vector borne and zoonotic diseases 
10: 977-988 
 
Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, Lennard NJ, Caler 
E, Hamlin NE, Haas B, Bohme U, Hannick L, Aslett MA, Shallom J, Marcello L, Hou L, Wickstead B, 
Alsmark UC, Arrowsmith C, Atkin RJ, Barron AJ, Bringaud F, Brooks K, Carrington M, Cherevach I, 
Chillingworth TJ, Churcher C, Clark LN, Corton CH, Cronin A, Davies RM, Doggett J, Djikeng A, 
Feldblyum T, Field MC, Fraser A, Goodhead I, Hance Z, Harper D, Harris BR, Hauser H, Hostetler J, 
Ivens A, Jagels K, Johnson D, Johnson J, Jones K, Kerhornou AX, Koo H, Larke N, Landfear S, Larkin 
C, Leech V, Line A, Lord A, Macleod A, Mooney PJ, Moule S, Martin DM, Morgan GW, Mungall K, 
Chapter VI - Bibliography 
219 
 
Norbertczak H, Ormond D, Pai G, Peacock CS, Peterson J, Quail MA, Rabbinowitsch E, Rajandream 
MA, Reitter C, Salzberg SL, Sanders M, Schobel S, Sharp S, Simmonds M, Simpson AJ, Tallon L, 
Turner CM, Tait A, Tivey AR, Van Aken S, Walker D, Wanless D, Wang S, White B, White O, 
Whitehead S, Woodward J, Wortman J, Adams MD, Embley TM, Gull K, Ullu E, Barry JD, Fairlamb 
AH, Opperdoes F, Barrell BG, Donelson JE, Hall N, Fraser CM, Melville SE, El-Sayed NM (2005) The 
genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422 
 
Besteiro S, Barrett MP, Riviere L, Bringaud F (2005) Energy generation in insect stages of 
Trypanosoma brucei: metabolism in flux. Trends in parasitology 21: 185-191 
 
Bezwoda WR, Derman DP, See N, Mansoor N (1985) Relative value of oestrogen receptor assay, 
lactoferrin content, and glucose-6-phosphate dehydrogenase activity as prognostic indicators in 
primary breast cancer. Oncology 42: 7-12 
 
Biebinger S, Rettenmaier S, Flaspohler J, Hartmann C, Pena-Diaz J, Wirtz LE, Hotz HR, Barry JD, 
Clayton C (1996) The PARP promoter of Trypanosoma brucei is developmentally regulated in a 
chromosomal context. Nucleic acids research 24: 1202-1211 
 
Bitonti AJ, Cross-Doersen DE, McCann PP (1988) Effects of alpha-difluoromethylornithine on 
protein synthesis and synthesis of the variant-specific glycoprotein (VSG) in Trypanosoma brucei 
brucei. The Biochemical journal 250: 295-298 
 
Blaise M, Frechin M, Olieric V, Charron C, Sauter C, Lorber B, Roy H, Kern D (2011) Crystal 
structure of the archaeal asparagine synthetase: interrelation with aspartyl-tRNA and asparaginyl-
tRNA synthetases. Journal of molecular biology 412: 437-452 
 
Blangy D, Buc H, Monod J (1968) Kinetics of the allosteric interactions of phosphofructokinase 
from Escherichia coli. Journal of molecular biology 31: 13-35 
 
Blattner FR, Plunkett G, 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, 
Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y 
(1997) The complete genome sequence of Escherichia coli K-12. Science 277: 1453-1462 
 
Blum J, Nkunku S, Burri C (2001) Clinical description of encephalopathic syndromes and risk 
factors for their occurrence and outcome during melarsoprol treatment of human African 
trypanosomiasis. Tropical medicine & international health : TM & IH 6: 390-400 
 
Bochud-Allemann N, Schneider A (2002) Mitochondrial substrate level phosphorylation is 
essential for growth of procyclic Trypanosoma brucei. The Journal of biological chemistry 277: 
32849-32854 
 
Bockstal V, Guirnalda P, Caljon G, Goenka R, Telfer JC, Frenkel D, Radwanska M, Magez S, Black SJ 
(2011) T. brucei infection reduces B lymphopoiesis in bone marrow and truncates compensatory 
splenic lymphopoiesis through transitional B-cell apoptosis. PLoS pathogens 7: e1002089 
 
Boehlein SK, Nakatsu T, Hiratake J, Thirumoorthy R, Stewart JD, Richards NG, Schuster SM (2001) 
Characterization of inhibitors acting at the synthetase site of Escherichia coli asparagine 
synthetase B. Biochemistry 40: 11168-11175 
 
Chapter VI - Bibliography 
220 
 
Boehlein SK, Richards NG, Schuster SM (1994) Glutamine-dependent nitrogen transfer in 
Escherichia coli asparagine synthetase B. Searching for the catalytic triad. The Journal of biological 
chemistry 269: 7450-7457 
 
Boehlein SK, Stewart JD, Walworth ES, Thirumoorthy R, Richards NG, Schuster SM (1998) Kinetic 
mechanism of Escherichia coli asparagine synthetase B. Biochemistry 37: 13230-13238 
 
Bour T, Akaddar A, Lorber B, Blais S, Balg C, Candolfi E, Frugier M (2009) Plasmodial aspartyl-tRNA 
synthetases and peculiarities in Plasmodium falciparum. The Journal of biological chemistry 284: 
18893-18903 
 
Bouteille B, Buguet A (2012) The detection and treatment of human African trypanosomiasis. 
Research and Reports in Tropical Medicine 3: 35-45 
 
Bowyer PW, Tate EW, Leatherbarrow RJ, Holder AA, Smith DF, Brown KA (2008) N-
myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem 3: 402-
408 
 
Bray PG, Barrett MP, Ward SA, de Koning HP (2003) Pentamidine uptake and resistance in 
pathogenic protozoa: past, present and future. Trends in parasitology 19: 232-239 
 
Bridges DJ, Gould MK, Nerima B, Maser P, Burchmore RJ, de Koning HP (2007) Loss of the high-
affinity pentamidine transporter is responsible for high levels of cross-resistance between 
arsenical and diamidine drugs in African trypanosomes. Molecular pharmacology 71: 1098-1108 
 
Brimacombe KR, Walsh MJ, Liu L, Vasquez-Valdivieso MG, Morgan HP, McNae I, Fothergill-
Gilmore LA, Michels PA, Auld DS, Simeonov A, Walkinshaw MD, Shen M, Boxer MB (2014) 
Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase. ACS 
medicinal chemistry letters 5: 12-17 
 
Bruce D. (1895) Preliminary report on the tsetse fly disease or nagana in Zululand Durban. In Davis 
Ba (ed.). 
 
Brun R, Blum J, Chappuis F, Burri C (2010) Human African trypanosomiasis. Lancet 375: 148-159 
 
Brun R, Schonenberger M (1981) Stimulating effect of citrate and cis-Aconitate on the 
transformation of Trypanosoma brucei bloodstream forms to procyclic forms in vitro. Zeitschrift 
fur Parasitenkunde 66: 17-24 
 
Brun R, Schumacher R, Schmid C, Kunz C, Burri C (2001) The phenomenon of treatment failures in 
Human African Trypanosomiasis. Tropical medicine & international health : TM & IH 6: 906-914 
 
Brysk MM, Corpe WA, Hankes LV (1969) Beta-cyanoalanine formation by Chromobacterium 
violaceum. Journal of bacteriology 97: 322-327 
 
Buguet A, Bisser S, Josenando T, Chapotot F, Cespuglio R (2005) Sleep structure: a new diagnostic 
tool for stage determination in sleeping sickness. Acta tropica 93: 107-117 
 
Chapter VI - Bibliography 
221 
 
Buguet A, Bouteille B, Mpandzou G. (2009) La recherche sur la maladie du sommeil 
(trypanosomose humaine africaine) en République du Congo de 2004 à 2009. Brazzaville:Editions 
Les Manguiers. 
 
Burri C, Brun R (2003) Eflornithine for the treatment of human African trypanosomiasis. 
Parasitology research 90 Supp 1: S49-52 
 
Caceres AJ, Michels PA, Hannaert V (2010) Genetic validation of aldolase and glyceraldehyde-3-
phosphate dehydrogenase as drug targets in Trypanosoma brucei. Molecular and biochemical 
parasitology 169: 50-54 
 
Campillo N, Carrington M (2003) The origin of the serum resistance associated (SRA) gene and a 
model of the structure of the SRA polypeptide from Trypanosoma brucei rhodesiense. Molecular 
and biochemical parasitology 127: 79-84 
 
Capewell P, Clucas C, DeJesus E, Kieft R, Hajduk S, Veitch N, Steketee PC, Cooper A, Weir W, 
MacLeod A (2013) The TgsGP gene is essential for resistance to human serum in Trypanosoma 
brucei gambiense. PLoS pathogens 9: e1003686 
 
Carter NS, Berger BJ, Fairlamb AH (1995) Uptake of diamidine drugs by the P2 nucleoside 
transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. The Journal of 
biological chemistry 270: 28153-28157 
 
Castric PA, Farnden KJ, Conn EE (1972) Cyanide metabolism in higher plants. V. The formation of 
asparagine from -cyanoalanine. Archives of biochemistry and biophysics 152: 62-69 
 
Castric PA, Strobel GA (1969) Cyanide metabolism by Bacillus megaterium. The Journal of 
biological chemistry 244: 4089-4094 
 
CDC. (2012) Parasites African Trypanosomiasis (also known as Sleeping Sickness). Centers for 
Disease Control and Prevention, http://www.cdc.gov/parasites/sleepingsickness/ Vol. 2014. 
 
Cedar H, Schwartz JH (1968) Production of L-asparaginase II by Escherichia coli. Journal of 
bacteriology 96: 2043-2048 
 
Cedar H, Schwartz JH (1969a) The asparagine synthetase of Escherichia coli. I. Biosynthetic role of 
the enzyme, purification, and characterization of the reaction products. J Biol Chem 244: 4112-
4121 
 
Cedar H, Schwartz JH (1969b) The asparagine synthetase of Escherichia coli. II. Studies on 
mechanism. The Journal of biological chemistry 244: 4122-4127 
 
Chambers JW, Fowler ML, Morris MT, Morris JC (2008) The anti-trypanosomal agent lonidamine 
inhibits Trypanosoma brucei hexokinase 1. Molecular and biochemical parasitology 158: 202-207 
 
Chappuis F, Loutan L, Simarro P, Lejon V, Buscher P (2005a) Options for field diagnosis of human 
african trypanosomiasis. Clinical microbiology reviews 18: 133-146 
 
Chapter VI - Bibliography 
222 
 
Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA (2005b) Eflornithine is safer than 
melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African 
trypanosomiasis. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 41: 748-751 
 
Chawla B, Madhubala R (2010) Drug targets in Leishmania. Journal of parasitic diseases : official 
organ of the Indian Society for Parasitology 34: 1-13 
 
Chen Y, Hung CH, Burderer T, Lee GS (2003) Development of RNA interference revertants in 
Trypanosoma brucei cell lines generated with a double stranded RNA expression construct driven 
by two opposing promoters. Molecular and biochemical parasitology 126: 275-279 
 
Chow C, Cloutier S, Dumas C, Chou MN, Papadopoulou B (2011) Promastigote to amastigote 
differentiation of Leishmania is markedly delayed in the absence of PERK eIF2alpha kinase-
dependent eIF2alpha phosphorylation. Cellular microbiology 13: 1059-1077 
 
Ciustea M, Gutierrez JA, Abbatiello SE, Eyler JR, Richards NG (2005) Efficient expression, 
purification, and characterization of C-terminally tagged, recombinant human asparagine 
synthetase. Archives of biochemistry and biophysics 440: 18-27 
 
Clasquin MF, Melamud E, Singer A, Gooding JR, Xu X, Dong A, Cui H, Campagna SR, Savchenko A, 
Yakunin AF, Rabinowitz JD, Caudy AA (2011) Riboneogenesis in yeast. Cell 145: 969-980 
 
Claustre S, Denier C, Lakhdar-Ghazal F, Lougare A, Lopez C, Chevalier N, Michels PA, Perie J, 
Willson M (2002) Exploring the active site of Trypanosoma brucei phosphofructokinase by 
inhibition studies: specific irreversible inhibition. Biochemistry 41: 10183-10193 
 
Clayton CE, Michels P (1996) Metabolic compartmentation in African trypanosomes. Parasitol 
Today 12: 465-471 
 
Cleland WW (1967) Enzyme kinetics. Annual review of biochemistry 36: 77-112 
 
Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O (2010) Conservative treatment of L-
asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. 
Pediatric blood & cancer 54: 703-706 
 
Coley AF, Dodson HC, Morris MT, Morris JC (2011) Glycolysis in the african trypanosome: targeting 
enzymes and their subcellular compartments for therapeutic development. Molecular biology 
international 2011: 123702 
 
Coller SP, Mansfield JM, Paulnock DM (2003) Glycosylinositolphosphate soluble variant surface 
glycoprotein inhibits IFN-gamma-induced nitric oxide production via reduction in STAT1 
phosphorylation in African trypanosomiasis. J Immunol 171: 1466-1472 
 
Coller SP, Paulnock DM (2001) Signaling pathways initiated in macrophages after engagement of 
type A scavenger receptors. Journal of leukocyte biology 70: 142-148 
 
Comini MA, Guerrero SA, Haile S, Menge U, Lunsdorf H, Flohe L (2004) Validation of Trypanosoma 
brucei trypanothione synthetase as drug target. Free radical biology & medicine 36: 1289-1302 
Chapter VI - Bibliography 
223 
 
 
Comini MA, Ortíz C, Cazzulo JJ (2013) Drug Targets in Trypanosomal and Leishmanial Pentose 
Phosphate Pathway. In Trypanosomatid Diseases: Molecular Routes to Drug Discovery, Jäger T KO, 
Flohé L (ed), pp 297-313. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 
 
Cooper AJ (1977) Asparagine transaminase from rat liver. The Journal of biological chemistry 252: 
2032-2038 
 
Cordeiro AT, Thiemann OH, Michels PA (2009) Inhibition of Trypanosoma brucei glucose-6-
phosphate dehydrogenase by human steroids and their effects on the viability of cultured 
parasites. Bioorganic & medicinal chemistry 17: 2483-2489 
 
Coruzzi GM (2003) Primary N-assimilation into Amino Acids in Arabidopsis. In Arabidopsis Book 
Vol. 2, 2003/01/01 edn, p e0010.  
 
Coustou V, Besteiro S, Biran M, Diolez P, Bouchaud V, Voisin P, Michels PA, Canioni P, Baltz T, 
Bringaud F (2003) ATP generation in the Trypanosoma brucei procyclic form: cytosolic substrate 
level is essential, but not oxidative phosphorylation. The Journal of biological chemistry 278: 
49625-49635 
 
Cox FE (2004) History of sleeping sickness (African trypanosomiasis). Infectious disease clinics of 
North America 18: 231-245 
 
Cronin CN, Nolan DP, Voorheis HP (1989) The enzymes of the classical pentose phosphate 
pathway display differential activities in procyclic and bloodstream forms of Trypanosoma brucei. 
FEBS letters 244: 26-30 
 
Cross GA (1975) Identification, purification and properties of clone-specific glycoprotein antigens 
constituting the surface coat of Trypanosoma brucei. Parasitology 71: 393-417 
 
Crowe JS, Barry JD, Luckins AG, Ross CA, Vickerman K (1983) All metacyclic variable antigen types 
of Trypanosoma congolense identified using monoclonal antibodies. Nature 306: 389-391 
 
Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, Higashino F, Hamuro J, Okada F, 
Kobayashi M, Nakagawa K, Koide H, Kobayashi M (2007) Enhanced expression of asparagine 
synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis 
induced by glucose deprivation and cisplatin. Cancer research 67: 3345-3355 
 
Curnow AW, Tumbula DL, Pelaschier JT, Min B, Soll D (1998) Glutamyl-tRNA(Gln) 
amidotransferase in Deinococcus radiodurans may be confined to asparagine biosynthesis. 
Proceedings of the National Academy of Sciences of the United States of America 95: 12838-12843 
 
Czichos J, Nonnengaesser C, Overath P (1986) Trypanosoma brucei: cis-aconitate and temperature 
reduction as triggers of synchronous transformation of bloodstream to procyclic trypomastigotes 
in vitro. Experimental parasitology 62: 283-291 
 
Dagenais TR, Freeman BE, Demick KP, Paulnock DM, Mansfield JM (2009) Processing and 
presentation of variant surface glycoprotein molecules to T cells in African trypanosomiasis. J 
Immunol 183: 3344-3355 
Chapter VI - Bibliography 
224 
 
 
Dardonville C, Rinaldi E, Barrett MP, Brun R, Gilbert IH, Hanau S (2004) Selective inhibition of 
Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and 
transition-state analogues. Journal of medicinal chemistry 47: 3427-3437 
 
Dardonville C, Rinaldi E, Hanau S, Barrett MP, Brun R, Gilbert IH (2003) Synthesis and biological 
evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs 
against African trypanosomiasis. Bioorganic & medicinal chemistry 11: 3205-3214 
 
DaRocha WD, Otsu K, Teixeira SM, Donelson JE (2004) Tests of cytoplasmic RNA interference 
(RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypanosoma cruzi. 
Molecular and biochemical parasitology 133: 175-186 
 
de A S Navarro MV, Gomes Dias SM, Mello LV, da Silva Giotto MT, Gavalda S, Blonski C, Garratt 
RC, Rigden DJ (2007) Structural flexibility in Trypanosoma brucei enolase revealed by X-ray 
crystallography and molecular dynamics. The FEBS journal 274: 5077-5089 
 
De Koning HP (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three 
distinct transporters: implications for cross-resistance with arsenicals. Molecular pharmacology 
59: 586-592 
 
de la Fuente J, Rodriguez M, Redondo M, Montero C, Garcia-Garcia JC, Mendez L, Serrano E, 
Valdes M, Enriquez A, Canales M, Ramos E, Boue O, Machado H, Lleonart R, de Armas CA, Rey S, 
Rodriguez JL, Artiles M, Garcia L (1998) Field studies and cost-effectiveness analysis of vaccination 
with Gavac against the cattle tick Boophilus microplus. Vaccine 16: 366-373 
 
De Raadt P (1976) African sleeping sickness today. Trans R Soc Trop Med Hyg 70: 114–116 
 
Dean S, Marchetti R, Kirk K, Matthews KR (2009) A surface transporter family conveys the 
trypanosome differentiation signal. Nature 459: 213-217 
 
Deborggraeve S, Claes F, Laurent T, Mertens P, Leclipteux T, Dujardin JC, Herdewijn P, Buscher P 
(2006) Molecular dipstick test for diagnosis of sleeping sickness. Journal of clinical microbiology 
44: 2884-2889 
 
Delarue M, Duclert-Savatier N, Miclet E, Haouz A, Giganti D, Ouazzani J, Lopez P, Nilges M, Stoven 
V (2007) Three dimensional structure and implications for the catalytic mechanism of 6-
phosphogluconolactonase from Trypanosoma brucei. Journal of molecular biology 366: 868-881 
 
Delespaux V, de Koning HP (2007) Drugs and drug resistance in African trypanosomiasis. Drug 
resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 10: 
30-50 
 
Dempsey WL, Mansfield JM (1983) Lymphocyte function in experimental African trypanosomiasis. 
VI. Parasite-specific immunosuppression. J Immunol 130: 2896-2898 
 
den Boer ML, Evans WE, Pieters R (2005) TELAML1-positive ALL: a discordant genotype. Cell cycle 
4: 997-998 
 
Chapter VI - Bibliography 
225 
 
Devine DV, Falk RJ, Balber AE (1986) Restriction of the alternative pathway of human complement 
by intact Trypanosoma brucei subsp. gambiense. Infection and immunity 52: 223-229 
 
Dickens F, Glock GE (1951) Direct oxidation of glucose-6-phosphate, 6-phosphogluconate and 
pentose-5-phosphates by enzymes of animal origin. The Biochemical journal 50: 81-95 
 
Dodson HC, Lyda TA, Chambers JW, Morris MT, Christensen KA, Morris JC (2011) Quercetin, a 
fluorescent bioflavanoid, inhibits Trypanosoma brucei hexokinase 1. Experimental parasitology 
127: 423-428 
 
Doua F, Miezan TW, Sanon Singaro JR, Boa Yapo F, Baltz T (1996) The efficacy of pentamidine in 
the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. The American 
journal of tropical medicine and hygiene 55: 586-588 
 
Downie MJ, Kirk K, Mamoun CB (2008) Purine salvage pathways in the intraerythrocytic malaria 
parasite Plasmodium falciparum. Eukaryotic cell 7: 1231-1237 
 
Doyle JJ, Hirumi H, Hirumi K, Lupton EN, Cross GA (1980) Antigenic variation in clones of animal-
infective Trypanosoma brucei derived and maintained in vitro. Parasitology 80: 359-369 
 
Drain J, Bishop JR, Hajduk SL (2001) Haptoglobin-related protein mediates trypanosome lytic 
factor binding to trypanosomes. The Journal of biological chemistry 276: 30254-30260 
 
Drennan MB, Stijlemans B, Van den Abbeele J, Quesniaux VJ, Barkhuizen M, Brombacher F, De 
Baetselier P, Ryffel B, Magez S (2005) The induction of a type 1 immune response following a 
Trypanosoma brucei infection is MyD88 dependent. J Immunol 175: 2501-2509 
 
Drew ME, Morris JC, Wang Z, Wells L, Sanchez M, Landfear SM, Englund PT (2003) The adenosine 
analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference 
library. The Journal of biological chemistry 278: 46596-46600 
 
Duclert-Savatier N, Poggi L, Miclet E, Lopes P, Ouazzani J, Chevalier N, Nilges M, Delarue M, 
Stoven V (2009) Insights into the enzymatic mechanism of 6-phosphogluconolactonase from 
Trypanosoma brucei using structural data and molecular dynamics simulation. Journal of 
molecular biology 388: 1009-1021 
 
Duff SM, Qi Q, Reich T, Wu X, Brown T, Crowley JH, Fabbri B (2011) A kinetic comparison of 
asparagine synthetase isozymes from higher plants. Plant physiology and biochemistry : PPB / 
Societe francaise de physiologie vegetale 49: 251-256 
 
Duffieux F, Van Roy J, Michels PA, Opperdoes FR (2000) Molecular characterization of the first two 
enzymes of the pentose-phosphate pathway of Trypanosoma brucei. Glucose-6-phosphate 
dehydrogenase and 6-phosphogluconolactonase. The Journal of biological chemistry 275: 27559-
27565 
 
Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL, Godfrin Y (2012) Pancreatic tumor 
sensitivity to plasma L-asparagine starvation. Pancreas 41: 940-948 
 
Chapter VI - Bibliography 
226 
 
Durand-Dubief M, Bastin P (2003) TbAGO1, an argonaute protein required for RNA interference, is 
involved in mitosis and chromosome segregation in Trypanosoma brucei. BMC biology 1: 2 
 
Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC (2006) Thematic review series: 
lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. 
Journal of lipid research 47: 233-240 
 
Eberle C, Burkhard JA, Stump B, Kaiser M, Brun R, Krauth-Siegel RL, Diederich F (2009) Synthesis, 
inhibition potency, binding mode, and antiprotozoal activities of fluorescent inhibitors of 
trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds. ChemMedChem 
4: 2034-2044 
 
Eberle C, Lauber BS, Fankhauser D, Kaiser M, Brun R, Krauth-Siegel RL, Diederich F (2011) 
Improved inhibitors of trypanothione reductase by combination of motifs: synthesis, inhibitory 
potency, binding mode, and antiprotozoal activities. ChemMedChem 6: 292-301 
 
Ebikeme C (2007) Amino Acid Transporters & Amino Acid Metabolism in Trypanosoma brucei 
brucei. Doctor of Philosophy Thesis, Division of Infection & Immunity Faculty of Biomedical & Life 
Sciences-University of Glasgow  
 
Edwards TE, Abramov AB, Smith ER, Baydo RO, Leonard JT, Leibly DJ, Thompkins KB, Clifton MC, 
Gardberg AS, Staker BL, Van Voorhis WC, Myler PJ, Stewart LJ (2011) Structural characterization of 
a ribose-5-phosphate isomerase B from the pathogenic fungus Coccidioides immitis. BMC 
structural biology 11: 39 
 
El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran AN, Ghedin E, Worthey EA, 
Delcher AL, Blandin G, Westenberger SJ, Caler E, Cerqueira GC, Branche C, Haas B, Anupama A, 
Arner E, Aslund L, Attipoe P, Bontempi E, Bringaud F, Burton P, Cadag E, Campbell DA, Carrington 
M, Crabtree J, Darban H, da Silveira JF, de Jong P, Edwards K, Englund PT, Fazelina G, Feldblyum T, 
Ferella M, Frasch AC, Gull K, Horn D, Hou L, Huang Y, Kindlund E, Klingbeil M, Kluge S, Koo H, 
Lacerda D, Levin MJ, Lorenzi H, Louie T, Machado CR, McCulloch R, McKenna A, Mizuno Y, 
Mottram JC, Nelson S, Ochaya S, Osoegawa K, Pai G, Parsons M, Pentony M, Pettersson U, Pop M, 
Ramirez JL, Rinta J, Robertson L, Salzberg SL, Sanchez DO, Seyler A, Sharma R, Shetty J, Simpson 
AJ, Sisk E, Tammi MT, Tarleton R, Teixeira S, Van Aken S, Vogt C, Ward PN, Wickstead B, Wortman 
J, White O, Fraser CM, Stuart KD, Andersson B (2005) The genome sequence of Trypanosoma 
cruzi, etiologic agent of Chagas disease. Science 309: 409-415 
 
Emmer BT, Daniels MD, Taylor JM, Epting CL, Engman DM (2010) Calflagin inhibition prolongs host 
survival and suppresses parasitemia in Trypanosoma brucei infection. Eukaryotic cell 9: 934-942 
 
Emmer BT, Souther C, Toriello KM, Olson CL, Epting CL, Engman DM (2009) Identification of a 
palmitoyl acyltransferase required for protein sorting to the flagellar membrane. Journal of cell 
science 122: 867-874 
 
Engstler M, Pfohl T, Herminghaus S, Boshart M, Wiegertjes G, Heddergott N, Overath P (2007) 
Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes. Cell 131: 505-
515 
 
Chapter VI - Bibliography 
227 
 
Esposito D, Chatterjee DK (2006) Enhancement of soluble protein expression through the use of 
fusion tags. Current opinion in biotechnology 17: 353-358 
 
Esser KM, Schoenbechler MJ, Gingrich JB (1982) Trypanosoma rhodesiense blood forms express all 
antigen specificities relevant to protection against metacyclic (insect form) challenge. J Immunol 
129: 1715-1718 
 
Fairlamb AH (2003) Chemotherapy of human African trypanosomiasis: current and future 
prospects. Trends in parasitology 19: 488-494 
 
Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A (1985) Trypanothione: a novel 
bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 227: 
1485-1487 
 
Fairlamb AH, Cerami A (1992) Metabolism and functions of trypanothione in the Kinetoplastida. 
Annual review of microbiology 46: 695-729 
 
Fairlamb AH, Henderson GB, Bacchi CJ, Cerami A (1987) In vivo effects of difluoromethylornithine 
on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Molecular 
and biochemical parasitology 24: 185-191 
 
Fairlamb AH, Henderson GB, Cerami A (1989) Trypanothione is the primary target for arsenical 
drugs against African trypanosomes. Proceedings of the National Academy of Sciences of the 
United States of America 86: 2607-2611 
 
Fairlamb AH, Smith K, Hunter KJ (1992) The interaction of arsenical drugs with dihydrolipoamide 
and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of 
Trypanosoma brucei brucei. Molecular and biochemical parasitology 53: 223-231 
 
Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD (2014) Quantitative flux analysis 
reveals folate-dependent NADPH production. Nature 510: 298-302 
 
Feng L, Yuan J, Toogood H, Tumbula-Hansen D, Soll D (2005) Aspartyl-tRNA synthetase requires a 
conserved proline in the anticodon-binding loop for tRNA(Asn) recognition in vivo. The Journal of 
biological chemistry 280: 20638-20641 
 
Ferrante A, Allison AC (1983) Alternative pathway activation of complement by African 
trypanosomes lacking a glycoprotein coat. Parasite immunology 5: 491-498 
 
Ferrari S, Losasso V, Saxena P, Costi MP (2013) Targeting the Trypanosomatidic Enzymes Pteridine 
Reductase and Dihydrofolate Reductase. In Trypanosomatid Diseases: Molecular Routes to Drug 
Discovery, Timo Jäger OKaLF (ed), 24, pp 445-472. Wiley-VCH Verlag GmbH & Co. KGaA 
 
Field MC, Carrington M (2009) The trypanosome flagellar pocket. Nature reviews Microbiology 7: 
775-786 
 
Flohe L (2012) The trypanothione system and its implications in the therapy of trypanosomatid 
diseases. International journal of medical microbiology : IJMM 302: 216-220 
 
Chapter VI - Bibliography 
228 
 
Fomina-Yadlin D, Gosink JJ, McCoy R, Follstad B, Morris A, Russell CB, McGrew JT (2014) Cellular 
responses to individual amino-acid depletion in antibody-expressing and parental CHO cell lines. 
Biotechnology and bioengineering 111: 965-979 
 
Franco JR, Simarro PP, Diarra A, Jannin JG (2014) Epidemiology of human African trypanosomiasis. 
Clinical epidemiology 6: 257-275 
 
Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, Stojanovski L, Price HP, Guther ML, Torrie 
LS, Robinson DA, Hallyburton I, Mpamhanga CP, Brannigan JA, Wilkinson AJ, Hodgkinson M, Hui R, 
Qiu W, Raimi OG, van Aalten DM, Brenk R, Gilbert IH, Read KD, Fairlamb AH, Ferguson MA, Smith 
DF, Wyatt PG (2010) N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. 
Nature 464: 728-732 
 
Friedheim EA (1949) Mel B in the treatment of human trypanosomiasis. The American journal of 
tropical medicine and hygiene 29: 173-180 
 
Furuya T, Kessler P, Jardim A, Schnaufer A, Crudder C, Parsons M (2002) Glucose is toxic to 
glycosome-deficient trypanosomes. Proceedings of the National Academy of Sciences of the 
United States of America 99: 14177-14182 
 
Gamarro F, Yu PL, Zhao J, Edman U, Greene PJ, Santi D (1995) Trypanosoma brucei dihydrofolate 
reductase-thymidylate synthase: gene isolation and expression and characterization of the 
enzyme. Molecular and biochemical parasitology 72: 11-22 
 
Gatti DL, Tzagoloff A (1991) Structure and evolution of a group of related aminoacyl-tRNA 
synthetases. Journal of molecular biology 218: 557-568 
 
Gaufichon L, Masclaux-Daubresse C, Tcherkez G, Reisdorf-Cren M, Sakakibara Y, Hase T, Clement 
G, Avice JC, Grandjean O, Marmagne A, Boutet-Mercey S, Azzopardi M, Soulay F, Suzuki A (2013) 
Arabidopsis thaliana ASN2 encoding asparagine synthetase is involved in the control of nitrogen 
assimilation and export during vegetative growth. Plant, cell & environment 36: 328-342 
 
Geiger A, Simo G, Grebaut P, Peltier JB, Cuny G, Holzmuller P (2011) Transcriptomics and 
proteomics in human African trypanosomiasis: current status and perspectives. Journal of 
proteomics 74: 1625-1643 
 
Geiser F, Luscher A, de Koning HP, Seebeck T, Maser P (2005) Molecular pharmacology of 
adenosine transport in Trypanosoma brucei: P1/P2 revisited. Molecular pharmacology 68: 589-
595 
 
Gesbert G, Ramond E, Rigard M, Frapy E, Dupuis M, Dubail I, Barel M, Henry T, Meibom K, Charbit 
A (2014) Asparagine assimilation is critical for intracellular replication and dissemination of 
Francisella. Cellular microbiology 16: 434-449 
 
Gibson W (2007) Resolution of the species problem in African trypanosomes. International journal 
for parasitology 37: 829-838 
 
Gibson WC (1986) Will the real Trypanosoma b. gambiense please stand up. Parasitol Today 2: 
255-257 
Chapter VI - Bibliography 
229 
 
 
Gibson WC, de CMTF, Godfrey DG (1980) Numerical analysis of enzyme polymorphism: a new 
approach to the epidemiology and taxonomy of trypanosomes of the subgenus Trypanozoon. 
Advances in parasitology 18: 175-246 
 
Giffin BF, McCann PP, Bitonti AJ, Bacchi CJ (1986) Polyamine depletion following exposure to DL-
alpha-difluoromethylornithine both in vivo and in vitro initiates morphological alterations and 
mitochondrial activation in a monomorphic strain of Trypanosoma brucei brucei. The Journal of 
protozoology 33: 238-243 
 
Ginger ML, Fairlamb, A.H. & Opperdoes, F.R. (2007) Comparative genomics of trypanosome 
metabolism. In Trypanosomes : after the genome, JD Barry JM, R McCulloch & A Acosta-Serrano 
(ed), pp 373-417. London: Horizon Bioscience 
 
Glaser L, Brown DH (1955) Purification and properties of d-glucose-6-phosphate dehydrogenase. 
The Journal of biological chemistry 216: 67-79 
 
Gong SS, Guerrini L, Basilico C (1991) Regulation of asparagine synthetase gene expression by 
amino acid starvation. Molecular and cellular biology 11: 6059-6066 
 
Gouzy A, Larrouy-Maumus G, Bottai D, Levillain F, Dumas A, Wallach JB, Caire-Brandli I, de 
Chastellier C, Wu TD, Poincloux R, Brosch R, Guerquin-Kern JL, Schnappinger D, Sorio de Carvalho 
LP, Poquet Y, Neyrolles O (2014) Mycobacterium tuberculosis exploits asparagine to assimilate 
nitrogen and resist acid stress during infection. PLoS pathogens 10: e1003928 
 
Gowri VS, Ghosh I, Sharma A, Madhubala R (2012) Unusual domain architecture of aminoacyl 
tRNA synthetases and their paralogs from Leishmania major. BMC genomics 13: 621 
 
Grant IF (2001) Insecticides for tsetse and trypanosomiasis control: is the environmental risk 
acceptable? Trends in parasitology 17: 10-14 
 
Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ (1999) X-ray structure of ornithine 
decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with 
alpha-difluoromethylornithine. Biochemistry 38: 15174-15184 
 
Guler JL, Kriegova E, Smith TK, Lukes J, Englund PT (2008) Mitochondrial fatty acid synthesis is 
required for normal mitochondrial morphology and function in Trypanosoma brucei. Molecular 
microbiology 67: 1125-1142 
 
Gull K (2002) The cell biology of parasitism in Trypanosoma brucei: insights and drug targets from 
genomic approaches? Current pharmaceutical design 8: 241-256 
 
Gupta S, Cordeiro AT, Michels PA (2011) Glucose-6-phosphate dehydrogenase is the target for the 
trypanocidal action of human steroids. Molecular and biochemical parasitology 176: 112-115 
 
Gutierrez JA, Pan YX, Koroniak L, Hiratake J, Kilberg MS, Richards NG (2006) An inhibitor of human 
asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line. 
Chemistry & biology 13: 1339-1347 
 
Chapter VI - Bibliography 
230 
 
Haanstra JR, Kerkhoven EJ, van Tuijl A, Blits M, Wurst M, van Nuland R, Albert MA, Michels PA, 
Bouwman J, Clayton C, Westerhoff HV, Bakker BM (2011) A domino effect in drug action: from 
metabolic assault towards parasite differentiation. Molecular microbiology 79: 94-108 
 
Haanstra JR, van Tuijl A, Kessler P, Reijnders W, Michels PA, Westerhoff HV, Parsons M, Bakker 
BM (2008) Compartmentation prevents a lethal turbo-explosion of glycolysis in trypanosomes. 
Proceedings of the National Academy of Sciences of the United States of America 105: 17718-
17723 
 
Haberkorn A, Harder A, Greif G (2001) Milestones of protozoan research at Bayer. Parasitology 
research 87: 1060-1062 
 
Hainard A, Tiberti N, Robin X, Lejon V, Ngoyi DM, Matovu E, Enyaru JC, Fouda C, Ndung'u JM, 
Lisacek F, Muller M, Turck N, Sanchez JC (2009) A combined CXCL10, CXCL8 and H-FABP panel for 
the staging of human African trypanosomiasis patients. PLoS neglected tropical diseases 3: e459 
 
Hajduk SL, Moore DR, Vasudevacharya J, Siqueira H, Torri AF, Tytler EM, Esko JD (1989) Lysis of 
Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. The Journal of 
biological chemistry 264: 5210-5217 
 
Hall BS, Bot C, Wilkinson SR (2011) Nifurtimox activation by trypanosomal type I nitroreductases 
generates cytotoxic nitrile metabolites. The Journal of biological chemistry 286: 13088-13095 
 
Hall JP, Wang H, Barry JD (2013) Mosaic VSGs and the scale of Trypanosoma brucei antigenic 
variation. PLoS pathogens 9: e1003502 
 
Hanau S, Rinaldi E, Dallocchio F, Gilbert IH, Dardonville C, Adams MJ, Gover S, Barrett MP (2004) 
6-phosphogluconate dehydrogenase: a target for drugs in African trypanosomes. Current 
medicinal chemistry 11: 2639-2650 
 
Hannaert V, Bringaud F, Opperdoes FR, Michels PA (2003a) Evolution of energy metabolism and 
its compartmentation in Kinetoplastida. Kinetoplastid biology and disease 2: 11 
 
Hannaert V, Saavedra E, Duffieux F, Szikora JP, Rigden DJ, Michels PA, Opperdoes FR (2003b) 
Plant-like traits associated with metabolism of Trypanosoma parasites. Proceedings of the 
National Academy of Sciences of the United States of America 100: 1067-1071 
 
Hanrahan O, Webb H, O'Byrne R, Brabazon E, Treumann A, Sunter JD, Carrington M, Voorheis HP 
(2009) The glycosylphosphatidylinositol-PLC in Trypanosoma brucei forms a linear array on the 
exterior of the flagellar membrane before and after activation. PLoS pathogens 5: e1000468 
 
Hargrove JW, Omolo S, Msalilwa JS, Fox B (2000) Insecticide-treated cattle for tsetse control: the 
power and the problems. Medical and veterinary entomology 14: 123-130 
 
Harris TH, Cooney NM, Mansfield JM, Paulnock DM (2006) Signal transduction, gene transcription, 
and cytokine production triggered in macrophages by exposure to trypanosome DNA. Infection 
and immunity 74: 4530-4537 
 
Chapter VI - Bibliography 
231 
 
Hassell AM, An G, Bledsoe RK, Bynum JM, Carter HL, 3rd, Deng SJ, Gampe RT, Grisard TE, Madauss 
KP, Nolte RT, Rocque WJ, Wang L, Weaver KL, Williams SP, Wisely GB, Xu R, Shewchuk LM (2007) 
Crystallization of protein-ligand complexes. Acta crystallographica Section D, Biological 
crystallography 63: 72-79 
 
Heby O, Persson L, Rentala M (2007) Targeting the polyamine biosynthetic enzymes: a promising 
approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino acids 
33: 359-366 
 
Heby O, Roberts SC, Ullman B (2003) Polyamine biosynthetic enzymes as drug targets in parasitic 
protozoa. Biochemical Society transactions 31: 415-419 
 
Heinz E, Williams TA, Nakjang S, Noel CJ, Swan DC, Goldberg AV, Harris SR, Weinmaier T, Markert 
S, Becher D, Bernhardt J, Dagan T, Hacker C, Lucocq JM, Schweder T, Rattei T, Hall N, Hirt RP, 
Embley TM (2012) The genome of the obligate intracellular parasite Trachipleistophora hominis: 
new insights into microsporidian genome dynamics and reductive evolution. PLoS pathogens 8: 
e1002979 
 
Heise N, Opperdoes FR (1999) Purification, localisation and characterisation of glucose-6-
phosphate dehydrogenase of Trypanosoma brucei. Molecular and biochemical parasitology 99: 
21-32 
 
Helfert S, Estevez AM, Bakker B, Michels P, Clayton C (2001) Roles of triosephosphate isomerase 
and aerobic metabolism in Trypanosoma brucei. The Biochemical journal 357: 117-125 
 
Hide G, Cattand P, LeRay D, Barry JD, Tait A (1990) The identification of Trypanosoma brucei 
subspecies using repetitive DNA sequences. Molecular and biochemical parasitology 39: 213-225 
 
Hinchman SK, Henikoff S, Schuster SM (1992) A relationship between asparagine synthetase A and 
aspartyl tRNA synthetase. The Journal of biological chemistry 267: 144-149 
 
Hofreuter D, Novik V, Galan JE (2008) Metabolic diversity in Campylobacter jejuni enhances 
specific tissue colonization. Cell host & microbe 4: 425-433 
 
Holm L, Rosenstrom P (2010) Dali server: conservation mapping in 3D. Nucleic acids research 38: 
W545-549 
 
Hong Y, Kinoshita T (2009) Trypanosome glycosylphosphatidylinositol biosynthesis. The Korean 
journal of parasitology 47: 197-204 
 
Horn D (2014) Antigenic variation in African trypanosomes. Molecular and biochemical 
parasitology 195: 123-129 
 
Horowitz B, Meister A (1972) Glutamine-dependent asparagine synthetase from leukemia cells. 
Chloride dependence, mechanism of action, and inhibition. The Journal of biological chemistry 
247: 6708-6719 
 
Huang XH, H.M.; and Raushel, F. (2001) Channeling of substrates and intermediates in enzyme-
catalyzed reactions. Annual Review in Biochemistry 70: 149-180 
Chapter VI - Bibliography 
232 
 
 
Hudson KM, Byner C, Freeman J, Terry RJ (1976) Immunodepression, high IgM levels and evasion 
of the immune response in murine trypanosomiasis. Nature 264: 256-258 
 
Humbert R, Simoni RD (1980) Genetic and biomedical studies demonstrating a second gene 
coding for asparagine synthetase in Escherichia coli. Journal of bacteriology 142: 212-220 
 
Hunter DR, Segel IH (1971) Acidic and basic amino acid transport systems of Penicillium 
chrysogenum. Archives of biochemistry and biophysics 144: 168-183 
 
Hunter DR, Segel IH (1973) Control of the general amino acid permease of Penicillium 
chrysogenum by transinhibition and turnover. Archives of biochemistry and biophysics 154: 387-
399 
 
Husain A, Sato D, Jeelani G, Soga T, Nozaki T (2012) Dramatic increase in glycerol biosynthesis 
upon oxidative stress in the anaerobic protozoan parasite Entamoeba histolytica. PLoS neglected 
tropical diseases 6: e1831 
 
Hutchinson OC, Webb H, Picozzi K, Welburn S, Carrington M (2004) Candidate protein selection 
for diagnostic markers of African trypanosomiasis. Trends in parasitology 20: 519-523 
 
Hutson RG, Kilberg MS (1994) Cloning of rat asparagine synthetase and specificity of the amino 
acid-dependent control of its mRNA content. The Biochemical journal 304 ( Pt 3): 745-750 
 
Igoillo-Esteve M, Cazzulo JJ (2006) The glucose-6-phosphate dehydrogenase from Trypanosoma 
cruzi: its role in the defense of the parasite against oxidative stress. Molecular and biochemical 
parasitology 149: 170-181 
 
Inoue N, Otsu K, Ferraro DM, Donelson JE (2002) Tetracycline-regulated RNA interference in 
Trypanosoma congolense. Molecular and biochemical parasitology 120: 309-313 
 
Ireland RJ, Joy KW (1983) Purification and properties of an asparagine aminotransferase from 
Pisum sativum leaves. Archives of biochemistry and biophysics 223: 291-296 
 
Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R (1997) Alterations in ornithine 
decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-
alpha-difluoromethylornithine. Antimicrobial agents and chemotherapy 41: 1922-1925 
 
Jacobs RT, Nare B, Phillips MA (2011) State of the art in African trypanosome drug discovery. 
Current topics in medicinal chemistry 11: 1255-1274 
 
Jamonneau V, Ilboudo H, Kabore J, Kaba D, Koffi M, Solano P, Garcia A, Courtin D, Laveissiere C, 
Lingue K, Buscher P, Bucheton B (2012) Untreated human infections by Trypanosoma brucei 
gambiense are not 100% fatal. PLoS neglected tropical diseases 6: e1691 
 
Jamonneau V, Ravel S, Garcia A, Koffi M, Truc P, Laveissiere C, Herder S, Grebaut P, Cuny G, 
Solano P (2004) Characterization of Trypanosoma brucei s.l. infecting asymptomatic sleeping-
sickness patients in Cote d'Ivoire: a new genetic group? Annals of tropical medicine and 
parasitology 98: 329-337 
Chapter VI - Bibliography 
233 
 
 
Janne J, Alhonen-Hongisto L, Seppanen P, Siimes M (1981) Use of polyamine antimetabolites in 
experimental tumours and in human leukemia. Medical biology 59: 448-457 
 
Jones GE (1978) L-Asparagine auxotrophs of Saccharomyces cerevisiae: genetic and phenotypic 
characterization. Journal of bacteriology 134: 200-207 
 
Jones SM, Urch JE, Brun R, Harwood JL, Berry C, Gilbert IH (2004) Analogues of thiolactomycin as 
potential anti-malarial and anti-trypanosomal agents. Bioorganic & medicinal chemistry 12: 683-
692 
 
Jung J, Kim JK, Yeom SJ, Ahn YJ, Oh DK, Kang LW (2011) Crystal structure of Clostridium 
thermocellum ribose-5-phosphate isomerase B reveals properties critical for fast enzyme kinetics. 
Applied microbiology and biotechnology 90: 517-527 
 
Kalidas S, Cestari I, Monnerat S, Li Q, Regmi S, Hasle N, Labaied M, Parsons M, Stuart K, Phillips 
MA (2014) Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma 
brucei. Eukaryotic cell 13: 504-516 
 
Kardon T, Stroobant V, Veiga-da-Cunha M, Schaftingen EV (2008) Characterization of mammalian 
sedoheptulokinase and mechanism of formation of erythritol in sedoheptulokinase deficiency. 
FEBS letters 582: 3330-3334 
 
Karioti A, Skaltsa H, Linden A, Perozzo R, Brun R, Tasdemir D (2007) Anthecularin: a novel 
sesquiterpene lactone from Anthemis auriculata with antiprotozoal activity. The Journal of 
organic chemistry 72: 8103-8106 
 
Kathir KM, Kumar TK, Rajalingam D, Yu C (2005) Time-dependent changes in the denatured 
state(s) influence the folding mechanism of an all beta-sheet protein. The Journal of biological 
chemistry 280: 29682-29688 
 
Kaur PK, Dinesh N, Soumya N, Babu NK, Singh S (2012) Identification and characterization of a 
novel Ribose 5-phosphate isomerase B from Leishmania donovani. Biochemical and biophysical 
research communications 421: 51-56 
 
Kaushik RS, Uzonna JE, Zhang Y, Gordon JR, Tabel H (2000) Innate resistance to experimental 
African trypanosomiasis: differences in cytokine (TNF-alpha, IL-6, IL-10 and IL-12) production by 
bone marrow-derived macrophages from resistant and susceptible mice. Cytokine 12: 1024-1034 
 
Kayembe D, Wery M (1972) [Observations on the diamidine sensitivity of strains of Trypanosoma 
gambiense recently isolated in the Republic of Zaire]. Annales de la Societe belge de medecine 
tropicale 52: 1-8 
 
Kazibwe AJ, Nerima B, de Koning HP, Maser P, Barrett MP, Matovu E (2009) Genotypic status of 
the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from 
Northwestern Uganda following melarsoprol withdrawal. PLoS neglected tropical diseases 3: e523 
 
Kennedy PG (2008) Diagnosing central nervous system trypanosomiasis: two stage or not to 
stage? Trans R Soc Trop Med Hyg 102: 306-307 
Chapter VI - Bibliography 
234 
 
 
Kennedy PG (2010) Novel biomarkers for late-stage human African trypanosomiasis--the search 
goes on. The American journal of tropical medicine and hygiene 82: 981-982 
 
Kennedy PG (2013) Clinical features, diagnosis, and treatment of human African trypanosomiasis 
(sleeping sickness). The Lancet Neurology 12: 186-194 
 
Kerkhoven EJ, Achcar F, Alibu VP, Burchmore RJ, Gilbert IH, Trybilo M, Driessen NN, Gilbert D, 
Breitling R, Bakker BM, Barrett MP (2013) Handling uncertainty in dynamic models: the pentose 
phosphate pathway in Trypanosoma brucei. PLoS computational biology 9: e1003371 
 
Kessler PS, Parsons M (2005) Probing the role of compartmentation of glycolysis in procyclic form 
Trypanosoma brucei: RNA interference studies of PEX14, hexokinase, and phosphofructokinase. 
The Journal of biological chemistry 280: 9030-9036 
 
Khow O, Suntrarachun S (2012) Strategies for production of active eukaryotic proteins in bacterial 
expression system. Asian Pacific journal of tropical biomedicine 2: 159-162 
 
Kilberg MS, Shan J, Su N (2009) ATF4-dependent transcription mediates signaling of amino acid 
limitation. Trends in endocrinology and metabolism: TEM 20: 436-443 
 
Kinyua JK, Nguu EK, Mulaa F, Ndung'u JM (2005) Immunization of rabbits with Glossina pallidipes 
tsetse fly midgut proteins: effects on the fly and trypanosome transmission. Vaccine 23: 3824-
3828 
 
Kobayakawa T, Louis J, Izui S, Lambert PH (1979) Autoimmune response to DNA, red blood cells, 
and thymocyte antigens in association with polyclonal antibody synthesis during experimental 
African trypanosomiasis. J Immunol 122: 296-301 
 
Koffi M, Solano P, Barnabe C, de Meeus T, Bucheton B, Cuny G, Jamonneau V (2007) Genetic 
characterisation of Trypanosoma brucei s.l. using microsatellite typing: new perspectives for the 
molecular epidemiology of human African trypanosomiasis. Infection, genetics and evolution : 
journal of molecular epidemiology and evolutionary genetics in infectious diseases 7: 675-684 
 
Koizumi M, Nakatsu T, Kato H, Oda J (1999) A Potent Transition-State Analogue Inhibitor of 
Escherichia coli Asparagine Synthetase A. J Am Chem Soc 121: 5799-5800 
 
Kolev NG, Tschudi C, Ullu E (2011) RNA interference in protozoan parasites: achievements and 
challenges. Eukaryotic cell 10: 1156-1163 
 
Krauth-Siegel RL, Comini MA (2008) Redox control in trypanosomatids, parasitic protozoa with 
trypanothione-based thiol metabolism. Biochimica et biophysica acta 1780: 1236-1248 
 
Krauth-Siegel RL, Meiering SK, Schmidt H (2003) The parasite-specific trypanothione metabolism 
of trypanosoma and leishmania. Biological chemistry 384: 539-549 
 
Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C (2000) 
Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to 
oxidative stress. Molecular microbiology 35: 542-552 
Chapter VI - Bibliography 
235 
 
 
Kruger A, Gruning NM, Wamelink MM, Kerick M, Kirpy A, Parkhomchuk D, Bluemlein K, Schweiger 
MR, Soldatov A, Lehrach H, Jakobs C, Ralser M (2011) The pentose phosphate pathway is a 
metabolic redox sensor and regulates transcription during the antioxidant response. Antioxidants 
& redox signaling 15: 311-324 
 
Kuboki N, Inoue N, Sakurai T, Di Cello F, Grab DJ, Suzuki H, Sugimoto C, Igarashi I (2003) Loop-
mediated isothermal amplification for detection of African trypanosomes. Journal of clinical 
microbiology 41: 5517-5524 
 
Kullas AL, McClelland M, Yang HJ, Tam JW, Torres A, Porwollik S, Mena P, McPhee JB, 
Bogomolnaya L, Andrews-Polymenis H, van der Velden AW (2012) L-asparaginase II produced by 
Salmonella typhimurium inhibits T cell responses and mediates virulence. Cell host & microbe 12: 
791-798 
 
Lalmanach G, Boulange A, Serveau C, Lecaille F, Scharfstein J, Gauthier F, Authie E (2002) 
Congopain from Trypanosoma congolense: drug target and vaccine candidate. Biological 
chemistry 383: 739-749 
 
Langousis G, Hill KL (2014) Motility and more: the flagellum of Trypanosoma brucei. Nature 
reviews Microbiology 12: 505-518 
 
Lanteri CA, Tidwell RR, Meshnick SR (2008) The mitochondrion is a site of trypanocidal action of 
the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrobial agents 
and chemotherapy 52: 875-882 
 
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace 
IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG (2007) Clustal W and Clustal X version 
2.0. Bioinformatics 23: 2947-2948 
 
Le Ray D, Barry JD, Vickerman K (1978) Antigenic heterogeneity of metacyclic forms of 
Trypanosoma brucei. Nature 273: 300-302 
 
Lee SH, Stephens JL, Englund PT (2007) A fatty-acid synthesis mechanism specialized for 
parasitism. Nature reviews Microbiology 5: 287-297 
 
Lee SH, Stephens JL, Paul KS, Englund PT (2006) Fatty acid synthesis by elongases in 
trypanosomes. Cell 126: 691-699 
 
Lee WN, Boros LG, Puigjaner J, Bassilian S, Lim S, Cascante M (1998) Mass isotopomer study of the 
nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. The American journal of 
physiology 274: E843-851 
 
Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D (1999) Risk factors for treatment failure after 
melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med 
Hyg 93: 439-442 
 
Lejon V, Boelaert M, Jannin J, Moore A, Buscher P (2003a) The challenge of Trypanosoma brucei 
gambiense sleeping sickness diagnosis outside Africa. The Lancet infectious diseases 3: 804-808 
Chapter VI - Bibliography 
236 
 
 
Lejon V, Buscher P (2005) Review Article: cerebrospinal fluid in human African trypanosomiasis: a 
key to diagnosis, therapeutic decision and post-treatment follow-up. Tropical medicine & 
international health : TM & IH 10: 395-403 
 
Lejon V, Buscher P, Magnus E, Moons A, Wouters I, Van Meirvenne N (1998) A semi-quantitative 
ELISA for detection of Trypanosoma brucei gambiense specific antibodies in serum and 
cerebrospinal fluid of sleeping sickness patients. Acta tropica 69: 151-164 
 
Lejon V, Legros D, Richer M, Ruiz JA, Jamonneau V, Truc P, Doua F, Dje N, N'Siesi FX, Bisser S, 
Magnus E, Wouters I, Konings J, Vervoort T, Sultan F, Buscher P (2002) IgM quantification in the 
cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test. Tropical 
medicine & international health : TM & IH 7: 685-692 
 
Lejon V, Mumba Ngoyi D, Kestens L, Boel L, Barbe B, Kande Betu V, van Griensven J, Bottieau E, 
Muyembe Tamfum JJ, Jacobs J, Buscher P (2014) Gambiense human african trypanosomiasis and 
immunological memory: effect on phenotypic lymphocyte profiles and humoral immunity. PLoS 
pathogens 10: e1003947 
 
Lejon V, Reiber H, Legros D, Dje N, Magnus E, Wouters I, Sindic CJ, Buscher P (2003b) Intrathecal 
immune response pattern for improved diagnosis of central nervous system involvement in 
trypanosomiasis. The Journal of infectious diseases 187: 1475-1483 
 
Leppert BJ, Mansfield JM, Paulnock DM (2007) The soluble variant surface glycoprotein of African 
trypanosomes is recognized by a macrophage scavenger receptor and induces I kappa B alpha 
degradation independently of TRAF6-mediated TLR signaling. J Immunol 179: 548-556 
 
Li F, Hua SB, Wang CC, Gottesdiener KM (1996) Procyclic Trypanosoma brucei cell lines deficient in 
ornithine decarboxylase activity. Molecular and biochemical parasitology 78: 227-236 
 
Li F, Hua SB, Wang CC, Gottesdiener KM (1998) Trypanosoma brucei brucei: characterization of an 
ODC null bloodstream form mutant and the action of alpha-difluoromethylornithine. Experimental 
parasitology 88: 255-257 
 
Li SQ, Fung MC, Reid SA, Inoue N, Lun ZR (2007) Immunization with recombinant beta-tubulin 
from Trypanosoma evansi induced protection against T. evansi, T. equiperdum and T. b. brucei 
infection in mice. Parasite immunology 29: 191-199 
 
Li SQ, Yang WB, Ma LJ, Xi SM, Chen QL, Song XW, Kang J, Yang LZ (2009) Immunization with 
recombinant actin from Trypanosoma evansi induces protective immunity against T. evansi, T. 
equiperdum and T. b. brucei infection. Parasitology research 104: 429-435 
 
Lillig CH, Holmgren A (2007) Thioredoxin and related molecules--from biology to health and 
disease. Antioxidants & redox signaling 9: 25-47 
 
Lopez R, Demick KP, Mansfield JM, Paulnock DM (2008) Type I IFNs play a role in early resistance, 
but subsequent susceptibility, to the African trypanosomes. J Immunol 181: 4908-4917 
 
Chapter VI - Bibliography 
237 
 
Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn 
EC, Goldsmith PK, Birrer MJ, Weinstein JN (2008) Asparagine synthetase is a predictive biomarker 
of L-asparaginase activity in ovarian cancer cell lines. Molecular cancer therapeutics 7: 3123-3128 
 
Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, 
Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, 
Weinstein JN (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase 
activity in ovarian cancer cells. Molecular cancer therapeutics 5: 2613-2623 
 
Louis FJ, Simarro PP (2005) [Rough start for the fight against sleeping sickness in French equatorial 
Africa]. Medecine tropicale : revue du Corps de sante colonial 65: 251-257 
 
Loureiro I, Faria J, Clayton C, Macedo-Ribeiro S, Santarém N, Roy N, Cordeiro-da-Siva A, Tavares J 
(2015) Ribose 5-Phosphate Isomerase B Knockdown Compromises Trypanosoma brucei 
Bloodstream Form Infectivity. PLoS neglected tropical diseases 9: e3430 
 
Loureiro I, Faria J, Clayton C, Ribeiro SM, Roy N, Santarem N, Tavares J, Cordeiro-da-Silva A (2013) 
Knockdown of asparagine synthetase A renders Trypanosoma brucei auxotrophic to asparagine. 
PLoS neglected tropical diseases 7: e2578 
 
Lubega GW, Byarugaba DK, Prichard RK (2002) Immunization with a tubulin-rich preparation from 
Trypanosoma brucei confers broad protection against African trypanosomosis. Experimental 
parasitology 102: 9-22 
 
Luehr CA, Schuster SM (1985) Purification and characterization of beef pancreatic asparagine 
synthetase. Archives of biochemistry and biophysics 237: 335-346 
 
Lumsden WH, Kimber CD, Evans DA, Doig SJ (1979) Trypanosoma brucei: Miniature anion-
exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use. 
Trans R Soc Trop Med Hyg 73: 312-317 
 
Lye LF, Owens K, Shi H, Murta SM, Vieira AC, Turco SJ, Tschudi C, Ullu E, Beverley SM (2010) 
Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS pathogens 
6: e1001161 
 
MacGregor P, Szoor B, Savill NJ, Matthews KR (2012) Trypanosomal immune evasion, chronicity 
and transmission: an elegant balancing act. Nature reviews Microbiology 10: 431-438 
 
MacLean L, Odiit M, Sternberg JM (2001) Nitric oxide and cytokine synthesis in human African 
trypanosomiasis. The Journal of infectious diseases 184: 1086-1090 
 
Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M (2010) Current status of vaccination against 
African trypanosomiasis. Parasitology 137: 2017-2027 
 
Magez S, Radwanska M, Drennan M, Fick L, Baral TN, Allie N, Jacobs M, Nedospasov S, 
Brombacher F, Ryffel B, De Baetselier P (2007) Tumor necrosis factor (TNF) receptor-1 (TNFp55) 
signal transduction and macrophage-derived soluble TNF are crucial for nitric oxide-mediated 
Trypanosoma congolense parasite killing. The Journal of infectious diseases 196: 954-962 
 
Chapter VI - Bibliography 
238 
 
Magez S, Stijlemans B, Baral T, De Baetselier P (2002) VSG-GPI anchors of African trypanosomes: 
their role in macrophage activation and induction of infection-associated immunopathology. 
Microbes and infection / Institut Pasteur 4: 999-1006 
 
Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MA, De Baetselier P (1998) The glycosyl-
inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of 
the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. 
J Immunol 160: 1949-1956 
 
Magnus E, Vervoort T, Van Meirvenne N (1978) A card-agglutination test with stained 
trypanosomes (C.A.T.T.) for the serological diagnosis of T. b. gambiense trypanosomiasis. Annales 
de la Societe belge de medecine tropicale 58: 169-176 
 
Malvy D, Chappuis F (2011) Sleeping sickness. Clinical microbiology and infection : the official 
publication of the European Society of Clinical Microbiology and Infectious Diseases 17: 986-995 
 
Manhas R, Tripathi P, Khan S, Sethu Lakshmi B, Lal SK, Gowri VS, Sharma A, Madhubala R (2014) 
Identification and functional characterization of a novel bacterial type asparagine synthetase A: a 
tRNA synthetase paralog from Leishmania donovani. The Journal of biological chemistry 289: 
12096-12108 
 
Martin KL, Smith TK (2006) Phosphatidylinositol synthesis is essential in bloodstream form 
Trypanosoma brucei. The Biochemical journal 396: 287-295 
 
Maser P, Sutterlin C, Kralli A, Kaminsky R (1999) A nucleoside transporter from Trypanosoma 
brucei involved in drug resistance. Science 285: 242-244 
 
Matovu E, Geiser F, Schneider V, Maser P, Enyaru JC, Kaminsky R, Gallati S, Seebeck T (2001) 
Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse 
infections following melarsoprol therapy. Molecular and biochemical parasitology 117: 73-81 
 
Matovu E, Stewart ML, Geiser F, Brun R, Maser P, Wallace LJ, Burchmore RJ, Enyaru JC, Barrett 
MP, Kaminsky R, Seebeck T, de Koning HP (2003) Mechanisms of arsenical and diamidine uptake 
and resistance in Trypanosoma brucei. Eukaryotic cell 2: 1003-1008 
 
Maudlin I, Turner MJ, Dukes P, Miller N (1984) Maintenance of Glossina morsitans morsitans on 
antiserum to procyclic trypanosomes reduces infection rates with homologous and heterologous 
Trypanosoma congolense stocks. Acta tropica 41: 253-257 
 
Maugeri DA, Cazzulo JJ, Burchmore RJ, Barrett MP, Ogbunude PO (2003) Pentose phosphate 
metabolism in Leishmania mexicana. Molecular and biochemical parasitology 130: 117-125 
 
Maul DM, Schuster SM (1986) Kinetic properties and characteristics of mouse liver mitochondrial 
asparagine aminotransferase. Archives of biochemistry and biophysics 251: 585-593 
 
McCulloch R, Horn D (2009) What has DNA sequencing revealed about the VSG expression sites of 
African trypanosomes? Trends in parasitology 25: 359-363 
 
Chapter VI - Bibliography 
239 
 
Meadows AL, Kong B, Berdichevsky M, Roy S, Rosiva R, Blanch HW, Clark DS (2008) Metabolic and 
morphological differences between rapidly proliferating cancerous and normal breast epithelial 
cells. Biotechnology progress 24: 334-341 
 
Mehlitz D, Zillmann U, Scott CM, Godfrey DG (1982) Epidemiological studies on the animal 
reservoir of Gambiense sleeping sickness. Part III. Characterization of trypanozoon stocks by 
isoenzymes and sensitivity to human serum. Tropenmedizin und Parasitologie 33: 113-118 
 
Meister A, Fraser PE (1954) Enzymatic formation of L-asparagine by transamination. The Journal 
of biological chemistry 210: 37-43 
 
Merchant SS, Prochnik SE, Vallon O, Harris EH, Karpowicz SJ, Witman GB, Terry A, Salamov A, Fritz-
Laylin LK, Marechal-Drouard L, Marshall WF, Qu LH, Nelson DR, Sanderfoot AA, Spalding MH, 
Kapitonov VV, Ren Q, Ferris P, Lindquist E, Shapiro H, Lucas SM, Grimwood J, Schmutz J, Cardol P, 
Cerutti H, Chanfreau G, Chen CL, Cognat V, Croft MT, Dent R, Dutcher S, Fernandez E, Fukuzawa H, 
Gonzalez-Ballester D, Gonzalez-Halphen D, Hallmann A, Hanikenne M, Hippler M, Inwood W, 
Jabbari K, Kalanon M, Kuras R, Lefebvre PA, Lemaire SD, Lobanov AV, Lohr M, Manuell A, Meier I, 
Mets L, Mittag M, Mittelmeier T, Moroney JV, Moseley J, Napoli C, Nedelcu AM, Niyogi K, 
Novoselov SV, Paulsen IT, Pazour G, Purton S, Ral JP, Riano-Pachon DM, Riekhof W, Rymarquis L, 
Schroda M, Stern D, Umen J, Willows R, Wilson N, Zimmer SL, Allmer J, Balk J, Bisova K, Chen CJ, 
Elias M, Gendler K, Hauser C, Lamb MR, Ledford H, Long JC, Minagawa J, Page MD, Pan J, 
Pootakham W, Roje S, Rose A, Stahlberg E, Terauchi AM, Yang P, Ball S, Bowler C, Dieckmann CL, 
Gladyshev VN, Green P, Jorgensen R, Mayfield S, Mueller-Roeber B, Rajamani S, Sayre RT, 
Brokstein P, Dubchak I, Goodstein D, Hornick L, Huang YW, Jhaveri J, Luo Y, Martinez D, Ngau WC, 
Otillar B, Poliakov A, Porter A, Szajkowski L, Werner G, Zhou K, Grigoriev IV, Rokhsar DS, Grossman 
AR (2007) The Chlamydomonas genome reveals the evolution of key animal and plant functions. 
Science 318: 245-250 
 
Merritt C, Stuart K (2013) Identification of essential and non-essential protein kinases by a fusion 
PCR method for efficient production of transgenic Trypanosoma brucei. Molecular and 
biochemical parasitology 190: 44-49 
 
Meshnick SR, Blobstein SH, Grady RW, Cerami A (1978) An approach to the development of new 
drugs for African trypanosomiasis. The Journal of experimental medicine 148: 569-579 
 
Metallo CM, Vander Heiden MG (2013) Understanding metabolic regulation and its influence on 
cell physiology. Molecular cell 49: 388-398 
 
Michalska K, Jaskolski M (2006) Structural aspects of L-asparaginases, their friends and relations. 
Acta biochimica Polonica 53: 627-640 
 
Michels PA, Bringaud F, Herman M, Hannaert V (2006) Metabolic functions of glycosomes in 
trypanosomatids. Biochimica et biophysica acta 1763: 1463-1477 
 
Miclet E, Stoven V, Michels PA, Opperdoes FR, Lallemand JY, Duffieux F (2001) NMR spectroscopic 
analysis of the first two steps of the pentose-phosphate pathway elucidates the role of 6-
phosphogluconolactonase. The Journal of biological chemistry 276: 34840-34846 
 
Chapter VI - Bibliography 
240 
 
Min B, Pelaschier JT, Graham DE, Tumbula-Hansen D, Soll D (2002) Transfer RNA-dependent 
amino acid biosynthesis: an essential route to asparagine formation. Proceedings of the National 
Academy of Sciences of the United States of America 99: 2678-2683 
 
Mina JG, Pan SY, Wansadhipathi NK, Bruce CR, Shams-Eldin H, Schwarz RT, Steel PG, Denny PW 
(2009) The Trypanosoma brucei sphingolipid synthase, an essential enzyme and drug target. 
Molecular and biochemical parasitology 168: 16-23 
 
Mitschke L, Parthier C, Schroder-Tittmann K, Coy J, Ludtke S, Tittmann K (2010) The crystal 
structure of human transketolase and new insights into its mode of action. The Journal of 
biological chemistry 285: 31559-31570 
 
Mobley DL, Dill KA (2009) Binding of small-molecule ligands to proteins: "what you see" is not 
always "what you get". Structure 17: 489-498 
 
Molyneux DH (1980) Host-trypanosomes interactions in Glossina. Insect Science and its 
Application 1: 39-46 
 
Mony BM, MacGregor P, Ivens A, Rojas F, Cowton A, Young J, Horn D, Matthews K (2014) 
Genome-wide dissection of the quorum sensing signalling pathway in Trypanosoma brucei. 
Nature 505: 681-685 
 
Moraes MC, Jesus TC, Hashimoto NN, Dey M, Schwartz KJ, Alves VS, Avila CC, Bangs JD, Dever TE, 
Schenkman S, Castilho BA (2007) Novel membrane-bound eIF2alpha kinase in the flagellar pocket 
of Trypanosoma brucei. Eukaryotic cell 6: 1979-1991 
 
Moreno T, Pous J, Subirana JA, Campos JL (2010) Coiled-coil conformation of a pentamidine-DNA 
complex. Acta crystallographica Section D, Biological crystallography 66: 251-257 
 
Morgan HP, McNae IW, Nowicki MW, Zhong W, Michels PA, Auld DS, Fothergill-Gilmore LA, 
Walkinshaw MD (2011) The trypanocidal drug suramin and other trypan blue mimetics are 
inhibitors of pyruvate kinases and bind to the adenosine site. The Journal of biological chemistry 
286: 31232-31240 
 
Morris JC, Wang Z, Drew ME, Englund PT (2002) Glycolysis modulates trypanosome glycoprotein 
expression as revealed by an RNAi library. The EMBO journal 21: 4429-4438 
 
Motyka SA, Zhao Z, Gull K, Englund PT (2004) Integration of pZJM library plasmids into unexpected 
locations in the Trypanosoma brucei genome. Molecular and biochemical parasitology 134: 163-
167 
 
Mpamhanga CP, Spinks D, Tulloch LB, Shanks EJ, Robinson DA, Collie IT, Fairlamb AH, Wyatt PG, 
Frearson JA, Hunter WN, Gilbert IH, Brenk R (2009) One scaffold, three binding modes: novel and 
selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual 
screening. Journal of medicinal chemistry 52: 4454-4465 
 
Mugasa CM, Adams ER, Boer KR, Dyserinck HC, Buscher P, Schallig HD, Leeflang MM (2012) 
Diagnostic accuracy of molecular amplification tests for human African trypanosomiasis--
systematic review. PLoS neglected tropical diseases 6: e1438 
Chapter VI - Bibliography 
241 
 
 
Murguia JR, Serrano R (2012) New functions of protein kinase Gcn2 in yeast and mammals. IUBMB 
life 64: 971-974 
 
Musoke AJ, Barbet AF (1977) Activation of complement by variant-specific surface antigen of 
Trypanosoma brucei. Nature 270: 438-440 
 
Nakamura M, Yamada M, Hirota Y, Sugimoto K, Oka A, Takanami M (1981) Nucleotide sequence 
of the asnA gene coding for asparagine synthetase of E. coli K-12. Nucleic acids research 9: 4669-
4676 
 
Nakatsu T, Kato H, Oda J (1998) Crystal structure of asparagine synthetase reveals a close 
evolutionary relationship to class II aminoacyl-tRNA synthetase. Nature structural biology 5: 15-19 
 
Namangala B (2012) Contribution of innate immune responses towards resistance to African 
trypanosome infections. Scandinavian journal of immunology 75: 5-15 
 
Namangala B, Brys L, Magez S, De Baetselier P, Beschin A (2000a) Trypanosoma brucei brucei 
infection impairs MHC class II antigen presentation capacity of macrophages. Parasite 
immunology 22: 361-370 
 
Namangala B, De Baetselier P, Beschin A (2009) Both type-I and type-II responses contribute to 
murine trypanotolerance. The Journal of veterinary medical science / the Japanese Society of 
Veterinary Science 71: 313-318 
 
Namangala B, de Baetselier P, Brijs L, Stijlemans B, Noel W, Pays E, Carrington M, Beschin A 
(2000b) Attenuation of Trypanosoma brucei is associated with reduced immunosuppression and 
concomitant production of Th2 lymphokines. The Journal of infectious diseases 181: 1110-1120 
 
Namangala B, Sugimoto C, Inoue N (2007) Effects of exogenous transforming growth factor beta 
on Trypanosoma congolense infection in mice. Infection and immunity 75: 1878-1885 
 
Namangala B, Yokoyama N, Ikehara Y, Taguchi O, Tsujimura K, Sugimoto C, Inoue N (2008) Effect 
of CD4+CD25+ T cell-depletion on acute lethal infection of mice with Trypanosoma congolense. 
The Journal of veterinary medical science / the Japanese Society of Veterinary Science 70: 751-759 
 
Nantulya VM, Doyle JJ, Jenni L (1980) Studies on Trypanosoma (nannomonas) congolense IV. 
Experimental immunization of mice against tsetse fly challenge. Parasitology 80: 133-137 
 
Narasimhan J, Joyce BR, Naguleswaran A, Smith AT, Livingston MR, Dixon SE, Coppens I, Wek RC, 
Sullivan WJ, Jr. (2008) Translation regulation by eukaryotic initiation factor-2 kinases in the 
development of latent cysts in Toxoplasma gondii. The Journal of biological chemistry 283: 16591-
16601 
 
Nerima B, Matovu E, Lubega GW, Enyaru JC (2007) Detection of mutant P2 adenosine transporter 
(TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-
specific polymerase chain reaction. Tropical medicine & international health : TM & IH 12: 1361-
1368 
 
Chapter VI - Bibliography 
242 
 
Newsholme EA, Rolleston FS, Taylor K (1967) Inhibition of brain hexokinase by glucose 6-
phosphate. The Biochemical journal 104: 47P 
 
Ngaira JM, Nantulya VM, Musoke AJ, Hirumi K (1983) Phagocytosis of antibody-sensitized 
Trypanosoma brucei in vitro by bovine peripheral blood monocytes. Immunology 49: 393-400 
 
Ngo H, Tschudi C, Gull K, Ullu E (1998) Double-stranded RNA induces mRNA degradation in 
Trypanosoma brucei. Proceedings of the National Academy of Sciences of the United States of 
America 95: 14687-14692 
 
Njiru ZK, Mikosza AS, Matovu E, Enyaru JC, Ouma JO, Kibona SN, Thompson RC, Ndung'u JM 
(2008) African trypanosomiasis: sensitive and rapid detection of the sub-genus Trypanozoon by 
loop-mediated isothermal amplification (LAMP) of parasite DNA. International journal for 
parasitology 38: 589-599 
 
Nogae I, Johnston M (1990) Isolation and characterization of the ZWF1 gene of Saccharomyces 
cerevisiae, encoding glucose-6-phosphate dehydrogenase. Gene 96: 161-169 
 
Nogge G, Giannetti M (1980) Specific antibodies: a potential insecticide. Science 209: 1028-1029 
 
Noireau F, Lemesre JL, Nzoukoudi MY, Louembet MT, Gouteux JP, Frezil JL (1988) Serodiagnosis of 
sleeping sickness in the Republic of the Congo: comparison of indirect immunofluorescent 
antibody test and card agglutination test. Trans R Soc Trop Med Hyg 82: 237-240 
 
Nowicki MW, Tulloch LB, Worralll L, McNae IW, Hannaert V, Michels PA, Fothergill-Gilmore LA, 
Walkinshaw MD, Turner NJ (2008) Design, synthesis and trypanocidal activity of lead compounds 
based on inhibitors of parasite glycolysis. Bioorganic & medicinal chemistry 16: 5050-5061 
 
Nwagwu M, Opperdoes FR (1982) Regulation of glycolysis in Trypanosoma brucei: hexokinase and 
phosphofructokinase activity. Acta tropica 39: 61-72 
 
Olsson T, Bakhiet M, Edlund C, Hojeberg B, Van der Meide PH, Kristensson K (1991) Bidirectional 
activating signals between Trypanosoma brucei and CD8+ T cells: a trypanosome-released factor 
triggers interferon-gamma production that stimulates parasite growth. European journal of 
immunology 21: 2447-2454 
 
Opigo J, Woodrow C (2009) NECT trial: more than a small victory over sleeping sickness. Lancet 
374: 7-9 
 
Opperdoes FR, Szikora JP (2006) In silico prediction of the glycosomal enzymes of Leishmania 
major and trypanosomes. Molecular and biochemical parasitology 147: 193-206 
 
Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, van Gemert GJ, van de Vegte-
Bolmer M, Sauerwein RW, Stunnenberg HG (2008) Correctly folded Pfs48/45 protein of 
Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proceedings of the 
National Academy of Sciences of the United States of America 105: 4301-4305 
 
Owino AV, Masiga KD, Limo KM (2008) RNA interference: a pathway to drug target identification 
and validation in trypanosome. African Journal of Biochemistry Research 2 066-073 
Chapter VI - Bibliography 
243 
 
 
Oza SL, Ariyanayagam MR, Aitcheson N, Fairlamb AH (2003) Properties of trypanothione 
synthetase from Trypanosoma brucei. Molecular and biochemical parasitology 131: 25-33 
 
Paindavoine P, Pays E, Laurent M, Geltmeyer Y, Le Ray D, Mehlitz D, Steinert M (1986) The use of 
DNA hybridization and numerical taxonomy in determining relationships between Trypanosoma 
brucei stocks and subspecies. Parasitology 92 ( Pt 1): 31-50 
 
Paindavoine P, Rolin S, Van Assel S, Geuskens M, Jauniaux JC, Dinsart C, Huet G, Pays E (1992) A 
gene from the variant surface glycoprotein expression site encodes one of several 
transmembrane adenylate cyclases located on the flagellum of Trypanosoma brucei. Molecular 
and cellular biology 12: 1218-1225 
 
Pal A, Hall BS, Field MC (2002) Evidence for a non-LDL-mediated entry route for the trypanocidal 
drug suramin in Trypanosoma brucei. Molecular and biochemical parasitology 122: 217-221 
 
Pall ML (1970) Amino acid transport in Neurospora crassa. 3. Acidic amino acid transport. 
Biochimica et biophysica acta 211: 513-520 
 
Pan W, Ogunremi O, Wei G, Shi M, Tabel H (2006) CR3 (CD11b/CD18) is the major macrophage 
receptor for IgM antibody-mediated phagocytosis of African trypanosomes: diverse effect on 
subsequent synthesis of tumor necrosis factor alpha and nitric oxide. Microbes and infection / 
Institut Pasteur 8: 1209-1218 
 
Panethymitaki C, Bowyer PW, Price HP, Leatherbarrow RJ, Brown KA, Smith DF (2006) 
Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from 
Trypanosoma brucei and Leishmania major. The Biochemical journal 396: 277-285 
 
Papadopoulos MC, Abel PM, Agranoff D, Stich A, Tarelli E, Bell BA, Planche T, Loosemore A, 
Saadoun S, Wilkins P, Krishna S (2004) A novel and accurate diagnostic test for human African 
trypanosomiasis. Lancet 363: 1358-1363 
 
Patterson MKJ, Orr GR (1968) Asparagine biosynthesis by the Novikoff Hepatoma isolation, 
purification, property, and mechanism studies of the enzyme system. J Biol Chem 243: 376-380 
 
Paul ML, Kaur A, Geete A, Sobhia ME (2014) Essential gene identification and drug target 
prioritization in Leishmania species. Molecular bioSystems 10: 1184-1195 
 
Paulnock DM, Coller SP (2001) Analysis of macrophage activation in African trypanosomiasis. 
Journal of leukocyte biology 69: 685-690 
 
Pays E, Vanhollebeke B, Uzureau P, Lecordier L, Perez-Morga D (2014) The molecular arms race 
between African trypanosomes and humans. Nature reviews Microbiology 12: 575-584 
 
Peacock L, Bailey M, Carrington M, Gibson W (2014) Meiosis and haploid gametes in the pathogen 
Trypanosoma brucei. Current biology : CB 24: 181-186 
 
Chapter VI - Bibliography 
244 
 
Peacock L, Ferris V, Sharma R, Sunter J, Bailey M, Carrington M, Gibson W (2011) Identification of 
the meiotic life cycle stage of Trypanosoma brucei in the tsetse fly. Proceedings of the National 
Academy of Sciences of the United States of America 108: 3671-3676 
 
Pedersen SN (1975) The glycolytic enzyme activity of the human cervix uteri. Cancer 35: 469-474 
 
Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, Jahnke W, James TL, Homans SW, Kessler H, 
Luchinat C, Meyer B, Oschkinat H, Peng J, Schwalbe H, Siegal G (2008) Perspectives on NMR in 
drug discovery: a technique comes of age. Nature reviews Drug discovery 7: 738-745 
 
Pepin J, Meda HA (2001) The epidemiology and control of human African trypanosomiasis. 
Advances in parasitology 49: 71-132 
 
Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, Vanhamme L, 
Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E (2005) Apolipoprotein L-I promotes 
trypanosome lysis by forming pores in lysosomal membranes. Science 309: 469-472 
 
Pham JS, Dawson KL, Jackson KE, Lim EE, Pasaje CF, Turner KE, Ralph SA (2014) Aminoacyl-tRNA 
synthetases as drug targets in eukaryotic parasites. International journal for parasitology Drugs 
and drug resistance 4: 1-13 
 
Phillips C, Dohnalek J, Gover S, Barrett MP, Adams MJ (1998) A 2.8 A resolution structure of 6-
phosphogluconate dehydrogenase from the protozoan parasite Trypanosoma brucei: comparison 
with the sheep enzyme accounts for differences in activity with coenzyme and substrate 
analogues. Journal of molecular biology 282: 667-681 
 
Phillips MA (2012) Stoking the drug target pipeline for human African trypanosomiasis. Molecular 
microbiology 86: 10-14 
 
Pink R, Hudson A, Mouries MA, Bendig M (2005) Opportunities and challenges in antiparasitic 
drug discovery. Nature reviews Drug discovery 4: 727-740 
 
Piotrowski M, Volmer JJ (2006) Cyanide metabolism in higher plants: cyanoalanine hydratase is a 
NIT4 homolog. Plant molecular biology 61: 111-122 
 
Poulin R, Lu L, Ackermann B, Bey P, Pegg AE (1992) Mechanism of the irreversible inactivation of 
mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences 
at the inhibitor and coenzyme binding sites. The Journal of biological chemistry 267: 150-158 
 
Preuss J, Jortzik E, Becker K (2012) Glucose-6-phosphate metabolism in Plasmodium falciparum. 
IUBMB life 64: 603-611 
 
Price HP, Menon MR, Panethymitaki C, Goulding D, McKean PG, Smith DF (2003) Myristoyl-
CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in 
kinetoplastid parasites. The Journal of biological chemistry 278: 7206-7214 
 
Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, Ralser M, Timmermann B, 
Adjaye J (2011) Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic 
Chapter VI - Bibliography 
245 
 
mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic 
reprogramming. Stem cells 29: 1338-1348 
 
Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, 
Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, 
Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage African 
Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-
inferiority trial. Lancet 374: 56-64 
 
Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, Hewison C, Balasegaram M (2008) 
Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping 
sickness in Sudan: cohort study. Bmj 336: 705-708 
 
Proto WR, Castanys-Munoz E, Black A, Tetley L, Moss CX, Juliano L, Coombs GH, Mottram JC 
(2011) Trypanosoma brucei metacaspase 4 is a pseudopeptidase and a virulence factor. The 
Journal of biological chemistry 286: 39914-39925 
 
Qian G, Liu C, Wu G, Yin F, Zhao Y, Zhou Y, Zhang Y, Song Z, Fan J, Hu B, Liu F (2013) AsnB, 
regulated by diffusible signal factor and global regulator Clp, is involved in aspartate metabolism, 
resistance to oxidative stress and virulence in Xanthomonas oryzae pv. oryzicola. Molecular plant 
pathology 14: 145-157 
 
Raczniak G, Becker HD, Min B, Soll D (2001) A single amidotransferase forms asparaginyl-tRNA and 
glutaminyl-tRNA in Chlamydia trachomatis. The Journal of biological chemistry 276: 45862-45867 
 
Radwanska M, Guirnalda P, De Trez C, Ryffel B, Black S, Magez S (2008) Trypanosomiasis-induced 
B cell apoptosis results in loss of protective anti-parasite antibody responses and abolishment of 
vaccine-induced memory responses. PLoS pathogens 4: e1000078 
 
Radwanska M, Magez S, Michel A, Stijlemans B, Geuskens M, Pays E (2000) Comparative analysis 
of antibody responses against HSP60, invariant surface glycoprotein 70, and variant surface 
glycoprotein reveals a complex antigen-specific pattern of immunoglobulin isotype switching 
during infection by Trypanosoma brucei. Infection and immunity 68: 848-860 
 
Ramey K, Eko FO, Thompson WE, Armah H, Igietseme JU, Stiles JK (2009) Immunolocalization and 
challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei 
Ca(2+) ATPase (TBCA2) antigen. The American journal of tropical medicine and hygiene 81: 407-
415 
 
Ramos F, Wiame JM (1979) Synthesis and activation of asparagine in asparagine auxotrophs of 
Saccharomyces cerevisiae. European journal of biochemistry / FEBS 94: 409-417 
 
Ramos F, Wiame JM (1980) Two asparagine synthetases in Saccharomyces cerevisiae. European 
journal of biochemistry / FEBS 108: 373-377 
 
Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S (1999) Characterization of a novel 
trypanosome lytic factor from human serum. Infection and immunity 67: 1910-1916 
 
Chapter VI - Bibliography 
246 
 
Rasooly R, Balaban N (2004) Trypanosome microtubule-associated protein p15 as a vaccine for 
the prevention of African sleeping sickness. Vaccine 22: 1007-1015 
 
Reitzer LJ, Magasanik B (1982) Asparagine synthetases of Klebsiella aerogenes: properties and 
regulation of synthesis. Journal of bacteriology 151: 1299-1313 
 
Richards NG, Schuster SM (1998) Mechanistic issues in asparagine synthetase catalysis. Advances 
in enzymology and related areas of molecular biology 72: 145-198 
 
Rifkin MR (1978) Identification of the trypanocidal factor in normal human serum: high density 
lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 75: 
3450-3454 
 
Rizzari C (2003) Asparaginase Treatment,  Treatment of Acute Leukemias: Humana Press 
 
Rizzari C, Conter V, Stary J, Colombini A, Moericke A, Schrappe M (2013) Optimizing asparaginase 
therapy for acute lymphoblastic leukemia. Current opinion in oncology 25 Suppl 1: S1-9 
 
Robello C, Navarro P, Castanys S, Gamarro F (1997) A pteridine reductase gene ptr1 contiguous to 
a P-glycoprotein confers resistance to antifolates in Trypanosoma cruzi. Molecular and 
biochemical parasitology 90: 525-535 
 
Roberts J, Holcenberg JS, Dolowy WC (1972) Isolation, crystallization, and properties of 
Achromobacteraceae glutaminase-asparaginase with antitumor activity. The Journal of biological 
chemistry 247: 84-90 
 
Robertson JG (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44: 5561-5571 
 
Robinette D, Neamati N, Tomer KB, Borchers CH (2006) Photoaffinity labeling combined with 
mass spectrometric approaches as a tool for structural proteomics. Expert review of proteomics 3: 
399-408 
 
Robinson KA, Beverley SM (2003) Improvements in transfection efficiency and tests of RNA 
interference (RNAi) approaches in the protozoan parasite Leishmania. Molecular and biochemical 
parasitology 128: 217-228 
 
Rogers DJ, Randolph SE (2002) A response to the aim of eradicating tsetse from Africa. Trends in 
parasitology 18: 534-536 
 
Roos AK (2007) Structural and Functional Studies of Ribose-5-phosphate isomerase B. Doctor of 
Phylosophy Thesis, Deparment of Cell and Molecular Biology, Uppsala Universitet,  
 
Roos AK, Andersson CE, Bergfors T, Jacobsson M, Karlen A, Unge T, Jones TA, Mowbray SL (2004) 
Mycobacterium tuberculosis ribose-5-phosphate isomerase has a known fold, but a novel active 
site. Journal of molecular biology 335: 799-809 
 
Roos AK, Burgos E, Ericsson DJ, Salmon L, Mowbray SL (2005) Competitive inhibitors of 
Mycobacterium tuberculosis ribose-5-phosphate isomerase B reveal new information about the 
reaction mechanism. The Journal of biological chemistry 280: 6416-6422 
Chapter VI - Bibliography 
247 
 
 
Roos AK, Mariano S, Kowalinski E, Salmon L, Mowbray SL (2008) D-ribose-5-phosphate isomerase 
B from Escherichia coli is also a functional D-allose-6-phosphate isomerase, while the 
Mycobacterium tuberculosis enzyme is not. Journal of molecular biology 382: 667-679 
 
Rotureau B, Subota I, Buisson J, Bastin P (2012) A new asymmetric division contributes to the 
continuous production of infective trypanosomes in the tsetse fly. Development 139: 1842-1850 
 
Roy H, Becker HD, Reinbolt J, Kern D (2003) When contemporary aminoacyl-tRNA synthetases 
invent their cognate amino acid metabolism. Proceedings of the National Academy of Sciences of 
the United States of America 100: 9837-9842 
 
Ruda GF, Campbell G, Alibu VP, Barrett MP, Brenk R, Gilbert IH (2010a) Virtual fragment screening 
for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorganic & medicinal chemistry 18: 
5056-5062 
 
Ruda GF, Wong PE, Alibu VP, Norval S, Read KD, Barrett MP, Gilbert IH (2010b) Aryl 
phosphoramidates of 5-phospho erythronohydroxamic acid, a new class of potent trypanocidal 
compounds. Journal of medicinal chemistry 53: 6071-6078 
 
Russo DC, Williams DJ, Grab DJ (1994) Mechanisms for the elimination of potentially lytic 
complement-fixing variable surface glycoprotein antibody-complexes in Trypanosoma brucei. 
Parasitology research 80: 487-492 
 
Salmon D, Vanwalleghem G, Morias Y, Denoeud J, Krumbholz C, Lhomme F, Bachmaier S, Kador 
M, Gossmann J, Dias FB, De Muylder G, Uzureau P, Magez S, Moser M, De Baetselier P, Van Den 
Abbeele J, Beschin A, Boshart M, Pays E (2012) Adenylate cyclases of Trypanosoma brucei inhibit 
the innate immune response of the host. Science 337: 463-466 
 
Sanderson L, Dogruel M, Rodgers J, De Koning HP, Thomas SA (2009) Pentamidine movement 
across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome 
infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. The 
Journal of pharmacology and experimental therapeutics 329: 967-977 
 
Sands M, Kron MA, Brown RB (1985) Pentamidine: a review. Reviews of infectious diseases 7: 625-
634 
 
Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira 
Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG, Jr., de Oliveira SM, Palatnik-de-
Sousa CB (2006) The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a 
transmission blocking vaccine. Vaccine 24: 2423-2431 
 
Schenk G, Duggleby RG, Nixon PF (1998) Properties and functions of the thiamin diphosphate 
dependent enzyme transketolase. The international journal of biochemistry & cell biology 30: 
1297-1318 
 
Schleifer KW, Filutowicz H, Schopf LR, Mansfield JM (1993) Characterization of T helper cell 
responses to the trypanosome variant surface glycoprotein. J Immunol 150: 2910-2919 
 
Chapter VI - Bibliography 
248 
 
Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, Nangouma A, Doua F, 
Asumu PN, Simarro PP, Burri C (2005) Effectiveness of a 10-day melarsoprol schedule for the 
treatment of late-stage human African trypanosomiasis: confirmation from a multinational study 
(IMPAMEL II). The Journal of infectious diseases 191: 1922-1931 
 
Schofield CJ, Maudlin I (2001) Trypanosomiasis control. International journal for parasitology 31: 
614-619 
 
Schopf LR, Filutowicz H, Bi XJ, Mansfield JM (1998) Interleukin-4-dependent immunoglobulin G1 
isotype switch in the presence of a polarized antigen-specific Th1-cell response to the 
trypanosome variant surface glycoprotein. Infection and immunity 66: 451-461 
 
Schumann Burkard G, Jutzi P, Roditi I (2011) Genome-wide RNAi screens in bloodstream form 
trypanosomes identify drug transporters. Molecular and biochemical parasitology 175: 91-94 
 
Schwarz F, Aebi M (2011) Mechanisms and principles of N-linked protein glycosylation. Current 
opinion in structural biology 21: 576-582 
 
Scofield MA, Lewis WS, Schuster SM (1990) Nucleotide sequence of Escherichia coli asnB and 
deduced amino acid sequence of asparagine synthetase B. The Journal of biological chemistry 265: 
12895-12902 
 
Scotti C, Sommi P, Pasquetto MV, Cappelletti D, Stivala S, Mignosi P, Savio M, Chiarelli LR, 
Valentini G, Bolanos-Garcia VM, Merrell DS, Franchini S, Verona ML, Bolis C, Solcia E, Manca R, 
Franciotta D, Casasco A, Filipazzi P, Zardini E, Vannini V (2010) Cell-cycle inhibition by Helicobacter 
pylori L-asparaginase. PloS one 5: e13892 
 
Semballa S, Geffard M, Daulouede S, Malvy D, Veyret B, Lemesre JL, Holzmuller P, Mnaimneh S, 
Vincendeau P (2004) Antibodies directed against nitrosylated neoepitopes in sera of patients with 
human African trypanosomiasis. Tropical medicine & international health : TM & IH 9: 1104-1110 
 
Seyfang A, Duszenko M (1991) Specificity of glucose transport in Trypanosoma brucei. Effective 
inhibition by phloretin and cytochalasin B. European journal of biochemistry / FEBS 202: 191-196 
 
Seyfang A, Mecke D, Duszenko M (1990) Degradation, recycling, and shedding of Trypanosoma 
brucei variant surface glycoprotein. The Journal of protozoology 37: 546-552 
 
Sharlow E, Golden JE, Dodson H, Morris M, Hesser M, Lyda T, Leimgruber S, Schroeder CE, 
Flaherty DP, Weiner WS, Simpson D, Lazo JS, Aubé J, Morris JC (2011) Identification of Inhibitors of 
Trypanosoma brucei Hexokinases. Probe Reports from the NIH Molecular Libraries Program 41: 
1859-1866 
 
Sharlow ER, Lyda TA, Dodson HC, Mustata G, Morris MT, Leimgruber SS, Lee KH, Kashiwada Y, 
Close D, Lazo JS, Morris JC (2010) A target-based high throughput screen yields Trypanosoma 
brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS neglected tropical 
diseases 4: e659 
 
Chapter VI - Bibliography 
249 
 
Shelton MD, Chock PB, Mieyal JJ (2005) Glutaredoxin: role in reversible protein s-glutathionylation 
and regulation of redox signal transduction and protein translocation. Antioxidants & redox 
signaling 7: 348-366 
 
Sheng C, Ji H, Miao Z, Che X, Yao J, Wang W, Dong G, Guo W, Lu J, Zhang W (2009) Homology 
modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: 
active site characterization and insights into rational inhibitor design. Journal of computer-aided 
molecular design 23: 375-389 
 
Sheppard J, Nielsen K, Tizard I, Holmes W (1978) Direct activation of complement by 
trypanosomes. The Journal of parasitology 64: 544-546 
 
Shi H, Chamond N, Djikeng A, Tschudi C, Ullu E (2009) RNA interference in Trypanosoma brucei: 
role of the n-terminal RGG domain and the polyribosome association of argonaute. The Journal of 
biological chemistry 284: 36511-36520 
 
Shi H, Djikeng A, Tschudi C, Ullu E (2004a) Argonaute protein in the early divergent eukaryote 
Trypanosoma brucei: control of small interfering RNA accumulation and retroposon transcript 
abundance. Molecular and cellular biology 24: 420-427 
 
Shi H, Tschudi C, Ullu E (2006a) An unusual Dicer-like1 protein fuels the RNA interference pathway 
in Trypanosoma brucei. Rna 12: 2063-2072 
 
Shi H, Ullu E, Tschudi C (2004b) Function of the Trypanosome Argonaute 1 protein in RNA 
interference requires the N-terminal RGG domain and arginine 735 in the Piwi domain. The 
Journal of biological chemistry 279: 49889-49893 
 
Shi M, Pan W, Tabel H (2003) Experimental African trypanosomiasis: IFN-gamma mediates early 
mortality. European journal of immunology 33: 108-118 
 
Shi M, Wei G, Pan W, Tabel H (2006b) Experimental African trypanosomiasis: a subset of 
pathogenic, IFN-gamma-producing, MHC class II-restricted CD4+ T cells mediates early mortality 
in highly susceptible mice. J Immunol 176: 1724-1732 
 
Shi MQ, Wei GJ, Tabel H (2007) Trypanosoma congolense infections: MHC class II-restricted 
immune responses mediate either protection or disease, depending on IL-10 function. Parasite 
immunology 29: 107-111 
 
Shiba K, Motegi H, Yoshida M, Noda T (1998) Human asparaginyl-tRNA synthetase: molecular 
cloning and the inference of the evolutionary history of Asx-tRNA synthetase family. Nucleic acids 
research 26: 5045-5051 
 
Shibayama K, Takeuchi H, Wachino J, Mori S, Arakawa Y (2011) Biochemical and 
pathophysiological characterization of Helicobacter pylori asparaginase. Microbiology and 
immunology 55: 408-417 
 
Sidoli C, Molteni A, Bellanti B, Redaelli L, Iuzzolino L, Rubino M, Arioli P, Nardese V, Carettoni D 
(2006) Biochemical assay development for drug discovery: a sequential optimization from protein 
expression to enzymatic activity. Microbial Cell Factories 5: 1-2 
Chapter VI - Bibliography 
250 
 
 
Sienkiewicz N, Jaroslawski S, Wyllie S, Fairlamb AH (2008) Chemical and genetic validation of 
dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. 
Molecular microbiology 69: 520-533 
 
Sienkiewicz N, Ong HB, Fairlamb AH (2010) Trypanosoma brucei pteridine reductase 1 is essential 
for survival in vitro and for virulence in mice. Molecular microbiology 77: 658-671 
 
Silva MS, Prazeres DM, Lanca A, Atouguia J, Monteiro GA (2009) Trans-sialidase from 
Trypanosoma brucei as a potential target for DNA vaccine development against African 
trypanosomiasis. Parasitology research 105: 1223-1229 
 
Skinner AJ, Cooper RA (1974) Genetic studies on ribose 5-phosphate isomerase mutants of 
Escherichia coli K-12. Journal of bacteriology 118: 1183-1185 
 
Smith TK, Butikofer P (2010) Lipid metabolism in Trypanosoma brucei. Molecular and biochemical 
parasitology 172: 66-79 
 
Smith TK, Crossman A, Borissow CN, Paterson MJ, Dix A, Brimacombe JS, Ferguson MA (2001) 
Specificity of GlcNAc-PI de-N-acetylase of GPI biosynthesis and synthesis of parasite-specific 
suicide substrate inhibitors. The EMBO journal 20: 3322-3332 
 
Snijder HJ, Van Eerde JH, Kingma RL, Kalk KH, Dekker N, Egmond MR, Dijkstra BW (2001) 
Structural investigations of the active-site mutant Asn156Ala of outer membrane phospholipase 
A: function of the Asn-His interaction in the catalytic triad. Protein science : a publication of the 
Protein Society 10: 1962-1969 
 
Solano P, Torr SJ, Lehane MJ (2013) Is vector control needed to eliminate gambiense human 
African trypanosomiasis? Frontiers in cellular and infection microbiology 3: 33 
 
Sorensen KI, Hove-Jensen B (1996) Ribose catabolism of Escherichia coli: characterization of the 
rpiB gene encoding ribose phosphate isomerase B and of the rpiR gene, which is involved in 
regulation of rpiB expression. Journal of bacteriology 178: 1003-1011 
 
Spinks D, Ong HB, Mpamhanga CP, Shanks EJ, Robinson DA, Collie IT, Read KD, Frearson JA, Wyatt 
PG, Brenk R, Fairlamb AH, Gilbert IH (2011) Design, synthesis and biological evaluation of novel 
inhibitors of Trypanosoma brucei pteridine reductase 1. ChemMedChem 6: 302-308 
 
Spinks D, Shanks EJ, Cleghorn LA, McElroy S, Jones D, James D, Fairlamb AH, Frearson JA, Wyatt 
PG, Gilbert IH (2009) Investigation of trypanothione reductase as a drug target in Trypanosoma 
brucei. ChemMedChem 4: 2060-2069 
 
Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER, Janka-Schaub GE, 
Evans WE, Pieters R (2005) Asparagine synthetase expression is linked with L-asparaginase 
resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic 
leukemia. Blood 105: 4223-4225 
 
Stanghellini A, Josenando T (2001) The situation of sleeping sickness in Angola: a calamity. 
Tropical medicine & international health : TM & IH 6: 330-334 
Chapter VI - Bibliography 
251 
 
 
Stephens JL, Lee SH, Paul KS, Englund PT (2007) Mitochondrial fatty acid synthesis in Trypanosoma 
brucei. The Journal of biological chemistry 282: 4427-4436 
 
Stephens NA, Hajduk SL (2011) Endosomal localization of the serum resistance-associated protein 
in African trypanosomes confers human infectivity. Eukaryotic cell 10: 1023-1033 
 
Stern AL, Burgos E, Salmon L, Cazzulo JJ (2007) Ribose 5-phosphate isomerase type B from 
Trypanosoma cruzi: kinetic properties and site-directed mutagenesis reveal information about the 
reaction mechanism. The Biochemical journal 401: 279-285 
 
Stern AL, Naworyta A, Cazzulo JJ, Mowbray SL (2011) Structures of type B ribose 5-phosphate 
isomerase from Trypanosoma cruzi shed light on the determinants of sugar specificity in the 
structural family. The FEBS journal 278: 793-808 
 
Sternberg JM, Rodgers J, Bradley B, Maclean L, Murray M, Kennedy PG (2005) 
Meningoencephalitic African trypanosomiasis: Brain IL-10 and IL-6 are associated with protection 
from neuro-inflammatory pathology. Journal of neuroimmunology 167: 81-89 
 
Stevens DR, Moulton JE (1978) Ultrastructural and immunological aspects of the phagocytosis of 
Trypanosoma brucei by mouse peritoneal macrophages. Infection and immunity 19: 972-982 
 
Steverding D (2008) The history of African trypanosomiasis. Parasites & vectors 1: 3 
 
Stewart ML, Burchmore RJ, Clucas C, Hertz-Fowler C, Brooks K, Tait A, Macleod A, Turner CM, De 
Koning HP, Wong PE, Barrett MP (2010) Multiple genetic mechanisms lead to loss of functional 
TbAT1 expression in drug-resistant trypanosomes. Eukaryotic cell 9: 336-343 
 
Stijlemans B, Baral TN, Guilliams M, Brys L, Korf J, Drennan M, Van Den Abbeele J, De Baetselier P, 
Magez S (2007) A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-
associated immunopathology. J Immunol 179: 4003-4014 
 
Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, 
Gruening NM, Krueger A, Tauqeer Alam M, Keller MA, Breitenbach M, Brindle KM, Rabinowitz JD, 
Ralser M (2014) The return of metabolism: biochemistry and physiology of the pentose phosphate 
pathway. Biological reviews of the Cambridge Philosophical Society 
 
Stoffel SA, Alibu VP, Hubert J, Ebikeme C, Portais JC, Bringaud F, Schweingruber ME, Barrett MP 
(2011) Transketolase in Trypanosoma brucei. Molecular and biochemical parasitology 179: 1-7 
 
Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, Kilberg MS (2008) Correlation between asparaginase 
sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic 
leukemia cell lines. Pediatric blood & cancer 50: 274-279 
 
Subramaniam C, Veazey P, Redmond S, Hayes-Sinclair J, Chambers E, Carrington M, Gull K, 
Matthews K, Horn D, Field MC (2006) Chromosome-wide analysis of gene function by RNA 
interference in the african trypanosome. Eukaryotic cell 5: 1539-1549 
 
Chapter VI - Bibliography 
252 
 
Sugiyama A, Kato H, Nishioka T, Oda J (1992) Overexpression and purification of asparagine 
synthetase from Escherichia coli. Bioscience, biotechnology, and biochemistry 56: 376-379 
 
Sunter J, Webb H, Carrington M (2013) Determinants of GPI-PLC localisation to the flagellum and 
access to GPI-anchored substrates in trypanosomes. PLoS pathogens 9: e1003566 
 
Swinney DC (2004) Biochemical mechanisms of drug action: what does it take for success? Nature 
reviews Drug discovery 3: 801-808 
 
Szathmary E (1999) The origin of the genetic code: amino acids as cofactors in an RNA world. 
Trends in genetics : TIG 15: 223-229 
 
Tachado SD, Gerold P, Schwarz R, Novakovic S, McConville M, Schofield L (1997) Signal 
transduction in macrophages by glycosylphosphatidylinositols of Plasmodium, Trypanosoma, and 
Leishmania: activation of protein tyrosine kinases and protein kinase C by inositolglycan and 
diacylglycerol moieties. Proceedings of the National Academy of Sciences of the United States of 
America 94: 4022-4027 
 
Tait A, Babiker EA, Le Ray D (1984) Enzyme variation in Trypanosoma brucei spp. I. Evidence for 
the sub-speciation of Trypanosoma brucei gambiense. Parasitology 89 ( Pt 2): 311-326 
 
Takayanagi T, Kawaguchi H, Yabu Y, Itoh M, Appawu MA (1987) Contribution of the complement 
system to antibody-mediated binding of Trypanosoma gambiense to macrophages. The Journal of 
parasitology 73: 333-341 
 
Tasdemir D, Guner ND, Perozzo R, Brun R, Donmez AA, Calis I, Ruedi P (2005) Anti-protozoal and 
plasmodial FabI enzyme inhibiting metabolites of Scrophularia lepidota roots. Phytochemistry 66: 
355-362 
 
Tasdemir D, Topaloglu B, Perozzo R, Brun R, O'Neill R, Carballeira NM, Zhang X, Tonge PJ, Linden 
A, Ruedi P (2007) Marine natural products from the Turkish sponge Agelas oroides that inhibit the 
enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli. 
Bioorganic & medicinal chemistry 15: 6834-6845 
 
Taylor MC, Kaur H, Blessington B, Kelly JM, Wilkinson SR (2008) Validation of spermidine synthase 
as a drug target in African trypanosomes. The Biochemical journal 409: 563-569 
 
Tetley L, Turner CM, Barry JD, Crowe JS, Vickerman K (1987) Onset of expression of the variant 
surface glycoproteins of Trypanosoma brucei in the tsetse fly studied using immunoelectron 
microscopy. Journal of cell science 87 ( Pt 2): 363-372 
 
Tielens AG, Van Hellemond JJ (1998) Differences in energy metabolism between 
trypanosomatidae. Parasitol Today 14: 265-272 
 
Tirados I, Esterhuizen J, Rayaisse JB, Diarrassouba A, Kaba D, Mpiana S, Vale GA, Solano P, Lehane 
MJ, Torr SJ (2011) How do tsetse recognise their hosts? The role of shape in the responses of 
tsetse (Glossina fuscipes and G. palpalis) to artificial hosts. PLoS neglected tropical diseases 5: 
e1226 
 
Chapter VI - Bibliography 
253 
 
Torrie LS, Wyllie S, Spinks D, Oza SL, Thompson S, Harrison JR, Gilbert IH, Wyatt PG, Fairlamb AH, 
Frearson JA (2009) Chemical validation of trypanothione synthetase: a potential drug target for 
human trypanosomiasis. The Journal of biological chemistry 284: 36137-36145 
 
Truc P, Tibayrenc M (1993) Population genetics of Trypanosoma brucei in central Africa: 
taxonomic and epidemiological significance. Parasitology 106 ( Pt 2): 137-149 
 
Tulloch LB, Martini VP, Iulek J, Huggan JK, Lee JH, Gibson CL, Smith TK, Suckling CJ, Hunter WN 
(2010) Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness 
and the leishmaniases. Journal of medicinal chemistry 53: 221-229 
 
Tumbula-Hansen D, Feng L, Toogood H, Stetter KO, Soll D (2002) Evolutionary divergence of the 
archaeal aspartyl-tRNA synthetases into discriminating and nondiscriminating forms. The Journal 
of biological chemistry 277: 37184-37190 
 
Tumbula DL, Becker HD, Chang WZ, Soll D (2000) Domain-specific recruitment of amide amino 
acids for protein synthesis. Nature 407: 106-110 
 
Ueno T, Ohtawa K, Mitsui K, Kodera Y, Hiroto M, Matsushima A, Inada Y, Nishimura H (1997) Cell 
cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia : official journal 
of the Leukemia Society of America, Leukemia Research Fund, UK 11: 1858-1861 
 
Urwyler S, Studer E, Renggli CK, Roditi I (2007) A family of stage-specific alanine-rich proteins on 
the surface of epimastigote forms of Trypanosoma brucei. Molecular microbiology 63: 218-228 
 
Uzonna JE, Kaushik RS, Gordon JR, Tabel H (1999) Cytokines and antibody responses during 
Trypanosoma congolense infections in two inbred mouse strains that differ in resistance. Parasite 
immunology 21: 57-71 
 
Uzureau P, Uzureau S, Lecordier L, Fontaine F, Tebabi P, Homble F, Grelard A, Zhendre V, Nolan 
DP, Lins L, Crowet JM, Pays A, Felu C, Poelvoorde P, Vanhollebeke B, Moestrup SK, Lyngso J, 
Pedersen JS, Mottram JC, Dufourc EJ, Perez-Morga D, Pays E (2013) Mechanism of Trypanosoma 
brucei gambiense resistance to human serum. Nature 501: 430-434 
 
Van Den Abbeele J, Caljon G, De Ridder K, De Baetselier P, Coosemans M (2010) Trypanosoma 
brucei modifies the tsetse salivary composition, altering the fly feeding behavior that favors 
parasite transmission. PLoS pathogens 6: e1000926 
 
Van Den Abbeele J, Claes Y, van Bockstaele D, Le Ray D, Coosemans M (1999) Trypanosoma brucei 
spp. development in the tsetse fly: characterization of the post-mesocyclic stages in the foregut 
and proboscis. Parasitology 118 ( Pt 5): 469-478 
 
van den Berg H (2011) Asparaginase revisited. Leukemia & lymphoma 52: 168-178 
 
van Hellemond JJ, Tielens AG (2006) Adaptations in the lipid metabolism of the protozoan parasite 
Trypanosoma brucei. FEBS letters 580: 5552-5558 
 
Van Schaftingen E, Opperdoes FR, Hers HG (1987) Effects of various metabolic conditions and of 
the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and 
Chapter VI - Bibliography 
254 
 
of glycolytic intermediates in Trypanosoma brucei. European journal of biochemistry / FEBS 166: 
653-661 
 
Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Pays A, 
Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane JP, De Baetselier P, Brasseur R, 
Pays E (2003) Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422: 83-
87 
 
Vanhollebeke B, De Muylder G, Nielsen MJ, Pays A, Tebabi P, Dieu M, Raes M, Moestrup SK, Pays 
E (2008) A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in 
humans. Science 320: 677-681 
 
Vansterkenburg EL, Coppens I, Wilting J, Bos OJ, Fischer MJ, Janssen LH, Opperdoes FR (1993) The 
uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by 
Trypanosoma brucei and its possible mode of action. Acta tropica 54: 237-250 
 
Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CAt, Ramalho-Santos J, Van Houten B, 
Schatten G (2011) Energy metabolism in human pluripotent stem cells and their differentiated 
counterparts. PloS one 6: e20914 
 
Vassella E, Probst M, Schneider A, Studer E, Renggli CK, Roditi I (2004) Expression of a major 
surface protein of Trypanosoma brucei insect forms is controlled by the activity of mitochondrial 
enzymes. Molecular biology of the cell 15: 3986-3993 
 
Vernet T, Tessier DC, Chatellier J, Plouffe C, Lee TS, Thomas DY, Storer AC, Menard R (1995) 
Structural and functional roles of asparagine 175 in the cysteine protease papain. The Journal of 
biological chemistry 270: 16645-16652 
 
Vickerman K (1985) Developmental cycles and biology of pathogenic trypanosomes. British 
medical bulletin 41: 105-114 
 
Vickerman K, Luckins AG (1969) Localization of variable antigens in the surface coat of 
Trypanosoma brucei using ferritin conjugated antibody. Nature 224: 1125-1126 
 
Vincendeau P, Gobert AP, Daulouede S, Moynet D, Mossalayi MD (2003) Arginases in parasitic 
diseases. Trends in parasitology 19: 9-12 
 
Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, Wong PE, Burchmore RJ, Barrett MP 
(2010) A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS 
pathogens 6: e1001204 
 
Vreysen MJ (2001) Principles of area-wide integrated tsetse fly control using the sterile insect 
technique. Medecine tropicale : revue du Corps de sante colonial 61: 397-411 
 
Vreysen MJ, Saleh KM, Ali MY, Abdulla AM, Zhu ZR, Juma KG, Dyck VA, Msangi AR, Mkonyi PA, 
Feldmann HU (2000) Glossina austeni (Diptera: Glossinidae) eradicated on the island of Unguja, 
Zanzibar, using the sterile insect technique. Journal of economic entomology 93: 123-135 
 
Chapter VI - Bibliography 
255 
 
Walsh MJ, Brimacombe KR, Vasquez-Valdivieso MG, Auld DS, Simeonov A, Morgan HP, Fothergill-
Gilmore LA, Michels PAM, Walkinshaw MD, Shen M, Boxer MB (2010) Identification of Selective 
Inhibitors of Phosphofructokinase as Lead Compounds Against Trypanosomiasis. In Probe Reports 
from the NIH Molecular Libraries Program. Bethesda (MD) 
 
Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment of African 
trypanosomiasis. Annual review of pharmacology and toxicology 35: 93-127 
 
Wang J, Yang W (2013) Concerted proton transfer mechanism of Clostridium thermocellum ribose-
5-phosphate isomerase. The journal of physical chemistry B 117: 9354-9361 
 
Wang Z, Morris JC, Drew ME, Englund PT (2000) Inhibition of Trypanosoma brucei gene expression 
by RNA interference using an integratable vector with opposing T7 promoters. The Journal of 
biological chemistry 275: 40174-40179 
 
Wastling SL, Welburn SC (2011) Diagnosis of human sleeping sickness: sense and sensitivity. 
Trends in parasitology 27: 394-402 
 
Webb H, Carnall N, Carrington M (1994) The role of GPI-PLC in Trypanosoma brucei. Brazilian 
journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / 
Sociedade Brasileira de Biofisica  [et al] 27: 349-356 
 
Webb H, Carnall N, Vanhamme L, Rolin S, Van Den Abbeele J, Welburn S, Pays E, Carrington M 
(1997) The GPI-phospholipase C of Trypanosoma brucei is nonessential but influences parasitemia 
in mice. The Journal of cell biology 139: 103-114 
 
Wei G, Tabel H (2008) Regulatory T cells prevent control of experimental African trypanosomiasis. 
J Immunol 180: 2514-2521 
 
WHO. (1998) Control and surveillance of African trypanosomiasis. In Committee RoaWE (ed.), 
WHO technical report series 881. World Health Organization, Geneva. 
 
Widener J, Nielsen MJ, Shiflett A, Moestrup SK, Hajduk S (2007) Hemoglobin is a co-factor of 
human trypanosome lytic factor. PLoS pathogens 3: 1250-1261 
 
Wiemer EA, Michels PA, Opperdoes FR (1995) The inhibition of pyruvate transport across the 
plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic 
implications. The Biochemical journal 312 ( Pt 2): 479-484 
 
Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I (2008) A mechanism for cross-resistance 
to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of 
Sciences of the United States of America 105: 5022-5027 
 
Willadsen P, Bird P, Cobon GS, Hungerford J (1995) Commercialisation of a recombinant vaccine 
against Boophilus microplus. Parasitology 110 Suppl: S43-50 
 
Willert EK, Fitzpatrick R, Phillips MA (2007) Allosteric regulation of an essential trypanosome 
polyamine biosynthetic enzyme by a catalytically dead homolog. Proceedings of the National 
Academy of Sciences of the United States of America 104: 8275-8280 
Chapter VI - Bibliography 
256 
 
 
Willert EK, Phillips MA (2008) Regulated expression of an essential allosteric activator of 
polyamine biosynthesis in African trypanosomes. PLoS pathogens 4: e1000183 
 
Williams DJ, Taylor K, Newson J, Gichuki B, Naessens J (1996) The role of anti-variable surface 
glycoprotein antibody responses in bovine trypanotolerance. Parasite immunology 18: 209-218 
 
Willis RC, Woolfolk CA (1975) L-asparagine uptake in Escherichia coli. Journal of bacteriology 123: 
937-945 
 
Willson M, Sanejouand YH, Perie J, Hannaert V, Opperdoes F (2002) Sequencing, modeling, and 
selective inhibition of Trypanosoma brucei hexokinase. Chemistry & biology 9: 839-847 
 
Wirtz E, Clayton C (1995) Inducible gene expression in trypanosomes mediated by a prokaryotic 
repressor. Science 268: 1179-1183 
 
Wirtz E, Hoek M, Cross GA (1998) Regulated processive transcription of chromatin by T7 RNA 
polymerase in Trypanosoma brucei. Nucleic acids research 26: 4626-4634 
 
Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible expression system for 
conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Molecular 
and biochemical parasitology 99: 89-101 
 
Woese CR, Olsen GJ, Ibba M, Soll D (2000) Aminoacyl-tRNA synthetases, the genetic code, and the 
evolutionary process. Microbiology and molecular biology reviews : MMBR 64: 202-236 
 
Wolf YI, Aravind L, Grishin NV, Koonin EV (1999) Evolution of aminoacyl-tRNA synthetases--
analysis of unique domain architectures and phylogenetic trees reveals a complex history of 
horizontal gene transfer events. Genome research 9: 689-710 
 
Wolf YI, Rogozin IB, Grishin NV, Tatusov RL, Koonin EV (2001) Genome trees constructed using five 
different approaches suggest new major bacterial clades. BMC evolutionary biology 1: 8 
 
Woo PT (1970) The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. 
Acta tropica 27: 384-386 
 
Wurst M, Robles A, Po J, Luu VD, Brems S, Marentije M, Stoitsova S, Quijada L, Hoheisel J, Stewart 
M, Hartmann C, Clayton C (2009) An RNAi screen of the RRM-domain proteins of Trypanosoma 
brucei. Molecular and biochemical parasitology 163: 61-65 
 
Wyllie S, Oza SL, Patterson S, Spinks D, Thompson S, Fairlamb AH (2009) Dissecting the essentiality 
of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and 
genetic methods. Molecular microbiology 74: 529-540 
 
Xiao Y, McCloskey DE, Phillips MA (2009) RNA interference-mediated silencing of ornithine 
decarboxylase and spermidine synthase genes in Trypanosoma brucei provides insight into 
regulation of polyamine biosynthesis. Eukaryotic cell 8: 747-755 
 
Chapter VI - Bibliography 
257 
 
Xong HV, Vanhamme L, Chamekh M, Chimfwembe CE, Van Den Abbeele J, Pays A, Van Meirvenne 
N, Hamers R, De Baetselier P, Pays E (1998) A VSG expression site-associated gene confers 
resistance to human serum in Trypanosoma rhodesiense. Cell 95: 839-846 
 
Yang H, He X, Zheng Y, Feng W, Xia X, Yu X, Lin Z (2014) Down-regulation of asparagine synthetase 
induces cell cycle arrest and inhibits cell proliferation of breast cancer. Chemical biology & drug 
design 84: 578-584 
 
Yarlett N, Bacchi CJ (1988) Effect of DL-alpha-difluoromethylornithine on methionine cycle 
intermediates in Trypanosoma brucei brucei. Molecular and biochemical parasitology 27: 1-10 
 
Ye J, Kumanova M, Hart LS, Sloane K, Zhang H, De Panis DN, Bobrovnikova-Marjon E, Diehl JA, Ron 
D, Koumenis C (2010) The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation 
in response to nutrient deprivation. The EMBO journal 29: 2082-2096 
 
Young SA, Smith TK (2010) The essential neutral sphingomyelinase is involved in the trafficking of 
the variant surface glycoprotein in the bloodstream form of Trypanosoma brucei. Molecular 
microbiology 76: 1461-1482 
 
Yun O, Priotto G, Tong J, Flevaud L, Chappuis F (2010) NECT is next: implementing the new drug 
combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS neglected 
tropical diseases 4: e720 
 
Zampella EJ, Bradley EL, Jr., Pretlow TG, 2nd (1982) Glucose-6-phosphate dehydrogenase: a 
possible clinical indicator for prostatic carcinoma. Cancer 49: 384-387 
 
Zhang J, Fan J, Venneti S, Cross JR, Takagi T, Bhinder B, Djaballah H, Kanai M, Cheng EH, Judkins 
AR, Pawel B, Baggs J, Cherry S, Rabinowitz JD, Thompson CB (2014) Asparagine plays a critical role 
in regulating cellular adaptation to glutamine depletion. Molecular cell 56: 205-218 
 
Zhang M, Fennell C, Ranford-Cartwright L, Sakthivel R, Gueirard P, Meister S, Caspi A, Doerig C, 
Nussenzweig RS, Tuteja R, Sullivan WJ, Jr., Roos DS, Fontoura BM, Menard R, Winzeler EA, 
Nussenzweig V (2010) The Plasmodium eukaryotic initiation factor-2alpha kinase IK2 controls the 
latency of sporozoites in the mosquito salivary glands. The Journal of experimental medicine 207: 
1465-1474 
 
Zhang Q, Lee J, Pandurangan S, Clarke M, Pajak A, Marsolais F (2013) Characterization of 
Arabidopsis serine:glyoxylate aminotransferase, AGT1, as an asparagine aminotransferase. 
Phytochemistry 85: 30-35 
 
Zhang RG, Andersson CE, Skarina T, Evdokimova E, Edwards AM, Joachimiak A, Savchenko A, 
Mowbray SL (2003) The 2.2 A resolution structure of RpiB/AlsB from Escherichia coli illustrates a 
new approach to the ribose-5-phosphate isomerase reaction. Journal of molecular biology 332: 
1083-1094 
 
Zheng S, Haselkorn R (1996) A glutamate/glutamine/aspartate/asparagine transport operon in 
Rhodobacter capsulatus. Molecular microbiology 20: 1001-1011 
 
Chapter VI - Bibliography 
258 
 
Ziegelbauer K, Overath P (1993) Organization of two invariant surface glycoproteins in the surface 
coat of Trypanosoma brucei. Infection and immunity 61: 4540-4545 
 
Zillmann U, Mehlitz D, Sachs R (1984) Identity of Trypanozoon stocks isolated from man and a 
domestic dog in Liberia. Tropenmedizin und Parasitologie 35: 105-108 
 
 
 
